{"PMC7190502": [["Hand rubs for surgical hand preparation ::: IntroductionThe vast demand for commercial alcohol-based hand rubs (ABHR) primarily for the control of SARS-CoV-2 in healthcare and the public has the side effect that well formulated products with a high quality (spore filtration, proven efficacy, and good dermal tolerance) are now only sparse in some hospitals.", [["hand", "ANATOMY", 23, 27], ["hand", "ANATOMY", 101, 105], ["dermal", "ANATOMY", 302, 308], ["alcohol", "CHEMICAL", 87, 94], ["SARS", "DISEASE", 147, 151], ["alcohol", "CHEMICAL", 87, 94], ["hand", "ORGANISM_SUBDIVISION", 23, 27], ["alcohol", "SIMPLE_CHEMICAL", 87, 94], ["SARS-CoV-2", "ORGANISM", 147, 157], ["dermal", "TISSUE", 302, 308], ["SARS-CoV", "SPECIES", 147, 155], ["surgical hand preparation", "TREATMENT", 14, 39], ["spore filtration", "TREATMENT", 258, 274], ["rubs", "OBSERVATION", 5, 9]]], ["While the number of surgical procedures being performed is limited during the ongoing pandemic, facilities need to ensure that reliable products remain available for surgery.", [["surgical procedures", "TREATMENT", 20, 39], ["surgery", "TREATMENT", 166, 173]]], ["In case of a shortage in the operating theatre the alternatives listed in Table Iare available.Hand rubs for hygienic hand disinfection ::: IntroductionThese days ABHR consumption has increased hugely in hospitals, but also outside healthcare facilities.", [["hand", "ANATOMY", 118, 122], ["ABHR", "CHEMICAL", 163, 167], ["hand", "ORGANISM_SUBDIVISION", 118, 122], ["rubs", "OBSERVATION", 100, 104], ["disinfection", "OBSERVATION", 123, 135]]], ["Commercial hand rubs can be found in shops, entrance halls of companies, public buildings and many other areas.", [["hand", "ANATOMY", 11, 15], ["rubs", "OBSERVATION", 16, 20]]], ["In addition, many citizens have bought hand rubs and use them regularly although thorough hand washing is considered to be sufficient in the community or home setting.", [["hand", "ANATOMY", 39, 43], ["hand", "ANATOMY", 90, 94], ["hand", "ORGANISM_SUBDIVISION", 90, 94], ["thorough hand washing", "TREATMENT", 81, 102]]], ["Despite an extensive increase in production by many manufacturers there is a substantial shortage of commercially produced hand rubs in more and more hospitals.", [["hand", "ANATOMY", 123, 127], ["hand rubs", "PROBLEM", 123, 132], ["extensive", "OBSERVATION_MODIFIER", 11, 20], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["substantial", "OBSERVATION_MODIFIER", 77, 88], ["shortage", "OBSERVATION_MODIFIER", 89, 97], ["rubs", "OBSERVATION", 128, 132]]], ["In case of short a shortage the alternatives listed in Table IIare available.Face masks ::: IntroductionSurgical face masks used in the operating room and FFP2 or N95 respirators recommended as single-use products and are used by HCWs treating COVID-19 patients [2].", [["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["IntroductionSurgical face masks", "TREATMENT", 92, 123], ["FFP2", "TREATMENT", 155, 159], ["N95 respirators", "TREATMENT", 163, 178]]], ["Under certain conditions, the increase in the duration of wearing a mask or their re-use may be authorized [11].", [["a mask", "TREATMENT", 66, 72], ["increase", "OBSERVATION_MODIFIER", 30, 38]]], ["In this situation the manufacturer should be contacted for advice on whether it is possible to disinfect or reprocess the face mask.", [["face", "ANATOMY", 122, 126], ["the face mask", "TREATMENT", 118, 131], ["face mask", "OBSERVATION", 122, 131]]], ["Coronaviruses are inactivated at 60\u00b0C in 30 min so that thermal disinfection may be an option [12].", [["Coronaviruses", "PROBLEM", 0, 13], ["thermal disinfection", "TREATMENT", 56, 76]]], ["The construction of the face mask may allow thermal disinfection [13].", [["the face mask", "TREATMENT", 20, 33], ["thermal disinfection", "TREATMENT", 44, 64]]], ["But some masks may lose their filtration capacity or the fitting in the face resulting in less protection for the user [13].", [["some masks", "TREATMENT", 4, 14], ["their filtration capacity", "PROBLEM", 24, 49], ["the fitting in the face", "PROBLEM", 53, 76], ["face", "ANATOMY", 72, 76]]], ["The WHO indicates that reprocessing masks or respirators should only be considered when there is critical shortage or lack of them [2].", [["reprocessing masks", "TREATMENT", 23, 41], ["respirators", "TREATMENT", 45, 56]]], ["Any type of reprocessing should ensure that the efficacy of the process is ensured, the reprocessing method does not result in residual toxicity for the healthcare workers and the functional integrity and shape of the item is maintained [2].", [["toxicity", "DISEASE", 136, 144], ["residual toxicity", "PROBLEM", 127, 144]]], ["The following options are available:\u2022The mask may be disinfected or sterilizedoOrganize re-use of face masks (ideally person-bound) and thermal disinfection or steam sterilization [14]oMark the mask (number of disinfections or sterilisations)oEvaluate any visible damage of the mask when disinfected or sterilized more often\u2022No informationoTry to find information from other manufacturers with similar face masks\u2022The mask should not be disinfected or sterilizedoFFP2 mask: Keep the same mask for up to 8 h maximum [11]oSurgical face mask: keep the same mask for up to 4 h (SFHH ) or 6 h (WHO) maximum [2, 11]oTry to find another supplier or accept the risk of a potentially insufficient protectionoThe use of face shields may be an alternative [2]\u2022The masks should be worn as long as possible [15].", [["face", "ANATOMY", 528, 532], ["person", "SPECIES", 118, 124], ["The mask", "TREATMENT", 37, 45], ["face masks", "TREATMENT", 98, 108], ["thermal disinfection", "TREATMENT", 136, 156], ["steam sterilization", "TREATMENT", 160, 179], ["Mark the mask", "TREATMENT", 185, 198], ["the mask", "TREATMENT", 274, 282], ["similar face masks", "TREATMENT", 394, 412], ["The mask", "TREATMENT", 413, 421], ["FFP2 mask", "TREATMENT", 462, 471], ["the same mask", "TREATMENT", 478, 491], ["Surgical face mask", "TREATMENT", 519, 537], ["the same mask", "TREATMENT", 544, 557], ["face shields", "TREATMENT", 709, 721], ["The masks", "TREATMENT", 748, 757], ["visible", "OBSERVATION_MODIFIER", 256, 263], ["damage", "OBSERVATION", 264, 270]]]], "32272283047b962dd7b5e1f0dcd838e2511e9145": [["of small sequence insertions relative m the trypanosomes, but the lower gene density in Leishmania is mostly explained by its larger inter-CDS regions.", [["CDS regions", "DNA", 139, 150], ["small sequence insertions", "PROBLEM", 3, 28], ["the trypanosomes", "PROBLEM", 40, 56], ["the lower gene density in Leishmania", "PROBLEM", 62, 98], ["small", "OBSERVATION_MODIFIER", 3, 8], ["trypanosomes", "OBSERVATION_MODIFIER", 44, 56], ["lower gene", "OBSERVATION_MODIFIER", 66, 76], ["density", "OBSERVATION", 77, 84], ["Leishmania", "OBSERVATION", 88, 98], ["larger", "OBSERVATION_MODIFIER", 126, 132]]], ["Each species contains a number of gene families of varying size.", [["varying", "OBSERVATION_MODIFIER", 51, 58], ["size", "OBSERVATION_MODIFIER", 59, 63]]], ["Predicted functions have been ascribed to -40% of the protein-coding genes, but this has been confirmed experimentally for only -5% of the proteins.", [["protein-coding genes", "DNA", 54, 74], ["the protein", "TEST", 50, 61]]], ["Most of the remaining genes encode conserved hypothetical proteins, of which slightly more than half are found only in trypanosomatids.", [["hypothetical proteins", "PROBLEM", 45, 66], ["hypothetical proteins", "OBSERVATION", 45, 66]]], ["Interestingly, -2-3% of the Tritryp proteins are related to those found in prokaryotes but not other eukaryotes.", [["Tritryp proteins", "GENE_OR_GENE_PRODUCT", 28, 44], ["Tritryp proteins", "PROTEIN", 28, 44], ["the Tritryp proteins", "PROBLEM", 24, 44]]], ["The Tritryp genomes display a remarkable degree of synteny, with -75% of the genes in L. major having orthologues in both other species and >90% of these occurring in the same genomic context (see Table 1 ).", [["L. major", "ORGANISM", 86, 94], ["Tritryp genomes", "DNA", 4, 19], ["remarkable", "OBSERVATION_MODIFIER", 30, 40], ["degree", "OBSERVATION_MODIFIER", 41, 47]]], ["The proteins within this Tritryp \"core\" proteome exhibit an average 57% identity between T. brucei and T. cruzi, and 44% identity between L. major and the two other trypanosomes, reflecting the expected phylogenetic relationships.", [["Tritryp", "GENE_OR_GENE_PRODUCT", 25, 32], ["T. brucei", "ORGANISM", 89, 98], ["T. cruzi", "ORGANISM", 103, 111], ["L. major", "ORGANISM", 138, 146], ["T. brucei", "SPECIES", 89, 98], ["T. cruzi", "SPECIES", 103, 111], ["L. major", "SPECIES", 138, 146], ["T. brucei", "SPECIES", 89, 98], ["T. cruzi", "SPECIES", 103, 111], ["L. major", "SPECIES", 138, 146], ["The proteins", "TEST", 0, 12], ["T. brucei", "TEST", 89, 98], ["T. cruzi", "TEST", 103, 111], ["44% identity between L. major and the two other trypanosomes", "PROBLEM", 117, 177], ["phylogenetic relationships", "OBSERVATION", 203, 229]]], ["5'6 Interestingly, substantially fewer orthologues are shared only between L. major and T. brucei than between L. major and T. cruzi, perhaps reflecting the common intracellular environment of their mammalian stages.", [["intracellular", "ANATOMY", 164, 177], ["L. major", "ORGANISM", 75, 83], ["T. brucei", "ORGANISM", 88, 97], ["L. major", "ORGANISM", 111, 119], ["T. cruzi", "ORGANISM", 124, 132], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 164, 177], ["5'6", "PROTEIN", 0, 3], ["L. major", "SPECIES", 75, 83], ["T. brucei", "SPECIES", 88, 97], ["L. major", "SPECIES", 111, 119], ["T. cruzi", "SPECIES", 124, 132], ["L. major", "SPECIES", 75, 83], ["T. brucei", "SPECIES", 88, 97], ["L. major", "SPECIES", 111, 119], ["T. cruzi", "SPECIES", 124, 132], ["substantially", "OBSERVATION_MODIFIER", 19, 32], ["fewer orthologues", "OBSERVATION", 33, 50], ["T. brucei", "OBSERVATION", 88, 97], ["cruzi", "OBSERVATION", 127, 132]]], ["However, all three genomes contain a significant number of species-specific genes, which account for .-21% and 38% of the protein-coding genes in T. brucei and T. cruzi, respectively, but only -13% of the L. major genes.", [["T. brucei", "ORGANISM", 146, 155], ["T. cruzi", "ORGANISM", 160, 168], ["L. major", "ORGANISM", 205, 213], ["protein-coding genes", "DNA", 122, 142], ["L. major genes", "DNA", 205, 219], ["T. brucei", "SPECIES", 146, 155], ["T. cruzi", "SPECIES", 160, 168], ["T. brucei", "SPECIES", 146, 155], ["T. cruzi", "SPECIES", 160, 168], ["the protein", "TEST", 118, 129], ["coding genes in T. brucei", "PROBLEM", 130, 155], ["T. cruzi", "TEST", 160, 168], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["number", "OBSERVATION_MODIFIER", 49, 55], ["species", "OBSERVATION", 59, 66]]], ["These species-speciflc genes (and pseudogenes) mostly encode large families of surface proteins, exemplified by the variant surface glycoproteins (VSGs) and Procyclic Acidic Repetitive Proteins (EP/PARP/procyclin) of T. brucei; the trans-sialidases, dispersed gene family protein 1 (DGF-1), mucins, and mucin-associated surface proteins (MASPs) of T. cruzi; and the amastins andpromastigote surface antigens (PSA-2) of L. major.", [["surface", "ANATOMY", 79, 86], ["speciflc", "GENE_OR_GENE_PRODUCT", 14, 22], ["variant surface glycoproteins", "GENE_OR_GENE_PRODUCT", 116, 145], ["VSGs", "GENE_OR_GENE_PRODUCT", 147, 151], ["Procyclic Acidic Repetitive Proteins", "GENE_OR_GENE_PRODUCT", 157, 193], ["PARP", "GENE_OR_GENE_PRODUCT", 198, 202], ["procyclin", "GENE_OR_GENE_PRODUCT", 203, 212], ["T. brucei", "ORGANISM", 217, 226], ["dispersed gene family protein 1", "GENE_OR_GENE_PRODUCT", 250, 281], ["DGF-1", "GENE_OR_GENE_PRODUCT", 283, 288], ["mucins", "GENE_OR_GENE_PRODUCT", 291, 297], ["mucin-associated surface proteins", "GENE_OR_GENE_PRODUCT", 303, 336], ["MASPs", "GENE_OR_GENE_PRODUCT", 338, 343], ["T. cruzi", "ORGANISM", 348, 356], ["amastins andpromastigote surface antigens", "GENE_OR_GENE_PRODUCT", 366, 407], ["PSA-2", "GENE_OR_GENE_PRODUCT", 409, 414], ["L. major", "ORGANISM", 419, 427], ["speciflc genes", "DNA", 14, 28], ["surface proteins", "PROTEIN", 79, 95], ["variant surface glycoproteins", "PROTEIN", 116, 145], ["VSGs", "PROTEIN", 147, 151], ["Procyclic Acidic Repetitive Proteins", "PROTEIN", 157, 193], ["EP", "PROTEIN", 195, 197], ["PARP", "PROTEIN", 198, 202], ["procyclin", "PROTEIN", 203, 212], ["trans-sialidases", "PROTEIN", 232, 248], ["dispersed gene family protein 1 (DGF-1", "PROTEIN", 250, 288], ["mucins", "PROTEIN", 291, 297], ["mucin-associated surface proteins", "PROTEIN", 303, 336], ["MASPs", "PROTEIN", 338, 343], ["amastins andpromastigote surface antigens", "PROTEIN", 366, 407], ["PSA", "PROTEIN", 409, 412], ["T. brucei", "SPECIES", 217, 226], ["T. cruzi", "SPECIES", 348, 356], ["L. major", "SPECIES", 419, 427], ["T. brucei", "SPECIES", 217, 226], ["T. cruzi", "SPECIES", 348, 356], ["L. major", "SPECIES", 419, 427], ["These species", "TEST", 0, 13], ["speciflc genes (and pseudogenes", "PROBLEM", 14, 45], ["surface proteins", "PROBLEM", 79, 95], ["VSGs", "TEST", 147, 151], ["Procyclic Acidic Repetitive Proteins", "TEST", 157, 193], ["EP", "TEST", 195, 197], ["/PARP/procyclin", "TREATMENT", 197, 212], ["T. brucei", "PROBLEM", 217, 226], ["the trans-sialidases", "TEST", 228, 248], ["family protein", "TEST", 265, 279], ["DGF", "TEST", 283, 286], ["mucins", "TEST", 291, 297], ["mucin-associated surface proteins", "TEST", 303, 336], ["MASPs", "TEST", 338, 343], ["T. cruzi", "PROBLEM", 348, 356], ["the amastins andpromastigote surface antigens", "TEST", 362, 407], ["PSA", "TEST", 409, 412], ["large", "OBSERVATION_MODIFIER", 61, 66]]], ["In addition to these species-speciflc genes, all three species demonstrate differential paralogous gene expansion or contraction, with the ESAG4 adenylate/guanylate cyclases and leucine-rich repeat proteins being over-represented in T. brucei; GP63 surface proteases and recombination hot spot (RHS) proteins in T. cruzi; and mitochondrial carrier protein, ATP-Binding Cassette (ABC) transporters, and Heat Shock Protein (HSP) 90 gene families in L. major.", [["mitochondrial", "ANATOMY", 326, 339], ["leucine", "CHEMICAL", 178, 185], ["ATP", "CHEMICAL", 357, 360], ["adenylate", "CHEMICAL", 145, 154], ["guanylate", "CHEMICAL", 155, 164], ["leucine", "CHEMICAL", 178, 185], ["ATP", "CHEMICAL", 357, 360], ["speciflc", "GENE_OR_GENE_PRODUCT", 29, 37], ["ESAG4 adenylate/guanylate cyclases", "GENE_OR_GENE_PRODUCT", 139, 173], ["leucine-rich repeat proteins", "GENE_OR_GENE_PRODUCT", 178, 206], ["T. brucei", "ORGANISM", 233, 242], ["GP63 surface proteases and recombination hot spot (RHS)", "GENE_OR_GENE_PRODUCT", 244, 299], ["T. cruzi", "ORGANISM", 312, 320], ["mitochondrial", "CELLULAR_COMPONENT", 326, 339], ["ATP-Binding Cassette (ABC) transporters", "GENE_OR_GENE_PRODUCT", 357, 396], ["Heat Shock Protein (HSP) 90", "GENE_OR_GENE_PRODUCT", 402, 429], ["L. major", "ORGANISM", 447, 455], ["speciflc genes", "DNA", 29, 43], ["ESAG4 adenylate/guanylate cyclases", "PROTEIN", 139, 173], ["leucine-rich repeat proteins", "PROTEIN", 178, 206], ["T. brucei; GP63 surface proteases", "PROTEIN", 233, 266], ["recombination hot spot (RHS) proteins", "PROTEIN", 271, 308], ["mitochondrial carrier protein", "PROTEIN", 326, 355], ["ATP-Binding Cassette (ABC) transporters", "PROTEIN", 357, 396], ["Heat Shock Protein (HSP) 90 gene families", "PROTEIN", 402, 443], ["T. brucei", "SPECIES", 233, 242], ["T. cruzi", "SPECIES", 312, 320], ["L. major", "SPECIES", 447, 455], ["T. brucei", "SPECIES", 233, 242], ["T. cruzi", "SPECIES", 312, 320], ["L. major", "SPECIES", 447, 455], ["these species", "TEST", 15, 28], ["speciflc genes", "PROBLEM", 29, 43], ["differential paralogous gene expansion", "PROBLEM", 75, 113], ["contraction", "PROBLEM", 117, 128], ["the ESAG4 adenylate/guanylate cyclases", "PROBLEM", 135, 173], ["leucine", "TEST", 178, 185], ["repeat proteins", "TEST", 191, 206], ["T. brucei", "PROBLEM", 233, 242], ["GP63 surface proteases", "TREATMENT", 244, 266], ["recombination hot spot (RHS) proteins in T. cruzi", "PROBLEM", 271, 320], ["mitochondrial carrier protein", "TEST", 326, 355], ["ATP", "TEST", 357, 360], ["Heat Shock Protein", "TEST", 402, 420], ["gene expansion", "OBSERVATION", 99, 113]]], ["Many of these species-speciflc genes or paralogous expansions occur in telomeric and sub-telomeric gene dusters, possibly reflecting similar strategies used for immune evasion.", [["telomeric", "ANATOMY", 71, 80], ["speciflc", "GENE_OR_GENE_PRODUCT", 22, 30], ["telomeric", "CELLULAR_COMPONENT", 71, 80], ["telomeric", "CELLULAR_COMPONENT", 89, 98], ["speciflc genes", "DNA", 22, 36], ["telomeric and sub-telomeric gene dusters", "DNA", 71, 111], ["these species", "PROBLEM", 8, 21], ["speciflc genes", "PROBLEM", 22, 36], ["paralogous expansions", "PROBLEM", 40, 61], ["telomeric and sub-telomeric gene dusters", "PROBLEM", 71, 111], ["immune evasion", "TREATMENT", 161, 175], ["species", "OBSERVATION", 14, 21], ["paralogous expansions", "OBSERVATION", 40, 61], ["possibly reflecting", "UNCERTAINTY", 113, 132], ["similar strategies", "OBSERVATION", 133, 151]]]], "5da3f835dd8a4e112a76d21db78a85920453478a": [["Introduction, commonly referred to as coronavirus disease-19 has emerged as a fatal SARS infection 1 over the past few months.", [["coronavirus disease", "DISEASE", 38, 57], ["SARS infection", "DISEASE", 84, 98], ["coronavirus", "ORGANISM", 38, 49], ["coronavirus disease-19", "SPECIES", 38, 60], ["coronavirus disease", "PROBLEM", 38, 57], ["a fatal SARS infection", "PROBLEM", 76, 98], ["fatal", "OBSERVATION_MODIFIER", 78, 83], ["SARS", "OBSERVATION_MODIFIER", 84, 88], ["infection", "OBSERVATION", 89, 98]]], ["The symptoms of the disease resemble a typical viral, respiratory infection with an incubation time of214days.", [["respiratory", "ANATOMY", 54, 65], ["respiratory infection", "DISEASE", 54, 75], ["The symptoms", "PROBLEM", 0, 12], ["the disease", "PROBLEM", 16, 27], ["a typical viral, respiratory infection", "PROBLEM", 37, 75], ["disease", "OBSERVATION", 20, 27], ["typical", "OBSERVATION_MODIFIER", 39, 46], ["viral", "OBSERVATION", 47, 52], ["respiratory", "ANATOMY", 54, 65], ["infection", "OBSERVATION", 66, 75]]], ["However, as this disease progresses, the affected experiences shortness of breath, nausea culminating in pneumonia and multiple organ failure 3, 5 .IntroductionGiven the deadly and debilitating condition that it is, the entire world now is at high alert with thousands of cases being identified each day.", [["organ", "ANATOMY", 128, 133], ["shortness of breath", "DISEASE", 62, 81], ["nausea", "DISEASE", 83, 89], ["pneumonia", "DISEASE", 105, 114], ["organ failure", "DISEASE", 128, 141], ["organ", "ORGAN", 128, 133], ["this disease", "PROBLEM", 12, 24], ["shortness of breath", "PROBLEM", 62, 81], ["nausea", "PROBLEM", 83, 89], ["pneumonia", "PROBLEM", 105, 114], ["multiple organ failure", "PROBLEM", 119, 141], ["debilitating condition", "PROBLEM", 181, 203], ["pneumonia", "OBSERVATION", 105, 114], ["multiple", "OBSERVATION_MODIFIER", 119, 127], ["organ", "ANATOMY", 128, 133], ["failure", "OBSERVATION", 134, 141]]], ["Going by WHO statistics, as of now, there have been about 1.84 million identified cases with over 1, 13, 329 deaths 6 .", [["deaths", "DISEASE", 109, 115]]], ["Country-wise (top 10 India) statistical COVID-19 cases as of April 12, 2020, presented in Table 1 7 .", [["statistical COVID", "TEST", 28, 45]]], ["According to WHO 8 , geographical statistics of the confirmed COVID-19 cases have registered as of April 12, 2020 as depicted in the Figure 1 .", [["COVID", "TEST", 62, 67]]], ["International travel history and close contact with the infected have been identified as the causes of the worldwide spread of the disease.", [["the disease", "PROBLEM", 127, 138], ["disease", "OBSERVATION", 131, 138]]], ["An enormous amount of effort is being put into developing vaccines and drugs to help treat the infection 9, 10 .", [["infection", "DISEASE", 95, 104], ["developing vaccines", "TREATMENT", 47, 66], ["drugs", "TREATMENT", 71, 76], ["the infection", "PROBLEM", 91, 104], ["enormous", "OBSERVATION_MODIFIER", 3, 11], ["amount", "OBSERVATION_MODIFIER", 12, 18], ["effort", "OBSERVATION", 22, 28], ["infection", "OBSERVATION", 95, 104]]], ["Speaking of India, the country currently stands at 9, 205 confirmed cases and 331 deaths.", [["deaths", "DISEASE", 82, 88]]], ["There has been a 21-day complete lockdown in India as a measure to prevent further transmission, but whether India is coping up with the disease or not continues to be a big question.", [["the disease", "PROBLEM", 133, 144], ["21-", "OBSERVATION_MODIFIER", 17, 20]]], ["While these small numbers of confirmed and deceased cases may bring in a sigh of relief, they also challenge the state of medical testing and diagnosis in India 11 .", [["medical testing", "TEST", 122, 137], ["small", "OBSERVATION_MODIFIER", 12, 17], ["numbers", "OBSERVATION_MODIFIER", 18, 25]]], ["Whether these numbers are low or they are low because of insufficient testing remains unanswered 12 .IntroductionIn these times of emergency, researchers and scientists have come a long way in helping the society by indulging in scientific methods of identifying the virus inside humans through the technology of machine learning (ML) and deep learning(DL) algorithms.IntroductionIn recently, several classical image processing and machine or deep learning methods are used to automatically classify the diseases with digitized chest X-ray images 13, 14 .", [["humans", "ORGANISM", 280, 286], ["humans", "SPECIES", 280, 286], ["humans", "SPECIES", 280, 286], ["these numbers", "TEST", 8, 21], ["insufficient testing", "TEST", 57, 77], ["deep learning(DL) algorithms", "TREATMENT", 339, 367], ["deep learning methods", "TREATMENT", 443, 464], ["the diseases", "PROBLEM", 500, 512], ["digitized chest X-ray images", "TEST", 518, 546], ["low", "OBSERVATION_MODIFIER", 26, 29], ["diseases", "OBSERVATION", 504, 512], ["chest", "ANATOMY", 528, 533]]], ["Class decomposition of the coronavirus disease-2019 (COVID-19) in non-COVID and COVID viral infection with X-ray scans regarded as one of the critical subjects of matter for diagnosing this highly infectious disease [15] [16] [17] .", [["coronavirus disease", "DISEASE", 27, 46], ["viral infection", "DISEASE", 86, 101], ["non-COVID", "CANCER", 66, 75], ["coronavirus disease-2019 (COVID-19", "SPECIES", 27, 61], ["the coronavirus disease", "PROBLEM", 23, 46], ["COVID", "TEST", 53, 58], ["COVID viral infection", "PROBLEM", 80, 101], ["X-ray scans", "TEST", 107, 118], ["this highly infectious disease", "PROBLEM", 185, 215], ["coronavirus disease", "OBSERVATION", 27, 46], ["infection", "OBSERVATION", 92, 101]]], ["For eg., One of the chest X-ray slides pictorially represented as COVID-19, Regular, and Pneumonia patient in Figure 4 .IntroductionFast COVID-19 recognition can help control disease transmission and will help to monitor the progression of infectious disease.", [["Pneumonia", "DISEASE", 89, 98], ["infectious disease", "DISEASE", 240, 258], ["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["the chest X-ray slides", "TEST", 16, 38], ["COVID", "TEST", 66, 71], ["Pneumonia", "PROBLEM", 89, 98], ["Fast COVID", "TREATMENT", 132, 142], ["infectious disease", "PROBLEM", 240, 258], ["chest", "ANATOMY", 20, 25], ["Pneumonia", "OBSERVATION", 89, 98], ["infectious", "OBSERVATION", 240, 250]]], ["According to Tao et al. 18 , it seems that Chest CT is more prone to COVID-19 diagnosis with respect to the original reverse-transcription polymerase chain reaction (RT-PCR) that has been collected from swab samples from patients and reported an accuracy of 97.3% to classify COVID-19 viral highly infectious diseases.", [["swab samples", "ANATOMY", 203, 215], ["infectious diseases", "DISEASE", 298, 317], ["swab samples", "ORGANISM_SUBSTANCE", 203, 215], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 221, 229], ["Chest CT", "TEST", 43, 51], ["transcription polymerase chain reaction", "PROBLEM", 125, 164], ["RT-PCR", "TEST", 166, 172], ["swab samples", "TEST", 203, 215], ["an accuracy", "TEST", 243, 254], ["COVID", "TEST", 276, 281], ["viral highly infectious diseases", "PROBLEM", 285, 317], ["Chest", "ANATOMY", 43, 48], ["infectious", "OBSERVATION", 298, 308]]], ["Convolution neural network (CNN) is one of the most popular algorithms that have shown high precision in the ability to interpret the COVID-19 classification with medical images like X-rays or CT images.", [["neural network", "MULTI-TISSUE_STRUCTURE", 12, 26], ["COVID-19", "DNA", 134, 142], ["medical images", "TEST", 163, 177], ["CT images", "TEST", 193, 202], ["neural network", "OBSERVATION", 12, 26], ["high precision", "OBSERVATION_MODIFIER", 87, 101]]], ["Wang et al. 19 has proposed a COVID-19 classification technique by implementing the CNNs based on Inception Net over the pathogen-confirmed COVID-19, with 453 computed tomography (CT) images and reported an accuracy of 82.9%.", [["CNNs", "DNA", 84, 88], ["COVID-19", "DNA", 140, 148], ["a COVID-19 classification technique", "TREATMENT", 28, 63], ["the CNNs", "TREATMENT", 80, 88], ["the pathogen", "TEST", 117, 129], ["COVID", "TEST", 140, 145], ["computed tomography", "TEST", 159, 178], ["CT) images", "TEST", 180, 190], ["an accuracy", "TEST", 204, 215]]], ["Songet al 20 has implemented a multi-class classification to recognise the diseases (COVID-19 viral infection, non-COVID and bacterial pneumonia) with CT images (88 patients with COVID-19 infected, 86 non-COVID patients and 100 patients with bacterial pneumonia)by using a modified version of pre-trained ResNet-50 net-work, named as DRE-Net and reported an accuracy of 86% for bacterial pneumonia and viral pneumonia (COVID- 19) classification.IntroductionIn another study, Sethy et al. 21 used chest x-ray images to recognize COVID viral infection, firstly they have extracted deep features using CNN based on pre-trained ImageNETand at the last layer SVM were used in order to classify it.", [["viral infection", "DISEASE", 94, 109], ["bacterial pneumonia", "DISEASE", 125, 144], ["COVID-19 infected", "DISEASE", 179, 196], ["non-COVID", "DISEASE", 201, 210], ["bacterial pneumonia", "DISEASE", 242, 261], ["pneumonia", "DISEASE", 388, 397], ["pneumonia", "DISEASE", 408, 417], ["viral infection", "DISEASE", 534, 549], ["patients", "ORGANISM", 165, 173], ["patients", "ORGANISM", 211, 219], ["patients", "ORGANISM", 228, 236], ["pre-trained ImageNETand", "DNA", 612, 635], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 211, 219], ["patients", "SPECIES", 228, 236], ["the diseases", "PROBLEM", 71, 83], ["COVID", "TEST", 85, 90], ["viral infection", "PROBLEM", 94, 109], ["non-COVID", "PROBLEM", 111, 120], ["bacterial pneumonia", "PROBLEM", 125, 144], ["CT images", "TEST", 151, 160], ["COVID", "TEST", 179, 184], ["bacterial pneumonia", "PROBLEM", 242, 261], ["an accuracy", "TEST", 355, 366], ["bacterial pneumonia", "PROBLEM", 378, 397], ["viral pneumonia", "PROBLEM", 402, 417], ["COVID", "TEST", 419, 424], ["another study", "TEST", 460, 473], ["chest x-ray images", "TEST", 496, 514], ["COVID viral infection", "PROBLEM", 528, 549], ["pre-trained ImageNETand", "TREATMENT", 612, 635], ["bacterial", "OBSERVATION_MODIFIER", 125, 134], ["pneumonia", "OBSERVATION", 135, 144], ["pneumonia", "OBSERVATION", 252, 261], ["pneumonia", "OBSERVATION", 388, 397], ["viral", "OBSERVATION_MODIFIER", 402, 407], ["pneumonia", "OBSERVATION", 408, 417], ["chest", "ANATOMY", 496, 501], ["viral", "OBSERVATION_MODIFIER", 534, 539], ["infection", "OBSERVATION", 540, 549], ["deep", "ANATOMY_MODIFIER", 579, 583]]], ["In addition, Wang et al. 16 presented multi-class classification, deep convolutional neural network architecture named as COVID-Net implemented over 16, 756 chest radiography images that have been scanned with 13,645 patient to classify the COVID-19 and non-COVID also with a safe and bacterial infected patient.Results and DiscussionIn this section, the results for the proposed methodology is discussed.", [["neural network", "MULTI-TISSUE_STRUCTURE", 85, 99], ["patient", "ORGANISM", 217, 224], ["patient", "ORGANISM", 304, 311], ["COVID", "DNA", 122, 127], ["patient", "SPECIES", 217, 224], ["patient", "SPECIES", 304, 311], ["chest radiography images", "TEST", 157, 181], ["the COVID", "TEST", 237, 246], ["a safe and bacterial infected patient", "TREATMENT", 274, 311], ["deep", "ANATOMY_MODIFIER", 66, 70], ["chest", "ANATOMY", 157, 162], ["bacterial", "OBSERVATION_MODIFIER", 285, 294], ["infected", "OBSERVATION", 295, 303]]], ["It can be inferred that the metrics corresponding to the Random Forest (RF) classifier and the XGBoost (XGB) classifier outperformed from the rest indicating that they have a better understanding of the image features which were input to them.Study Population Characteristics:The corresponding performance metrics of RF and XGB in terms of Accuracy, Sensitivity, Specificity, F1-Score, and AUC are shown in Table 2 .", [["the XGBoost (XGB)", "TREATMENT", 91, 108], ["Accuracy", "TEST", 340, 348], ["Sensitivity", "TEST", 350, 361], ["Specificity", "TEST", 363, 374], ["AUC", "TEST", 390, 393]]], ["It seems that XGBoost performed the best among all the classifiers with an accuracy of 97.7%, while Logistic Regression (LR), k-Nearest Neighbour (kNN),3/10All rights reserved.", [["an accuracy", "TEST", 72, 83]]], ["No reuse allowed without permission.3/10(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 119, 122]]], ["Model Performance: Once the training of the model is performed, it becomes easy to further classify the features separately into 3 classes, namely, COVID-19, Pneumonia and Normal.", [["Pneumonia", "DISEASE", 158, 167], ["COVID", "TEST", 148, 153], ["Pneumonia", "PROBLEM", 158, 167], ["Pneumonia", "OBSERVATION", 158, 167], ["Normal", "OBSERVATION", 172, 178]]], ["In real-time, for example, if some random patient comes for screening, we can determine whether he/she has COVID or he/she is suffering from Pneumonia or Healthy using the proposed model by taking the chest X-ray and sending it to the proposed model.3/10To evaluate the efficiency of the proposed framework, confusion matrix is estimated, which gives a detailed understanding of the classification process in Figure 2 .", [["Pneumonia", "DISEASE", 141, 150], ["confusion", "DISEASE", 308, 317], ["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["screening", "TEST", 60, 69], ["Pneumonia", "PROBLEM", 141, 150], ["the chest X-ray", "TEST", 197, 212], ["confusion matrix", "PROBLEM", 308, 324], ["Pneumonia", "OBSERVATION", 141, 150], ["chest", "ANATOMY", 201, 206]]], ["No reuse allowed without permission.4/10(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.4/10The copyright holder for this preprint this version posted April 17, 2020.Concoction of DatasetWe instantiated our proposed methodology with two publicly available datasets: Chest X-Ray Images (Pneumonia) 1 Figure 4 .", [["Pneumonia", "DISEASE", 373, 382], ["Chest X-Ray Images", "TEST", 353, 371], ["Pneumonia", "PROBLEM", 373, 382], ["med", "ANATOMY", 119, 122], ["Pneumonia", "OBSERVATION", 373, 382]]], ["The number of the images used in the experiment from both the datasets are as depicted in Table 3 and Table 4.", [["the images", "TEST", 14, 24]]], ["No reuse allowed without permission.5/10(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.5/10The copyright holder for this preprint this version posted April 17, 2020. .", [["med", "ANATOMY", 119, 122]]], ["Pre-processing of the Dataset It could be seen that all the acquired X-ray images are of variable shapes and sizes, which increases the difficulty in effective classification.", [["the acquired X-ray images", "TEST", 56, 81], ["variable shapes and sizes", "PROBLEM", 89, 114], ["variable", "OBSERVATION_MODIFIER", 89, 97], ["shapes", "OBSERVATION_MODIFIER", 98, 104], ["sizes", "OBSERVATION_MODIFIER", 109, 114]]], ["In order to effectively perform classification tasks, image preprocessing is performed.", [["classification tasks", "TEST", 32, 52], ["image preprocessing", "TEST", 54, 73]]], ["There exist many automatic and semi-automatic techniques for detecting abnormality in the body of the patient, but the absence of reliable and precise techniques can cause ambiguities in the classification process.", [["body", "ANATOMY", 90, 94], ["body", "ORGANISM_SUBDIVISION", 90, 94], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["abnormality in the body", "PROBLEM", 71, 94], ["abnormality", "OBSERVATION", 71, 82], ["body", "ANATOMY_MODIFIER", 90, 94]]], ["Keeping aforementioned challenges in the mind, ML based predictive classifiers are used for analyzing the chest X-ray images, which are further discussed in the following sections.", [["sections", "ANATOMY", 171, 179], ["analyzing the chest X-ray images", "TEST", 92, 124], ["chest", "ANATOMY", 106, 111]]], ["X-ray images are taken with a low resolution which may have a variable height to width ratio.", [["X-ray images", "TEST", 0, 12], ["a low resolution", "PROBLEM", 28, 44], ["a variable height to width ratio", "PROBLEM", 60, 92], ["low resolution", "OBSERVATION_MODIFIER", 30, 44], ["variable", "OBSERVATION_MODIFIER", 62, 70]]], ["In order to facilitate training and testing of the deep networks, necessary pre-processing steps like image cropping and resizing is performed.", [["deep networks", "MULTI-TISSUE_STRUCTURE", 51, 64], ["testing", "TEST", 36, 43], ["the deep networks", "TREATMENT", 47, 64], ["image cropping", "TREATMENT", 102, 116], ["deep", "ANATOMY_MODIFIER", 51, 55]]], ["In the proposed method, all input images are first converted to a standard size of 224 \u00d7 224 for a similar course of action in both the developed model.ArchitectureThe proposed framework for accurate prediction of COVID-19 using the chest X-ray images through deep feature learning model with SMOTE and machine learning classifiers consisted of the ResNet152 architecture for the training with later using the concerned features to classify the chest X-ray images using machine learning classifiers.", [["COVID-19", "DNA", 214, 222], ["SMOTE", "DNA", 293, 298], ["all input images", "TEST", 24, 40], ["COVID", "TEST", 214, 219], ["the chest X-ray images", "TEST", 229, 251], ["the training", "TREATMENT", 376, 388], ["the chest X-ray images", "TEST", 441, 463], ["machine learning classifiers", "TREATMENT", 470, 498], ["chest", "ANATOMY", 233, 238], ["deep", "ANATOMY_MODIFIER", 260, 264], ["chest", "ANATOMY", 445, 450]]], ["A detailed description of the architecture is explained below.Architecture\u2022 The X-ray images of COVID-19, Normal and Pneumonia infected patients were taken and resized into the size of 224x224.Architecture\u2022 A ResNet152 22 model was trained for the classification of Pneumonia and Normal patients.", [["Pneumonia infected", "DISEASE", 117, 135], ["Pneumonia", "DISEASE", 266, 275], ["COVID-19", "CELL", 96, 104], ["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 287, 295], ["The X-ray images", "TEST", 76, 92], ["COVID", "TEST", 96, 101], ["Pneumonia infected", "PROBLEM", 117, 135], ["Pneumonia", "PROBLEM", 266, 275], ["Normal", "OBSERVATION", 106, 112], ["Pneumonia", "OBSERVATION", 117, 126], ["size", "OBSERVATION_MODIFIER", 177, 181], ["Pneumonia", "OBSERVATION", 266, 275], ["Normal", "OBSERVATION", 280, 286]]], ["ResNet is known to be a better deep learning architecture as it is relatively easy to optimize and can attain higher accuracy.", [["Res", "CHEMICAL", 0, 3], ["known to be", "UNCERTAINTY", 10, 21]]], ["Due to a large number of layers in the network architecture, it has high time complexity.", [["layers", "TISSUE", 25, 31], ["network architecture", "MULTI-TISSUE_STRUCTURE", 39, 59], ["a large number of layers in the network architecture", "PROBLEM", 7, 59], ["large", "OBSERVATION_MODIFIER", 9, 14], ["number", "OBSERVATION_MODIFIER", 15, 21], ["layers", "OBSERVATION_MODIFIER", 25, 31], ["high time", "OBSERVATION_MODIFIER", 68, 77]]], ["This complexity can be reduced by utilizing a bottleneck design.", [["reduced", "OBSERVATION_MODIFIER", 23, 30]]], ["Further, there is always a problem of vanishing gradient, which is resolved using the skip connections in the network.", [["vanishing gradient", "PROBLEM", 38, 56], ["vanishing gradient", "OBSERVATION", 38, 56], ["resolved", "OBSERVATION_MODIFIER", 67, 75]]], ["Finally, the last fully connected (FC) layer of the network is followed by a Logarithmic Softmax layer with Adam optimizer to optimize the neural network.Architecture\u2022 After completion of the training process, the last three layers from the ResNet152 were replaced with a ReLU, an FC layer, and an output layer.", [["neural network", "ANATOMY", 139, 153], ["neural network", "MULTI-TISSUE_STRUCTURE", 139, 153], ["ResNet152", "DNA", 241, 250], ["a Logarithmic Softmax layer", "TREATMENT", 75, 102], ["Adam optimizer", "TREATMENT", 108, 122], ["the training process", "TREATMENT", 188, 208], ["an FC layer", "TREATMENT", 278, 289], ["an output layer", "TEST", 295, 310], ["neural network", "OBSERVATION", 139, 153], ["layers", "OBSERVATION_MODIFIER", 225, 231], ["FC", "OBSERVATION_MODIFIER", 281, 283], ["layer", "OBSERVATION_MODIFIER", 284, 289], ["output", "OBSERVATION_MODIFIER", 298, 304], ["layer", "OBSERVATION_MODIFIER", 305, 310]]], ["The input images are now passed through this modified network to obtain 1024 features for each image in the dataset.Architecture\u2022 Now, in the dataset, the number of data points for one class is very less when compared to the other class corresponding to the COVID-19 patients.", [["patients", "ORGANISM", 267, 275], ["patients", "SPECIES", 267, 275], ["The input images", "TEST", 0, 16], ["very", "OBSERVATION_MODIFIER", 194, 198], ["less", "OBSERVATION_MODIFIER", 199, 203]]], ["This algorithm creates an equal number of samples for each class.", [["samples", "CANCER", 42, 49], ["equal", "OBSERVATION_MODIFIER", 26, 31]]], ["The above method was incorporated to ensure the smooth working of many machine learning algorithms like Logistic Regression, Decision Tree, etc. which otherwise tends to be more biased towards a majority class.", [["many machine learning algorithms", "TREATMENT", 66, 98]]], ["The algorithm mentioned above generates virtual data points between existing points of the minority class by using linear interpolation.Architecture\u2022 After processing all the images and converting them into features and using SMOTE for intra-class variations, the next step involves fitting the dataset using different machine learning predictive classifiers.", [["SMOTE", "DNA", 226, 231], ["linear interpolation", "TREATMENT", 115, 135], ["all the images", "TEST", 167, 181], ["intra-class variations", "TEST", 236, 258]]], ["For this purpose, We have integrated Logistic Regression (LR) 25 , k-Nearest Neighbour (kNN) 26 , Decision Trees (DT) 27 , Random Forest (RF) 28 , Adaptive Boosting (AdaBoost) 29 , Naive Bayes (NB) 30 and XGBoost(XGB) 31 to classify the COVID-19, Normal, and Pneumonia (shown in the Table 2 ).Experimental SetupsWe have implemented the proposed classification system for COVID-19 diagnosis using Python 3.8 programming language with a processor of Intel R Core i5-8300H CPU @ 2.30GHz \u00d7 8 and RAM of 8 GB running on Windows 10 with NVIDIA Geforce GTX 1050 with 4GB Graphics.Evaluation criteria:To evaluate the efficacy of the model, the confusion matrix along with Area under Curve (AUC) 32 are estimated and gives an understanding of the proposed methodology and its potential for detailed classification.", [["Pneumonia", "DISEASE", 259, 268], ["NVIDIA Geforce GTX", "CHEMICAL", 531, 549], ["confusion", "DISEASE", 636, 645], ["integrated Logistic Regression (LR)", "TREATMENT", 26, 61], ["k-Nearest Neighbour (kNN)", "TREATMENT", 67, 92], ["Random Forest (RF)", "TREATMENT", 123, 141], ["Adaptive Boosting (AdaBoost)", "TREATMENT", 147, 175], ["Naive Bayes (NB)", "TREATMENT", 181, 197], ["XGBoost(XGB)", "TREATMENT", 205, 217], ["the COVID", "TEST", 233, 242], ["Pneumonia", "PROBLEM", 259, 268], ["COVID", "TEST", 371, 376], ["CPU", "TEST", 470, 473], ["NVIDIA Geforce GTX", "TREATMENT", 531, 549], ["the confusion matrix", "PROBLEM", 632, 652], ["Area under Curve", "TEST", 664, 680], ["Normal", "OBSERVATION", 247, 253], ["Pneumonia", "OBSERVATION", 259, 268]]], ["The classification of COVID-19 patients and Normal or Pneumonia patients and between Normal patients and Pneumonia is termed as Accuracy, Sensitivity, Specificity, and F1-score are represented mathematically in terms of confusion matrix as given in Equations 1, 2, 3, and 4, respectively.Evaluation criteria:Accuracy = T P + T N T P + FP + FN + T N (1) Sensitivity = T P T P + FNEvaluation criteria:(2)Evaluation criteria:Speci f icity = T N T N + FP (3)Evaluation criteria:where TP, TN, FP, and FN are True Positive, True Negative, False Positive, and False Negative, respectively.Evaluation criteria:1993 C C Z weigCONCLUSIONIn this work, we have presented the use of ResNet152 and machine learning classifiers for the effective classification of COVID-19.", [["Pneumonia", "DISEASE", 54, 63], ["Pneumonia", "DISEASE", 105, 114], ["confusion", "DISEASE", 220, 229], ["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 92, 100], ["TP", "GENE_OR_GENE_PRODUCT", 480, 482], ["FN", "PROTEIN", 340, 342], ["TP", "PROTEIN", 480, 482], ["TN", "PROTEIN", 484, 486], ["FP", "PROTEIN", 488, 490], ["FN", "PROTEIN", 496, 498], ["COVID-19", "DNA", 749, 757], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 92, 100], ["COVID", "TEST", 22, 27], ["Pneumonia", "PROBLEM", 54, 63], ["Pneumonia", "PROBLEM", 105, 114], ["Accuracy", "TEST", 128, 136], ["Sensitivity", "TEST", 138, 149], ["Specificity", "TEST", 151, 162], ["confusion matrix", "PROBLEM", 220, 236], ["Evaluation", "TEST", 288, 298], ["criteria", "TEST", 299, 307], ["Accuracy", "TEST", 308, 316], ["P", "TEST", 321, 322], ["T", "TEST", 325, 326], ["P", "TEST", 331, 332], ["FP", "TEST", 335, 337], ["FN", "TEST", 340, 342], ["Sensitivity", "TEST", 353, 364], ["Evaluation criteria", "TEST", 402, 421], ["Speci", "TEST", 422, 427], ["icity", "TEST", 430, 435], ["Evaluation criteria", "TEST", 454, 473], ["TP", "TEST", 480, 482], ["TN", "TEST", 484, 486], ["FP", "TEST", 488, 490], ["FN", "TEST", 496, 498], ["True", "TEST", 518, 522], ["False", "TEST", 533, 538], ["False", "TEST", 553, 558], ["Evaluation criteria", "TEST", 582, 601], ["COVID", "TEST", 749, 754], ["Normal", "OBSERVATION", 44, 50], ["Pneumonia", "OBSERVATION", 54, 63], ["Pneumonia", "OBSERVATION", 105, 114]]], ["We also encompassed the SMOTE algorithm for balancing the intra-class variation among the datasets.", [["the SMOTE algorithm", "TEST", 20, 39]]], ["With the SMOTE based features, machine learning algorithms are applied for final classification leading to the best result obtained by Random Forest with the Accuracy, Sensitivity, Specificity, F1-score and AUC of 0.973, 0.974, 0.986, 0.973, and 0.997 (for Random Forest) and 0.977, 0.977, 0.988, 0.977, and 0.998 (for XGBoost), respectively.", [["SMOTE", "DNA", 9, 14], ["the Accuracy", "TEST", 154, 166], ["Sensitivity", "TEST", 168, 179], ["Specificity", "TEST", 181, 192], ["AUC", "TEST", 207, 210]]], ["Therefore, this approach of using X-ray images and computer-aided diagnosis can be used as a massive, faster and cost-effective way of screening.", [["X-ray images", "TEST", 34, 46], ["screening", "TEST", 135, 144]]], ["Also, it brings down the time for testing drastically.", [["testing", "TEST", 34, 41]]], ["To make a clinically effective prediction of COVID-19, training with more massive datasets and testing in the field with a larger cohort can be immensely useful.", [["COVID-19", "DNA", 45, 53], ["COVID", "TEST", 45, 50], ["testing", "TEST", 95, 102]]]], "395788708e7535f045dcf9c91b6f852aff083e1d": [["We consider here the new model of manipulation in the spatial model.", [["new", "OBSERVATION_MODIFIER", 21, 24]]], ["The manipulability in the IC, IAC models is considered in [4] , and the manipulability in one-dimensional Downsian model is evaluated in [2] .", [["the manipulability", "TEST", 68, 86]]], ["For the spatial model, in [12] it is inferred, that least manipulable among the positional methods with any number of alternatives is the Borda rule, while the plurality rule is one of the most manipulable of the positional methods.Manipulability ModelIn the framework of the two-dimensional Downsian model [6] the profiles are generated, representing a set of preferences of agents.", [["agents", "TREATMENT", 376, 382], ["positional", "OBSERVATION_MODIFIER", 80, 90], ["positional", "OBSERVATION_MODIFIER", 213, 223]]], ["There are m alternatives, (m = 3, 4, or 5) and n ideal points of agents (n > 3) on the rectangle in the planar space.", [["planar space", "ANATOMY", 104, 116]]], ["The alternatives are ordered by proximity to the ideal point, the closest alternative is put on the first place, the next on the second place, etc., the farthest alternative is put on the last place.Manipulability ModelAfter positions of agents and alternatives are determined, agents can manipulate by reporting insincere preferences.", [["agents and alternatives", "TREATMENT", 238, 261]]], ["Agents can shift their ideal position in such a way that provides them better result of collective choice.", [["Agents", "TREATMENT", 0, 6]]], ["There are several different methods to do so.", [["several", "OBSERVATION_MODIFIER", 10, 17], ["different", "OBSERVATION_MODIFIER", 18, 27]]], ["First, the agent can only move its position inside the feasible area, in this case, a rectangle.", [["the agent", "TREATMENT", 7, 16], ["feasible", "OBSERVATION_MODIFIER", 55, 63], ["area", "OBSERVATION_MODIFIER", 64, 68]]], ["In the second version of manipulation, the agent's insincere position, in the case of going beyond the boundaries of the limited space, may not be permissible from the substantive considerations in terms of interpretations of the axes in space.", [["manipulation", "TREATMENT", 25, 37], ["the agent's insincere position", "TREATMENT", 39, 69], ["may not be", "UNCERTAINTY", 136, 146]]], ["In the third version of manipulation, the presentation of unacceptable preferences can be unambiguously recognized by other participants in the vote as manipulation.", [["participants", "SPECIES", 124, 136]]], ["Thus, in the evaluations, the first version of manipulation is considered.", [["the evaluations", "TEST", 9, 24]]], ["Tie-breaking situations and degenerated cases are not considered.Manipulability ModelIn the two-dimensional Downsian model, for example, for 3 alternatives, for the non-degenerated case, in the entire space, all orderings of the alternatives are feasible.", [["degenerated cases", "PROBLEM", 28, 45], ["the non-degenerated case", "PROBLEM", 161, 185], ["not considered", "UNCERTAINTY", 50, 64]]], ["However, if the agent for the purpose of manipulation is forced to move far beyond the boundaries of the considered limited space, usually a rectangle, then such orderings are not considered as the possible ones.Manipulability ModelLet us consider the example of manipulation for 3 alternatives, 4 agents, for the Leximin extension of preferences for the Minimal dominant set procedure.", [["3 alternatives", "TREATMENT", 280, 294], ["the Leximin extension of preferences", "TREATMENT", 310, 346], ["the Minimal dominant set procedure", "TREATMENT", 351, 385], ["Minimal", "OBSERVATION_MODIFIER", 355, 362], ["dominant", "OBSERVATION", 363, 371]]], ["Let the alternatives and agents are located on the planar space as shown on the left image of Fig. 1 .", [["agents", "TREATMENT", 25, 31], ["planar", "ANATOMY_MODIFIER", 51, 57], ["left", "ANATOMY_MODIFIER", 80, 84]]], ["Note that negative positions of the Y axis are also possible.Manipulability ModelLet agent Ag1 manipulate, shifting her position towards alternative b as shown on the right image of Fig. 1 .Manipulability ModelFor each agent, the ordering of alternatives is built by proximity to the ideal point of the agent.", [["Manipulability ModelLet agent", "TREATMENT", 61, 90], ["the agent", "TREATMENT", 299, 308], ["negative", "OBSERVATION", 10, 18], ["right", "ANATOMY_MODIFIER", 167, 172]]], ["For example, for Ag1, the ordering is as follows: c > b > a.", [["Ag1", "CHEMICAL", 17, 20], ["Ag1", "CHEMICAL", 17, 20], ["Ag1", "SIMPLE_CHEMICAL", 17, 20], ["Ag1", "PROTEIN", 17, 20]]], ["The profile consisting of the preferences of 4 agents for 3 alternatives is presented in Table 1 .Manipulability ModelThe majority relation matrix has the following form (see definition of the majority relation below).Manipulability ModelIn this matrix in Table 2 the number \"1\" means that the alternative b dominates the alternative a.", [["matrix", "CELLULAR_COMPONENT", 140, 146], ["matrix", "CELLULAR_COMPONENT", 246, 252]]], ["\"0\" means that the pair of alternatives does not dominate each other.Manipulability ModelThe choice according to the Minimal dominant set is {a, b, c} (see the definitions of the aggregation procedures below).", [["the aggregation procedures", "TREATMENT", 175, 201]]], ["If the ordering of the agent Ag1 according to sincere preferences was c > b > a, then after manipulating the agent reports the following ordering of alternatives b > c > a.", [["Ag1", "SIMPLE_CHEMICAL", 29, 32], ["the agent Ag1", "TREATMENT", 19, 32]]], ["The profile after manipulation of the agent Ag1 has the form ( Table 3) :Manipulability ModelThe corresponding majority relation matrix has the form Table 1 .", [["Ag1", "CHEMICAL", 44, 47], ["Ag1", "SIMPLE_CHEMICAL", 44, 47], ["matrix", "CELLULAR_COMPONENT", 129, 135], ["the agent", "TREATMENT", 34, 43]]], ["The profile for 3 alternatives, 4 agents for sincere positions on Fig. 1 Ag1 Ag2 Ag3 Ag4Manipulability Modela c c Table 2 .", [["3 alternatives", "TREATMENT", 16, 30]]], ["Majority matrix for the profile in Table 1 .Manipulability Modela b c a 0 0 0 b 1 0 0 c 0 0 0 Table 3 .", [["matrix", "CELLULAR_COMPONENT", 9, 15], ["Manipulability", "TEST", 44, 58], ["Modela", "TEST", 59, 65]]], ["Table 4 the number \"1\" means that the alternative in the row dominates the alternative in the column, that is b > a and b > c.", [["column", "ANATOMY", 94, 100]]], ["The number \"0\" means that there is no domination between the pair of the alternatives.Manipulability ModelThe choice made by the Minimal dominant set after manipulation by the agent Ag1 is {b}.Manipulability ModelIn accordance with the Leximin extension, for the Ag1 agent, the choice resulting from manipulation is more preferable than that with sincere preferences.", [["Ag1", "SIMPLE_CHEMICAL", 182, 185], ["{b}", "GENE_OR_GENE_PRODUCT", 189, 192], ["{b}", "PROTEIN", 189, 192], ["the Leximin extension", "TREATMENT", 232, 253], ["the Ag1 agent", "TREATMENT", 259, 272], ["Minimal", "OBSERVATION_MODIFIER", 129, 136], ["dominant", "OBSERVATION", 137, 145]]], ["Thus, the profile shown in Fig. 1 . is manipulable for the Minimum Dominant Set procedure, for the Leximin extension.Manipulability ModelManipulability is evaluated for the following aggregation procedures based on the majoritarian relation.Manipulability ModelMinimal The description of the procedures, except for the k-stable set rule, is given in [5] .", [["the Minimum Dominant Set procedure", "TREATMENT", 55, 89], ["the Leximin extension", "TREATMENT", 95, 116], ["aggregation procedures", "TREATMENT", 183, 205], ["the procedures", "TREATMENT", 288, 302], ["the k-stable set rule", "TEST", 315, 336]]], ["Different versions of the k-stable set were introduced in [3] .", [["the k-stable set", "TREATMENT", 22, 38]]], ["In [1] , extended preferences were introduced, in which many alternatives are ordered based on the singlevalued preferences of the agents.", [["the agents", "TREATMENT", 127, 137]]], ["To evaluate the degree of manipulability of aggregation procedures, the Nitzan -Kelly index is used, which was introduced in [7, 8] .", [["aggregation procedures", "TREATMENT", 44, 66], ["aggregation", "OBSERVATION", 44, 55]]], ["The index is defined asManipulability Modelwhere d 0 -number of manipulable profiles, d total -total number of profiles.The Aggregation ProceduresWe present definitions of the choice procedures, for which the degree of manipulability is evaluated.", [["The index", "TEST", 0, 9], ["the choice procedures", "TREATMENT", 172, 193], ["index", "OBSERVATION_MODIFIER", 4, 9]]], ["The Upper counter set of an alternative x in the relation P is the set D\u00f0x\u00de such that D\u00f0x\u00de \u00bc y 2 A yPx j f g .", [["P", "DNA", 58, 59], ["Upper counter", "OBSERVATION_MODIFIER", 4, 17]]], ["The Lower counter set of x in the relation P is the set L\u00f0x\u00de such that L\u00f0x\u00de \u00bc y 2 A xPy j f g .", [["P", "DNA", 43, 44], ["Lower", "OBSERVATION_MODIFIER", 4, 9]]], ["The alternative x belongs to the k-stable set for k = 1, 2, 3, if one of following two conditions hold: a) the alternative x is undominated by alternatives outside the k-stable set via majority relation l, or b) if 9y 6 2 kSS : ylx then 9z 1 ; . . .; z k , z 1 2 kSS and z 1 lz 2 l. . .z k ly.", [["k", "TEST", 50, 51], ["k", "TEST", 253, 254], ["z", "TEST", 257, 258], ["kSS", "TEST", 263, 266], ["z", "TEST", 271, 272], ["lz", "TEST", 275, 277], ["k ly", "TEST", 288, 292]]], ["In general, k = 1, 2, or 3.", [["k", "TEST", 12, 13]]], ["The k-stable set is minimal, if no proper subsets of it are k-stable.The Aggregation ProceduresIf there are several different k-stable sets, then the union is taken.", [["minimal", "OBSERVATION_MODIFIER", 20, 27], ["several", "OBSERVATION_MODIFIER", 108, 115], ["different", "OBSERVATION_MODIFIER", 116, 125]]], ["12. (kSSII) k-stable set II.The Aggregation ProceduresThe k-stable set II consists of the alternatives, that are not dominated by alternatives outside the set.", [["k-stable set II", "PROTEIN", 58, 73]]], ["And for each alternative outside the set, there is an alternative in the set, which dominates it via majority relation in not more than k steps. k steps here means that 9z 1 ; . . .; z k , z 1 2 kSS and z 1 lz 2 l. . .z k ly.Extended PreferencesFor the case of multiple choice, the sets of alternatives also should be compared as an extension to the agents' preferences.", [["k steps", "TEST", 145, 152], ["z k", "TEST", 183, 186], ["z", "TEST", 189, 190], ["kSS", "TEST", 195, 198], ["z", "TEST", 203, 204], ["lz", "TEST", 207, 209], ["k ly", "TEST", 220, 224], ["alternatives", "TREATMENT", 290, 302]]], ["For 3 alternatives, the extended preferences look as follows, (agent's single-valued ordering is assumed to be a > b > c):Extended Preferencesc f g 1 c f g For 4 alternatives let us preset one out of ten extensions (single-valued ordering of the agent is assumed to be a > b > c > d).Extended PreferencesPWorst (4 alts): The preference extensions are defined axiomatically.", [["the agent", "TREATMENT", 242, 251]]], ["Let us place alternatives and agents on the two-dimensional space.", [["alternatives", "TREATMENT", 13, 25], ["agents", "TREATMENT", 30, 36]]], ["Let us also construct a profile of preferences, in which each agent's ordering is induced by the distances of the alternatives to this agent.", [["this agent", "TREATMENT", 130, 140]]], ["Then we move the position of each agent individually within some area, not too far from the positions of the alternatives and other agents.", [["the alternatives", "TREATMENT", 105, 121], ["other agents", "TREATMENT", 126, 138]]], ["The changes in the profiles yield different choices, obtained via the aggregation procedures.", [["the aggregation procedures", "TREATMENT", 66, 92]]], ["If the result of such shift of the position is better for the agent, then the profile is manipulable.", [["the agent", "TREATMENT", 58, 67]]], ["The goal is to evaluate the share of such manipulable profiles for each aggregation procedure considered.The Scheme of CalculationThe calculation is performed in the following way.", [["each aggregation procedure", "TREATMENT", 67, 93], ["The calculation", "TEST", 130, 145]]], ["On the two-dimensional coordinate space, the rectangle, centered at the point [0; 0], with side X to side Y ratio 1:2 is defined.", [["side X to side Y ratio", "TREATMENT", 91, 113]]], ["The restricted rectangle area can be formally defined as set of points with coordinates 0 x 1 and \u00c01 y 1.The Scheme of CalculationThere are m alternatives (m = 3, 4, 5) and n agents (n = 4-20), even number, generated randomly with X coordinates from 0 to 1 and Y from \u22121 to 1.", [["The restricted rectangle area", "PROBLEM", 0, 29], ["restricted", "OBSERVATION_MODIFIER", 4, 14], ["rectangle", "OBSERVATION_MODIFIER", 15, 24]]], ["Without loss of generality we can assume that in any profile there are two alternatives that are farthest from each other, for example, a and e in the case of 5 alternatives, are placed in fixed positions: a in [0,0], and e in [1, 0] and all alternatives are sorted alphabetically along the X axe.", [["loss of generality", "PROBLEM", 8, 26]]], ["For the generated profile, the choice is calculated for each of the considered aggregation procedures.The Scheme of CalculationIndividual manipulation by agents is considered.", [["aggregation procedures", "TREATMENT", 79, 101]]], ["The evaluations are performed in the following way.", [["The evaluations", "TEST", 0, 15]]], ["For each agent individually, on the grid of L steps, the agent's manipulating point with the coordinates (lx, ly) for lx and ly with a step of 1/L is positioned.", [["1/L", "PROTEIN", 143, 146], ["the agent", "TREATMENT", 53, 62]]], ["The agent's insincere preferences are constructed, as if the manipulating point was the ideal point of the agent.", [["the agent", "TREATMENT", 103, 112]]], ["For a profile constructed in such a way with insincere preferences of the manipulating agent, the choice is evaluated according to all considered aggregation procedures.The Scheme of CalculationFor a manipulating agent, for each choice procedure, the choices obtained by sincere preferences and by insincere preferences are compared using all considered preferences extensions.", [["the manipulating agent", "TREATMENT", 70, 92], ["aggregation procedures", "TREATMENT", 146, 168], ["a manipulating agent", "TREATMENT", 198, 218], ["each choice procedure", "TREATMENT", 224, 245]]], ["(The results are presented for Leximin, Leximax, PWorst, and PBest extensions for 3 alternatives, for PWorst extension for 4 alternatives, and for Rank increasing power leximin for 5 alternatives.)", [["Leximin", "CHEMICAL", 31, 38], ["Leximin", "CHEMICAL", 31, 38], ["leximin", "CHEMICAL", 169, 176], ["Leximin", "SIMPLE_CHEMICAL", 31, 38], ["Leximin", "TREATMENT", 31, 38], ["Leximax", "TREATMENT", 40, 47], ["Rank increasing power leximin", "TREATMENT", 147, 176]]], ["If the collective choice obtained on the profile, which consists of insincere preferences of the manipulating agent is better for the manipulating agent than a choice obtained from the sincere preferences, then manipulation is considered to be a successful one for a given profile, a given rule and the type of extended preferences.The Scheme of CalculationFor each rule and extended preferences the number of manipulable profiles is calculated, and the Nitzan-Kelly manipulability index is calculated as the ratio of the number of manipulated profiles to the total number of generated profiles.Calculation ResultsFor even number of agents, the procedures MDS, F, US1, R, C1, C2 have high degree of manipulability for most extensions in the cases for 3, 4, and 5 alternatives.Calculation ResultsWe present the results of the evaluation of the degree of individual manipulability for 3, 4, and 5 alternatives in two-dimensional space for even number of agents from 4 to 20.", [["MDS", "DISEASE", 656, 659], ["the manipulating agent", "TREATMENT", 93, 115], ["Calculation", "TEST", 346, 357], ["the Nitzan-Kelly manipulability index", "TEST", 450, 487], ["agents", "TREATMENT", 633, 639], ["the procedures MDS", "TEST", 641, 659], ["US1", "TEST", 664, 667], ["high degree of manipulability", "PROBLEM", 684, 713], ["the evaluation", "TEST", 821, 835], ["C1", "ANATOMY", 672, 674], ["C2", "ANATOMY", 676, 678], ["high degree", "OBSERVATION_MODIFIER", 684, 695]]], ["For example, for 3 alternatives for the Leximin extension, it can be seen from the Fig. 2 . and Table 5 , that there are 3 groups of procedures with more or less same level of manipulability.", [["Leximin", "SIMPLE_CHEMICAL", 40, 47], ["the Leximin extension", "PROBLEM", 36, 57], ["procedures", "TREATMENT", 133, 143]]], ["The high-manipulable group consists of US1, R, and C2.", [["C2", "PROTEIN", 51, 53], ["US1, R, and C2", "PROBLEM", 39, 53], ["high", "OBSERVATION_MODIFIER", 4, 8], ["R", "ANATOMY_MODIFIER", 44, 45], ["C2", "ANATOMY", 51, 53]]], ["There are MDS and C1 procedures, which have middle level of manipulability for low number of agents and then their level of manipulability decreases.", [["MDS", "DISEASE", 10, 13], ["MDS and C1 procedures", "TREATMENT", 10, 31], ["manipulability", "TREATMENT", 60, 74], ["agents", "TREATMENT", 93, 99], ["MDS", "OBSERVATION", 10, 13], ["C1", "ANATOMY", 18, 20], ["procedures", "OBSERVATION", 21, 31], ["middle", "OBSERVATION_MODIFIER", 44, 50]]], ["The third group with small level of manipulability consists of MUS, MWSS, F, US2, C3, 1SS, 2SS, 3SS, and 1SSII, 2SSII, and 3SSII.Calculation ResultsLet us present the NK index for the rest of extended preferences, Leximax, PWorst, and PBest (Tables 6, 7 and 8).", [["NK", "ANATOMY", 167, 169], ["3SSII", "PROTEIN", 123, 128], ["MUS", "TEST", 63, 66], ["MWSS", "TEST", 68, 72], ["US2", "TEST", 77, 80], ["C3", "TEST", 82, 84], ["1SS", "TEST", 86, 89], ["2SS", "TEST", 91, 94], ["3SS", "TEST", 96, 99], ["1SSII", "TEST", 105, 110], ["2SSII", "TEST", 112, 117], ["small", "OBSERVATION_MODIFIER", 21, 26]]], ["NK index, 3 alts, Leximax.", [["NK", "ANATOMY", 0, 2], ["NK", "CELL", 0, 2], ["NK index", "TEST", 0, 8], ["Leximax", "TREATMENT", 18, 25]]], ["NK index, 3 alts, PWorst.", [["NK", "ANATOMY", 0, 2], ["NK", "CELL", 0, 2], ["NK index", "TEST", 0, 8]]], ["NK index, 4 alts, PWorst.", [["NK", "ANATOMY", 0, 2], ["NK", "CELL", 0, 2], ["NK index", "TEST", 0, 8]]], ["For 5 alternatives, the same procedures: MUS, MWSS, F, US2, C3, 1SS, 2SS, 3SS, 1SSII, 2SSII, 3SSII show low level of manipulability (Table 10 , Fig. 4 ).ConclusionWe have considered a new model of manipulability of main majoritarian procedures in the Downsian model with extended preferences and show that almost all of them in this model have rather low level of manipulability.", [["US2", "TEST", 55, 58], ["1SS", "TEST", 64, 67], ["2SS", "TEST", 69, 72], ["3SS", "TEST", 74, 77], ["1SSII", "TEST", 79, 84], ["2SSII", "TEST", 86, 91], ["low level of manipulability", "PROBLEM", 104, 131], ["main majoritarian procedures", "TREATMENT", 215, 243], ["new", "OBSERVATION_MODIFIER", 184, 187]]], ["It is interesting to note that the following procedures have the level of manipulability close to minimum: Minimal Undominated Set, Minimal Weakly Stable Set, Fishburn's rule, Uncovered Set II, k-stable set, and kstable set II, for k = 1, 2, 3.", [["kstable set II", "PROTEIN", 212, 226], ["Fishburn's rule", "TEST", 159, 174], ["k", "TEST", 232, 233], ["Minimal", "OBSERVATION_MODIFIER", 132, 139], ["stable", "OBSERVATION_MODIFIER", 196, 202]]], ["In the current model the rectangle area of feasible points of alternatives and agents is restricted in y coordinates by \u00c01 y 1.", [["alternatives and agents", "TREATMENT", 62, 85], ["rectangle", "OBSERVATION_MODIFIER", 25, 34], ["area", "OBSERVATION_MODIFIER", 35, 39]]], ["It would be interesting to evaluate the sensitivity of the manipulability level depending on the size of the area.", [["the manipulability level", "TEST", 55, 79], ["size", "OBSERVATION_MODIFIER", 97, 101]]]], "219a8d40ca6546e36097a4e85f58acc98e00c1d8": [["CommentaryCoronavirus disease 2019 (COVID-19), the disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is spreading globally with over 206 countries and territories affected 1,051,635 confirmed cases, and 56,985 deaths recorded as of 4th April 2020 [1] .", [["Coronavirus disease", "DISEASE", 10, 29], ["COVID-19", "CHEMICAL", 36, 44], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 80, 118], ["deaths", "DISEASE", 244, 250], ["SARS-CoV-2", "ORGANISM", 122, 132], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 73, 132], ["CommentaryCoronavirus disease", "PROBLEM", 0, 29], ["COVID", "TEST", 36, 41], ["the disease", "PROBLEM", 47, 58], ["the Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 69, 118], ["SARS", "TEST", 122, 126], ["CoV", "TEST", 127, 130], ["Coronavirus disease", "OBSERVATION", 10, 29], ["disease", "OBSERVATION", 51, 58], ["Severe", "OBSERVATION_MODIFIER", 73, 79], ["Acute", "OBSERVATION_MODIFIER", 80, 85], ["Respiratory Syndrome", "OBSERVATION", 86, 106]]], ["Following rapid expansion, the World Health Organization (WHO) declared COVID-19 a pandemic on March 11th.", [["rapid", "OBSERVATION_MODIFIER", 10, 15], ["expansion", "OBSERVATION_MODIFIER", 16, 25]]], ["As the world mobilizes to support the WHO declaration of COVID-19 a Public Health Emergency, and subsequently struggles to manage the rapid emergence of the infection, scientists and public health experts are raising a serious alarm about the catastrophic effects that an outbreak in Africa could have, given that public health systems throughout Africa are weak and most of the continent lacks the global health security capabilities and social protection infrastructure necessary to adequately respond and manage outbreaks and the cascade of subsequent effects on society, in particular the most vulnerable sections.", [["sections", "ANATOMY", 609, 617], ["infection", "DISEASE", 157, 166], ["sections", "MULTI-TISSUE_STRUCTURE", 609, 617], ["the infection", "PROBLEM", 153, 166], ["a serious alarm", "PROBLEM", 217, 232], ["the catastrophic effects", "PROBLEM", 239, 263], ["weak", "PROBLEM", 358, 362], ["social protection infrastructure", "TREATMENT", 439, 471], ["infection", "OBSERVATION", 157, 166]]], ["History has taught us how new pathogens emerge randomly and cause outbreaks with global impact and the celebration of the 100th anniversary of the Spanish Flu pandemic in 2018 that infected 500 million people, resulting in over 100 million death around the world was a painful reminder.", [["Flu", "CHEMICAL", 155, 158], ["death", "DISEASE", 240, 245], ["people", "ORGANISM", 202, 208], ["people", "SPECIES", 202, 208], ["a painful reminder", "TREATMENT", 267, 285]]], ["Since then, the world has not seen a public health emergency of that scale, although the West African Ebola outbreak in 2014 was evidence that the planet remains vulnerable, and we are not aware of when and where the next global pandemic will occur.CommentaryThe original situation in China became a global concern, with the immediate and future health of more than 7 billion people now at stake and the gains made over recent decades in development and prosperity now at risk of being undermined unless interstate coordination is strengthened to contain the epidemic.", [["Ebola", "DISEASE", 102, 107], ["people", "ORGANISM", 376, 382], ["people", "SPECIES", 376, 382]]], ["The UN is an intergovernmental organization tasked with maintaining international peace and security as well as the development of friendly relationships among nations.", [["intergovernmental organization", "OBSERVATION", 13, 43]]], ["In the constitutive act of the AU, member states recognized the need for addressing the negative impact of diseases by adopting and implementing strategic policies to reduce the burden and improve public health in Africa [3] .", [["diseases", "PROBLEM", 107, 115], ["strategic policies", "TREATMENT", 145, 163], ["the burden", "PROBLEM", 174, 184]]], ["Concerned by Africa\u00b4s increasing disease burden, the AU established health institutions to ensure that member states develop and sustainably manage their health sectors by putting in place programs to support the training of health professionals, public health preparedness, and adequate response to emergencies and disease epidemics in the continent.", [["increasing disease burden", "PROBLEM", 22, 47], ["disease epidemics", "PROBLEM", 316, 333], ["increasing", "OBSERVATION_MODIFIER", 22, 32], ["disease", "OBSERVATION", 33, 40]]], ["As a technical guide, the AU developed the Africa Health Strategy 2016-2030 aligned with the international health regulations and aimed to steer member States [4] .CommentaryA stronger, more forward-looking interstate collaboration was achieved during the West Africa Ebola virus disease epidemic, where nations worldwide joined hands to support and contain the epidemic.", [["Ebola virus disease", "DISEASE", 268, 287], ["West Africa Ebola virus", "ORGANISM", 256, 279], ["Ebola virus", "SPECIES", 268, 279], ["West Africa Ebola virus", "SPECIES", 256, 279], ["Ebola virus disease epidemic", "PROBLEM", 268, 296], ["epidemic", "OBSERVATION_MODIFIER", 362, 370]]], ["In Africa, AU member states through the Peace and Security Council and the executive committee established the African Union Support to the Ebola Outbreak in West Africa (ASEOWA) tasked to assist the outbreak in Sierra Leone, Guinea and Liberia.", [["Ebola", "DISEASE", 140, 145]]], ["Based on the achievement of ASEOWA, the Africa Centres for Disease Control and Prevention (Africa CDC) was established in 2017 as the first public health institute mandated to harmonize infectious diseases capacity building, surveillance, and response to emergencies among a group of independent countries [5, 6] .", [["infectious diseases", "DISEASE", 186, 205], ["the Africa Centres", "TREATMENT", 36, 54], ["Disease Control", "TREATMENT", 59, 74]]], ["With the fallout from Ebola serving as a powerful lesson, the Africa CDC activated straight away its Emergency Operations Centre (EOC) and its Incident Management System (IMS) for the COVID-19 outbreak on 27 January 2020 to step-up with health authorities of AU member states protocols and implement emergency preparedness procedures.", [["Ebola", "DISEASE", 22, 27], ["Ebola", "ORGANISM", 22, 27], ["the COVID", "TEST", 180, 189], ["emergency preparedness procedures", "TREATMENT", 300, 333], ["fallout", "OBSERVATION", 9, 16]]], ["Africa CDC initial action was the selection together with WHO of 13 member states as high priority based on the volume of travel from China including Algeria, Angola, Ivory Coast, the Democratic Republic of the Congo, Ethiopia, Ghana, Kenya, Mauritius, Nigeria, South Africa, Tanzania, Uganda, and Zambia.", [["Tanzania", "TREATMENT", 276, 284]]], ["Subsequent activities implemented were the training of laboratory personnel across 27 countries and the distribution of test kits, infection prevention and control training for 22 countries, and Trainingof-Trainers events on points-of-entry surveillance for 18 countries [7] .CommentaryThe Bill & Melinda Gates Foundation and the Skoll Foundation announced a commitment of $12 million to the Africa CDC to help African nations scale up preparedness for a potential spread of SARS-CoV-2.", [["infection", "DISEASE", 131, 140], ["SARS", "DISEASE", 475, 479], ["SARS-CoV-2", "ORGANISM", 475, 485], ["SARS-CoV", "SPECIES", 475, 483], ["test kits", "TEST", 120, 129], ["infection prevention", "TREATMENT", 131, 151], ["control training", "TREATMENT", 156, 172]]], ["This includes funding for \"technical support to implement the screening and treatment of suspected cases, laboratory confirmation of 2019-nCoV diagnoses, and the safe isolation and care of identified cases.\"", [["the screening", "TEST", 58, 71], ["laboratory confirmation", "TEST", 106, 129], ["the safe isolation", "TREATMENT", 158, 176]]], ["An additional donation of 5.4 million face masks, more than 1 million testing kits, 40,000 items of protective clothing and 60,000 sets of face shields by the Jack Ma and Alibaba Foundations has consolidated emergency response and preparedness actions towards implementation of the Africa joint continental strategy for COVID-19 led by the AU through Africa CDC [8, 9] .", [["5.4 million face masks", "TREATMENT", 26, 48], ["protective clothing", "TREATMENT", 100, 119], ["face shields", "TREATMENT", 139, 151], ["the Africa joint continental strategy", "TREATMENT", 278, 315], ["COVID", "TEST", 320, 325]]], ["COVID-19 outbreak represents Africa CDC\u00b4s second complex health challenge alongside the ongoing Ebola and measles outbreaks in DR Congo.", [["Ebola and measles outbreaks", "DISEASE", 96, 123], ["Ebola", "ORGANISM", 96, 101], ["COVID", "TEST", 0, 5]]], ["However, the extraordinary commitment and intensive cross-continent coordination with sister organizations such as the US CDC, European CDC, China CDC, WHO, among others has enabled Africa CDC to adequately contain confirmed cases so far of COVID-19 disease reported in all African countries except in Sao Tome and Principe, Comoros, Lesotho, and South Sudan currently uninfected by COVID-19 [7] .CommentaryHow long this position can be maintained remains to be seen.", [["the US CDC", "TEST", 115, 125], ["COVID-19 disease", "PROBLEM", 241, 257], ["extraordinary", "OBSERVATION_MODIFIER", 13, 26], ["commitment", "OBSERVATION_MODIFIER", 27, 37]]], ["The infectiousness, fatality rate, and transmission patterns of SARS-CoV-2 in Africa are uncertain and the current fatality rate appears to be approximately 2 percent.", [["SARS", "DISEASE", 64, 68], ["SARS-CoV-2", "ORGANISM", 64, 74], ["CoV-2", "SPECIES", 69, 74], ["SARS-CoV", "SPECIES", 64, 72], ["The infectiousness", "PROBLEM", 0, 18], ["fatality rate", "TEST", 20, 33], ["SARS", "PROBLEM", 64, 68], ["CoV", "TEST", 69, 72], ["infectiousness", "OBSERVATION", 4, 18]]], ["By comparison, the outbreaks of Ebola and measles still ongoing in DR Congo have, respectively, fatality rates of over 60 and over 90 percent.", [["Ebola", "DISEASE", 32, 37], ["measles", "DISEASE", 42, 49], ["Ebola", "ORGANISM", 32, 37], ["Ebola", "PROBLEM", 32, 37], ["measles", "PROBLEM", 42, 49], ["fatality rates", "TEST", 96, 110], ["Ebola", "OBSERVATION", 32, 37]]], ["However, as we witness the rapid spread of SARS-CoV-2 across increasingly diverse and large parts of the world\u00b4s population, within countries with greater resource and organizational capacity to draw upon than most in Africa, and despite radical restrictions on population movement, we can only brace ourselves and demand extensive planning based on evidence and pre-mobilization of the resource.", [["SARS", "DISEASE", 43, 47], ["SARS-CoV", "SPECIES", 43, 51], ["SARS", "PROBLEM", 43, 47], ["organizational capacity", "PROBLEM", 168, 191], ["radical restrictions", "TREATMENT", 238, 258], ["demand extensive planning", "TREATMENT", 315, 340], ["large", "OBSERVATION_MODIFIER", 86, 91], ["radical", "OBSERVATION", 238, 245]]], ["The secondary effects on society in the most affected countries, of extensive steps being taken to prevent further spread, are also become increasingly apparent.", [["extensive steps", "TREATMENT", 68, 83], ["secondary", "OBSERVATION_MODIFIER", 4, 13], ["effects", "OBSERVATION_MODIFIER", 14, 21]]], ["It is to be hoped that the additional time our governments and populations have had to prepare and raise awareness, will translate into more managed outbreaks; but given the fragility of our health systems, it is hard to foresee how any level of a surge in demand for high-intensity health care will be accommodated.CommentaryWhile the virus has stretched the resources of industrialized nations in Europe and the US to breaking point, in a globalized world, the case needs to urgently be made for richer countries to look beyond their pressing domestic needs and pragmatically support the response in Africa as their own.", [["high-intensity health care", "TREATMENT", 268, 294], ["the virus", "PROBLEM", 332, 341], ["virus", "OBSERVATION", 336, 341]]], ["In the midst of the uncertainly and deep concern about how African states will cope with epidemic SARS-CoV-2, there is perhaps one note of cautious optimism for life beyond the present.", [["SARS", "DISEASE", 98, 102], ["SARS-CoV", "SPECIES", 98, 106], ["epidemic SARS", "PROBLEM", 89, 102]]], ["Fear about the virus is widespread, and it may be that some of the long-standing messages about simple measures to reduce the spread of disease, such as hand washing, may finally be absorbed and become more universally adopted by health workers and the public.", [["hand", "ANATOMY", 153, 157], ["the virus", "PROBLEM", 11, 20], ["simple measures", "TREATMENT", 96, 111], ["disease", "PROBLEM", 136, 143], ["hand washing", "TREATMENT", 153, 165], ["virus", "OBSERVATION", 15, 20], ["disease", "OBSERVATION", 136, 143]]], ["Is it possible that regardless of the terrible threat posed by SARS-CoV-2, the increased adoption of these health protection measures may also result in a reduction in the spread of other infections that have blighted our populations for too long?", [["SARS", "DISEASE", 63, 67], ["infections", "DISEASE", 188, 198], ["SARS-CoV-2", "ORGANISM", 63, 73], ["SARS-CoV", "SPECIES", 63, 71], ["these health protection measures", "TREATMENT", 101, 133], ["other infections", "PROBLEM", 182, 198], ["increased", "OBSERVATION_MODIFIER", 79, 88]]], ["The establishment of Africa CDC was an unprecedented move toward strengthening national responses enabling countries to adequately respond to a potential outbreak in Africa and identify threats early enough, respond effectively, while combating infectious diseases burden including HIV/AIDS, TB, and Malaria, among others.", [["infectious diseases", "DISEASE", 245, 264], ["HIV/AIDS", "DISEASE", 282, 290], ["TB", "DISEASE", 292, 294], ["Malaria", "DISEASE", 300, 307], ["HIV", "SPECIES", 282, 285], ["HIV", "SPECIES", 282, 285], ["infectious diseases burden", "PROBLEM", 245, 271], ["HIV/AIDS", "PROBLEM", 282, 290], ["TB", "PROBLEM", 292, 294], ["Malaria", "PROBLEM", 300, 307], ["Malaria", "OBSERVATION", 300, 307]]], ["We are now in a period that will test the robustness of our capacity to respond in a way seldom seen before, and the willingness of richer nations to support us do so, in the interests of the global community.", [["our capacity", "PROBLEM", 56, 68]]]], "785cea04eb686e58dd7717123958a26d6add3045": [["En esa misma fecha se hab\u00eda identificado al menos un caso confirmado de Covid-19 en un total de 30 centros asistidos en el condado de King.ResumenConclusiones: En el contexto del r\u00e1pido aumento de los brotes de Covid-19, se necesitan medidas proactivas por parte de las residencias geri\u00e1tricas para identificar y excluir al personal y a los visitantes potencialmente infectados, vigilar activamente a los pacientes potencialmente infectados y aplicar medidas apropiadas de prevenci\u00f3n y control de la infecci\u00f3n para evitar la introducci\u00f3n del Covid-19.ComentarioEn el momento en que escribimos estas l\u00edneas, 5 de abril de 2020, cerca de 4000 personas residentes en centros geri\u00e1tricos en Espa\u00f1a han fallecido por el nuevo coronavirus causante del s\u00edndrome respiratorio agudo severo SARS-CoV-2, y cerca de 7000 est\u00e1n contagiadas.", [["del s\u00edndrome", "TEST", 742, 754], ["respiratorio", "TEST", 755, 767], ["severo SARS", "PROBLEM", 774, 785]]], ["El impacto del brote de COVID-19 est\u00e1 siendo dram\u00e1tico en una poblaci\u00f3n que, por distintas circunstancias individuales y ambientales, es altamente vulnerable 1,2 .", [["COVID", "TEST", 24, 29]]], ["El COVID-19 puede propagarse r\u00e1pidamente en las residencias de mayores, como se muestra en el art\u00edculo elegido.ComentarioLas personas con enfermedades cr\u00f3nicas tienen mayor riesgo de experimentar la infecci\u00f3n por COVID-19 en su forma m\u00e1s severa.", [["ComentarioLas personas con enfermedades cr\u00f3nicas tienen mayor riesgo de experimentar la infecci\u00f3n por COVID-19 en su forma m\u00e1s severa", "SPECIES", 111, 244], ["El COVID", "TEST", 0, 8]]], ["Ello se debe a varias causas: a un espacio vital que, en ocasiones, puede estar saturado con pocos metros por habitante; a una ventilaci\u00f3n inadecuada y una higiene deficiente si se compara con las medidas higi\u00e9nicas recomendadas para hacer frente al COVID-19 (por ejemplo, la fijaci\u00f3n de este coronavirus en objetos met\u00e1licos como andadores y objetos de pl\u00e1stico de uso compartido); y a la falta de un personal cualificado para el control de la infecci\u00f3n y, en particular, para prevenir la transmisi\u00f3n del COVID-19.ComentarioPor otra parte, las personas residentes en geri\u00e1tricos, debido a su fragilidad y comorbilidades, suelen frecuentar los servicios de salud, incluidos los hospitalarios, aumentando as\u00ed su riesgo de exposici\u00f3n a los agentes infecciosos presentes en estas instituciones.", [["Comentario", "CHEMICAL", 515, 525], ["Comentario", "SPECIES", 515, 525], ["la fijaci\u00f3n de este coronavirus en objetos", "TREATMENT", 273, 315]]], ["En Espa\u00f1a, en 2019, el 72,8% de las residencias de mayores eran privadas frente a un 27,2% de residencias p\u00fablicas, siendo en su mayor\u00eda residencias sociales no asistidas, a diferencia de las recogidas en el art\u00edculo seleccionado 5 .", [["asistidas", "PROBLEM", 161, 170]]], ["Estos factores puedan haber agravado el impacto del COVID-19 en las residencias de nuestro entorno, unido a la falta de recursos b\u00e1sicos para el control de infecciones como los equipos de protecci\u00f3n individual (EPIs) y de tests para la detecci\u00f3n y el seguimiento activo de las personas infectadas.", [["COVID", "TEST", 52, 57], ["a la falta de recursos", "TREATMENT", 106, 128], ["para el control", "TREATMENT", 137, 152]]], ["Teniendo en cuenta todos estos factores se podr\u00eda explicar c\u00f3mo a partir de un caso \u00edndice, ya sea residente, profesional o visitante, pueden producirse J o u r n a l P r e -p r o o f numerosos casos secundarios y fallecimientos.", [["numerosos", "PROBLEM", 184, 193]]], ["Por ello, el art\u00edculo seleccionado es un ejemplo para considerar.ComentarioLa experiencia descrita en el art\u00edculo permite entender aspectos del esfuerzo epidemiol\u00f3gico, y de las tareas de prevenci\u00f3n y control que actualmente se llevan a cabo en la tarea de contener y resolver la situaci\u00f3n que nos ocupa.", [["a cabo en la tarea", "TREATMENT", 235, 253]]], ["Entre las acciones fundamentales figuran: \uf0a7 La aplicaci\u00f3n de medidas detecci\u00f3n de s\u00edntomas, y de restricci\u00f3n para visitantes y personal no esencial. \uf0a7 La detecci\u00f3n activa de infecci\u00f3n sintom\u00e1tica en el personal, incluyendo la medici\u00f3n y documentaci\u00f3n de la temperatura corporal y la determinaci\u00f3n de los s\u00edntomas respiratorios para identificar y excluir a los trabajadores sintom\u00e1ticos. \uf0a7 La vigilancia de s\u00edntomas en los residentes, prestando especial atenci\u00f3n a los ancianos con pluripatolog\u00edas, alta dependencia, demencias y deterioro cognitivo, en los cabe la presencia de signos inespec\u00edficos como reducci\u00f3n del estado de alerta, reducci\u00f3n del movimiento, diarrea y sintomatolog\u00eda como ansiedad, irritabilidad, nerviosismo agitaci\u00f3n o retraimiento 6 . \uf0a7 Las medidas anteriores de detecci\u00f3n de casos hacen referencia a, un escenario, como el que nos enfrentamos, en el que existe escasez de tests espec\u00edficos de detecci\u00f3n.", [["irritabilidad", "PROBLEM", 701, 714]]], ["Si se dispone de estos recursos se deber\u00edan utilizar para la detecci\u00f3n y seguimiento de casos, y facilitar\u00eda la identificaci\u00f3n de personas infectadas por COVID-19 pero asintom\u00e1ticas que constituyen un problema importante en estas instituciones y en la comunidad en general. \uf0a7 El distanciamiento social, incluida la restricci\u00f3n del movimiento de residentes y las actividades de grupo.Comentario\uf0a7 Considerar, adem\u00e1s, el efecto que medidas como el distanciamiento, el confinamiento y la restricci\u00f3n de visitas puede tener sobre a la salud mental de los residentes, buscando alternativas viables para mantener el bienestar emocional. \uf0a7 La desinfecci\u00f3n de los dispositivos compartidos tras su uso, as\u00ed como enfatizar en la limpieza minuciosa y desinfecci\u00f3n personal (lavado de manos) y del entorno. \uf0a7 La capacitaci\u00f3n del personal en el control de infecciones y el uso de EPI. \uf0a7 El establecimiento de planes para hacer frente a la escasez de recursos de detecci\u00f3n y de protecci\u00f3n frente al COVID-19 y la necesaria coordinaci\u00f3n con los servicios de apoyo y autoridades competentes informando de todos los casos sospechosos o confirmados. \uf0a7 Es imprescindible considerar las pautas que las autoridades sanitarias establecen en las que se desarrollan y detallan las medidas anteriormente se\u00f1aladas.", [["Si", "CHEMICAL", 0, 2], ["La capacitaci\u00f3n del personal en el control", "TREATMENT", 796, 838]]], ["Si bien contamos con protocolos para prevenir el contagio, detectar a quienes se hayan contagiado, ofrecer el mejor cuidado a quienes lo precisan y contar con medidas de evacuaci\u00f3n a centros sanitarios a quienes as\u00ed lo requieran, es fundamental conocerlos, aplicarlos y asegurar que se usan.", [["Si", "CHEMICAL", 0, 2]]]], "PMC4036761": [["The StudyOn November 3, 2013, the Ministry of Health of Saudi Arabia was notified of a suspected case of MERS-CoV infection in a 43-year-old male patient at King Abdulaziz University Hospital in Jeddah.", [["MERS-CoV infection", "DISEASE", 105, 123], ["MERS-CoV", "ORGANISM", 105, 113], ["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["MERS-CoV", "SPECIES", 105, 113], ["MERS", "PROBLEM", 105, 109], ["CoV infection", "PROBLEM", 110, 123], ["CoV", "OBSERVATION_MODIFIER", 110, 113], ["infection", "OBSERVATION", 114, 123]]], ["The patient had cared for ill camels in his herd of 9 animals starting in early October, when the patient noted respiratory signs of illness with nasal discharge in several animals; he continued caring for the sick animals until October 27, the day of onset of his own illness.", [["respiratory", "ANATOMY", 112, 123], ["nasal", "ANATOMY", 146, 151], ["illness", "DISEASE", 133, 140], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 98, 105], ["nasal", "ORGANISM_SUBDIVISION", 146, 151], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 98, 105], ["respiratory signs of illness", "PROBLEM", 112, 140], ["nasal discharge", "PROBLEM", 146, 161], ["his own illness", "PROBLEM", 261, 276]]], ["The patient cared for the animals for \u22483 hours per day 3 days per week, applying herbal remedies to the animals\u2019 snouts and nostrils.", [["nostrils", "ANATOMY", 124, 132], ["patient", "ORGANISM", 4, 11], ["nostrils", "ORGANISM_SUBDIVISION", 124, 132], ["patient", "SPECIES", 4, 11], ["herbal remedies", "TREATMENT", 81, 96], ["nostrils", "ANATOMY", 124, 132]]], ["He did not clean the stables or milk the animals, but he routinely consumed raw, unpasteurized camel milk from the herd.The StudyPresence of MERS-CoV RNA in the patient was confirmed at Jeddah Regional Laboratory by using reverse transcription PCR (RT-PCR) targeting the upE and orfA gene fragments (11,12).", [["milk", "ORGANISM_SUBSTANCE", 32, 36], ["camel", "ORGANISM", 95, 100], ["milk", "ORGANISM_SUBSTANCE", 101, 105], ["herd", "ORGANISM_SUBDIVISION", 115, 119], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 141, 149], ["patient", "ORGANISM", 161, 168], ["upE", "GENE_OR_GENE_PRODUCT", 271, 274], ["orfA", "GENE_OR_GENE_PRODUCT", 279, 283], ["MERS-CoV RNA", "RNA", 141, 153], ["upE and orfA gene fragments", "DNA", 271, 298], ["camel", "SPECIES", 95, 100], ["patient", "SPECIES", 161, 168], ["camel", "SPECIES", 95, 100], ["MERS-CoV", "SPECIES", 141, 149], ["reverse transcription PCR", "TEST", 222, 247], ["RT-PCR", "TEST", 249, 255], ["the upE and orfA gene fragments", "PROBLEM", 267, 298], ["CoV RNA", "OBSERVATION", 146, 153], ["upE", "OBSERVATION_MODIFIER", 271, 274], ["gene fragments", "OBSERVATION", 284, 298]]], ["Respiratory swab specimens yielded detectable signal after 28 RT-PCR cycles, indicative of an approximate viral load of 350,000 RNA copies per sample.", [["Respiratory swab specimens", "ANATOMY", 0, 26], ["Respiratory swab specimens", "TEST", 0, 26], ["28 RT-PCR cycles", "TEST", 59, 75]]], ["A nearly complete viral genome was obtained (Jeddah_1_2013; GenBank accession no. KJ556336), confirming the presence of a typical MERS-CoV whose closest relatives were in the Riyadh_3 clade, as defined in (2) (phylogeny shown in online Technical Appendix Figure 1, wwwnc.cdc.gov/EID/article/20/6/14-0402-Techapp1.pdf).The StudyTo identify potential sources of infection, on November 9, the Ministry of Health investigated 5 close household contacts and the animal attendant on a farm owned by the patient.", [["infection", "DISEASE", 360, 369], ["MERS-CoV", "ORGANISM", 130, 138], ["patient", "ORGANISM", 497, 504], ["viral genome", "DNA", 18, 30], ["MERS-CoV", "DNA", 130, 138], ["Riyadh_3 clade", "DNA", 175, 189], ["wwwnc.cdc.gov/EID/article/20/6/14-0402-Techapp1.pdf", "DNA", 265, 316], ["patient", "SPECIES", 497, 504], ["MERS-CoV", "SPECIES", 130, 138], ["A nearly complete viral genome", "PROBLEM", 0, 30], ["The Study", "TEST", 318, 327], ["infection", "PROBLEM", 360, 369], ["viral genome", "OBSERVATION", 18, 30], ["infection", "OBSERVATION", 360, 369]]], ["Nasopharyngeal swab samples were taken and tested at Jeddah Regional Laboratory by using RT-PCR.", [["Nasopharyngeal swab samples", "ANATOMY", 0, 27], ["Nasopharyngeal swab samples", "ORGANISM_SUBSTANCE", 0, 27], ["Nasopharyngeal swab samples", "TEST", 0, 27], ["RT-PCR", "TEST", 89, 95]]], ["Deep nasal swab specimens were taken on the same day from 3 of the 9 camels at the farm.", [["nasal swab specimens", "ANATOMY", 5, 25], ["nasal swab specimens", "ORGANISM_SUBSTANCE", 5, 25], ["Deep nasal swab specimens", "TEST", 0, 25], ["nasal", "ANATOMY", 5, 10]]], ["Testing of all samples by RT-PCR using the upE assay (11,12) did not detect MERS-CoV RNA in any of the human patients, but 1 of the 3 camels (camel G) tested positive (cycle threshold [Ct] = 33).", [["samples", "ANATOMY", 15, 22], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 76, 84], ["human", "ORGANISM", 103, 108], ["patients", "ORGANISM", 109, 117], ["camels", "ORGANISM", 134, 140], ["MERS-CoV RNA", "RNA", 76, 88], ["human", "SPECIES", 103, 108], ["patients", "SPECIES", 109, 117], ["MERS-CoV", "SPECIES", 76, 84], ["human", "SPECIES", 103, 108], ["all samples", "TEST", 11, 22], ["RT", "TEST", 26, 28], ["PCR", "TEST", 29, 32], ["the upE assay", "TEST", 39, 52], ["CoV RNA", "PROBLEM", 81, 88], ["Ct", "TEST", 185, 187]]], ["On November 13, nasal swab samples were obtained from all 9 animals. upE RT-PCR results were positive for camel G (Ct = 38) and a second camel (camel B; Ct = 39).The StudySamples from November 13 and a small remaining amount of RNA extract from camel G from November 9 were sent to the Sanger Institute in Cambridge, UK, and confirmation of reactivity (Ct \u2248 38) was obtained for pooled samples with the upE assay from camel G but not for camel B. The result for camel G was confirmed at the Institute of Virology in Bonn, Germany, for the same samples by using real-time RT-PCRs targeting the upE and 1A diagnostic target regions.The StudyA sequence of \u224815% of the camel-derived genome was determined from 8 RT-PCR fragments, 2 of them partially overlapping (4,608 nt total) (13).", [["nasal swab samples", "ANATOMY", 16, 34], ["samples", "ANATOMY", 386, 393], ["samples", "ANATOMY", 544, 551], ["nasal swab samples", "ORGANISM_SUBSTANCE", 16, 34], ["camel", "ORGANISM", 665, 670], ["upE and 1A diagnostic target regions", "DNA", 593, 629], ["StudyA sequence", "DNA", 634, 649], ["camel-derived genome", "DNA", 665, 685], ["RT-PCR fragments", "DNA", 708, 724], ["camel", "SPECIES", 137, 142], ["camel", "SPECIES", 418, 423], ["camel B.", "SPECIES", 438, 446], ["camel", "SPECIES", 462, 467], ["nasal swab samples", "TEST", 16, 34], ["upE RT-PCR", "TEST", 69, 79], ["camel G", "TEST", 106, 113], ["Ct", "TEST", 115, 117], ["a second camel", "TEST", 128, 142], ["Ct", "TEST", 153, 155], ["The StudySamples", "TEST", 162, 178], ["RNA extract", "PROBLEM", 228, 239], ["reactivity", "TEST", 341, 351], ["Ct", "TEST", 353, 355], ["the upE assay", "TEST", 399, 412], ["camel G", "TEST", 462, 469], ["The StudyA sequence", "TEST", 630, 649], ["8 RT-PCR fragments", "TREATMENT", 706, 724], ["small", "OBSERVATION_MODIFIER", 202, 207], ["remaining", "OBSERVATION_MODIFIER", 208, 217], ["amount", "OBSERVATION_MODIFIER", 218, 224], ["RNA extract", "OBSERVATION", 228, 239]]], ["Phylogenetic analyses supported the conclusion that transmission occurred between camel and patient, but no direction was implied (e.g, camel to human vs. human to camel; online Technical Appendix Figure 1).", [["camel", "ORGANISM", 82, 87], ["patient", "ORGANISM", 92, 99], ["human", "ORGANISM", 145, 150], ["human", "ORGANISM", 155, 160], ["camel", "SPECIES", 82, 87], ["patient", "SPECIES", 92, 99], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 155, 160], ["camel", "SPECIES", 82, 87], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 155, 160], ["Phylogenetic analyses", "TEST", 0, 21]]], ["The human- and camel-derived sequences shared a signature of single nucleotide polymorphisms that occurred in no other known MERS-CoV sequences (Figure).", [["human", "ORGANISM", 4, 9], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 125, 133], ["human- and camel-derived sequences", "DNA", 4, 38], ["MERS-CoV sequences", "DNA", 125, 143], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["MERS-CoV", "SPECIES", 125, 133], ["single nucleotide polymorphisms", "PROBLEM", 61, 92]]], ["Single nucleotide exchanges occurred at nt positions 21945 and 29662; these exchanges might have arisen during virus transmission, as described (10).", [["nucleotide", "CHEMICAL", 7, 17], ["nucleotide", "CHEMICAL", 7, 17], ["Single nucleotide exchanges", "TREATMENT", 0, 27]]], ["However, because of the low RNA concentration in the samples, reamplification of the material and investigation of possible PCR-based mutations could not be done.The StudyA serum sample taken from camel G during the initial investigation on November 9 was tested by recombinant immunofluorescence assay (IFA) as described (6,14) and showed reactivity to MERS-CoV (titer 320).", [["samples", "ANATOMY", 53, 60], ["serum sample", "ANATOMY", 173, 185], ["StudyA", "ORGANISM_SUBSTANCE", 166, 172], ["serum", "ORGANISM_SUBSTANCE", 173, 178], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 354, 362], ["camel", "SPECIES", 197, 202], ["MERS-CoV", "SPECIES", 354, 362], ["the low RNA concentration", "PROBLEM", 20, 45], ["the material", "TEST", 81, 93], ["PCR", "TEST", 124, 127], ["based mutations", "PROBLEM", 128, 143], ["The StudyA serum sample", "TEST", 162, 185], ["the initial investigation", "TEST", 212, 237], ["MERS", "TEST", 354, 358], ["CoV", "TEST", 359, 362]]], ["To investigate signs of recent MERS-CoV infection in the group of camels, we obtained blood samples at short intervals from all 9 animals during November 14\u2013December 9, 2013.", [["blood samples", "ANATOMY", 86, 99], ["MERS-CoV infection", "DISEASE", 31, 49], ["MERS-CoV", "ORGANISM", 31, 39], ["camels", "ORGANISM", 66, 72], ["blood samples", "ORGANISM_SUBSTANCE", 86, 99], ["MERS-CoV", "SPECIES", 31, 39], ["camels", "SPECIES", 66, 72], ["recent MERS", "PROBLEM", 24, 35], ["CoV infection", "PROBLEM", 36, 49], ["blood samples", "TEST", 86, 99], ["CoV", "OBSERVATION_MODIFIER", 36, 39], ["infection", "OBSERVATION", 40, 49]]], ["All samples were tested by ELISA against recombinant MERS-CoV spike antigen domain S1 fused to human Fc fragment, using a formulation as described (15).", [["samples", "ANATOMY", 4, 11], ["MERS-CoV spike antigen domain S1", "GENE_OR_GENE_PRODUCT", 53, 85], ["human", "ORGANISM", 95, 100], ["recombinant MERS-CoV spike antigen domain S1", "PROTEIN", 41, 85], ["human Fc fragment", "PROTEIN", 95, 112], ["human", "SPECIES", 95, 100], ["MERS-CoV", "SPECIES", 53, 61], ["human", "SPECIES", 95, 100], ["All samples", "TEST", 0, 11], ["ELISA", "TEST", 27, 32], ["recombinant MERS", "PROBLEM", 41, 57], ["CoV spike antigen", "PROBLEM", 58, 75], ["human Fc fragment", "TREATMENT", 95, 112], ["a formulation", "TREATMENT", 120, 133], ["Fc fragment", "OBSERVATION", 101, 112]]], ["Serum samples from all 9 animals showed reactivity to the MERS-CoV antigen; serum samples from control animals showed no reactivity (online Technical Appendix Figure 2, panel A).", [["Serum samples", "ANATOMY", 0, 13], ["serum samples", "ANATOMY", 76, 89], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["MERS-CoV antigen", "GENE_OR_GENE_PRODUCT", 58, 74], ["serum samples", "ORGANISM_SUBSTANCE", 76, 89], ["MERS-CoV antigen", "PROTEIN", 58, 74], ["MERS-CoV", "SPECIES", 58, 66], ["Serum samples", "TEST", 0, 13], ["reactivity", "TEST", 40, 50], ["the MERS", "TEST", 54, 62], ["CoV antigen", "TEST", 63, 74], ["serum samples from control animals", "TEST", 76, 110], ["reactivity", "PROBLEM", 121, 131], ["no", "UNCERTAINTY", 118, 120]]], ["ELISA signals were constant over time in most animals, but a small, yet visible, change of signal over the observation period was noted for camels B and G. To clarify the reasons for this putative signal increase, the first and last serum samples (obtained on November 14 and December 9) from all animals were re-tested by IFA.", [["serum samples", "ANATOMY", 233, 246], ["serum samples", "ORGANISM_SUBSTANCE", 233, 246], ["animals", "ORGANISM", 297, 304], ["ELISA signals", "TEST", 0, 13], ["this putative signal increase", "PROBLEM", 183, 212], ["last serum samples", "TEST", 228, 246], ["constant", "OBSERVATION_MODIFIER", 19, 27], ["small", "OBSERVATION_MODIFIER", 61, 66], ["increase", "OBSERVATION_MODIFIER", 204, 212]]], ["As summarized in the Table, camels B and G showed 4-fold increases of titer for the paired first and last serum samples.", [["serum samples", "ANATOMY", 106, 119], ["camels B", "CELL", 28, 36], ["G", "GENE_OR_GENE_PRODUCT", 41, 42], ["serum samples", "ORGANISM_SUBSTANCE", 106, 119], ["camels B and G", "TEST", 28, 42], ["last serum samples", "TEST", 101, 119]]], ["In serologic tests that rely on 2-fold endpoint titrations, a titer increase >2 dilution steps is considered a significant sign of recent acute infection.", [["infection", "DISEASE", 144, 153], ["serologic tests", "TEST", 3, 18], ["2-fold endpoint titrations", "TREATMENT", 32, 58], ["a titer increase", "PROBLEM", 60, 76], ["recent acute infection", "PROBLEM", 131, 153], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["infection", "OBSERVATION", 144, 153]]], ["For additional confirmation of rises of titer, sequential samples from camels B and G were compared with sequential samples from camels E and I by using IFA with endpoint titration.", [["samples", "ANATOMY", 58, 65], ["samples", "ANATOMY", 116, 123], ["camels B", "CELL", 71, 79], ["rises of titer", "PROBLEM", 31, 45], ["sequential samples from camels B and G", "TEST", 47, 85], ["endpoint titration", "TREATMENT", 162, 180]]], ["These data confirmed the increases of titers for camels B and G (online Technical Appendix Figure 2, panel B).The StudyBecause bovine CoV occurs in camels, we tested for antibodies against bovine CoV in camels B and G to exclude potential cross-reactions.", [["bovine", "ORGANISM", 127, 133], ["CoV", "ORGANISM", 134, 137], ["camels", "ORGANISM", 148, 154], ["bovine", "ORGANISM", 189, 195], ["CoV", "ORGANISM", 196, 199], ["camels B", "CELL", 203, 211], ["antibodies", "PROTEIN", 170, 180], ["bovine", "SPECIES", 127, 133], ["bovine", "SPECIES", 189, 195], ["StudyBecause bovine CoV", "SPECIES", 114, 137], ["bovine CoV", "SPECIES", 189, 199], ["These data", "TEST", 0, 10], ["the increases of titers", "PROBLEM", 21, 44], ["The StudyBecause bovine CoV", "TEST", 110, 137], ["antibodies", "TEST", 170, 180], ["bovine CoV in camels", "TEST", 189, 209], ["potential cross-reactions", "PROBLEM", 229, 254], ["bovine CoV", "OBSERVATION", 127, 137]]], ["Using IFA (6), we found no bovine CoV antibodies in camel G, but camel B showed rising bovine CoV antibody titers (Table).", [["bovine", "ORGANISM", 27, 33], ["CoV", "ORGANISM", 34, 37], ["camel", "ORGANISM", 52, 57], ["G", "GENE_OR_GENE_PRODUCT", 58, 59], ["camel B", "ORGANISM", 65, 72], ["bovine", "ORGANISM", 87, 93], ["CoV", "ORGANISM", 94, 97], ["bovine CoV antibodies", "PROTEIN", 27, 48], ["bovine", "SPECIES", 27, 33], ["camel", "SPECIES", 52, 57], ["camel", "SPECIES", 65, 70], ["bovine", "SPECIES", 87, 93], ["CoV", "SPECIES", 34, 37], ["camel", "SPECIES", 52, 57], ["camel B", "SPECIES", 65, 72], ["bovine CoV", "SPECIES", 87, 97], ["IFA", "TEST", 6, 9], ["bovine CoV antibodies", "TEST", 27, 48], ["camel G", "TEST", 52, 59], ["camel B", "TEST", 65, 72], ["rising bovine CoV antibody titers", "PROBLEM", 80, 113], ["no", "UNCERTAINTY", 24, 26]]], ["To obtain further differentiation, we performed neutralization assays against MERS-CoV and bovine CoV (7).", [["MERS-CoV", "ORGANISM", 78, 86], ["bovine", "ORGANISM", 91, 97], ["CoV", "ORGANISM", 98, 101], ["bovine", "SPECIES", 91, 97], ["MERS-CoV", "SPECIES", 78, 86], ["bovine CoV", "SPECIES", 91, 101], ["neutralization assays", "TEST", 48, 69], ["MERS", "TEST", 78, 82], ["bovine CoV", "TEST", 91, 101]]], ["Titers in serum samples from November 14 and December 9, respectively, were 160 and 320 for camel B and 160 and 160 for camel G. None of the animals showed serum neutralization against bovine CoV.ConclusionsThese data add to recent findings showing high similarity of MERS-CoVs carried by humans and camels (8,10), supporting the hypothesis that human MERS-CoV infection may be acquired directly from camels.", [["serum samples", "ANATOMY", 10, 23], ["serum", "ANATOMY", 156, 161], ["infection", "DISEASE", 361, 370], ["serum samples", "ORGANISM_SUBSTANCE", 10, 23], ["animals", "ORGANISM", 141, 148], ["serum", "ORGANISM_SUBSTANCE", 156, 161], ["bovine", "ORGANISM", 185, 191], ["CoV.", "ORGANISM", 192, 196], ["MERS-CoVs", "GENE_OR_GENE_PRODUCT", 268, 277], ["humans", "ORGANISM", 289, 295], ["human", "ORGANISM", 346, 351], ["MERS-CoV", "ORGANISM", 352, 360], ["camels", "ORGANISM_SUBDIVISION", 401, 407], ["MERS-CoVs", "DNA", 268, 277], ["bovine", "SPECIES", 185, 191], ["humans", "SPECIES", 289, 295], ["human", "SPECIES", 346, 351], ["camel B", "SPECIES", 92, 99], ["camel", "SPECIES", 120, 125], ["bovine", "SPECIES", 185, 191], ["humans", "SPECIES", 289, 295], ["human MERS-CoV", "SPECIES", 346, 360], ["Titers in serum samples", "TEST", 0, 23], ["camel G.", "TEST", 120, 128], ["serum neutralization", "TEST", 156, 176], ["bovine CoV.", "PROBLEM", 185, 196], ["recent findings", "TEST", 225, 240], ["CoV infection", "PROBLEM", 357, 370]]], ["In addition, both animals that showed signs of recent infection were juvenile, which provides further support to previous findings that mainly young animals are infected by MERS-CoV (7,8).", [["infection", "DISEASE", 54, 63], ["animals", "ORGANISM", 149, 156], ["MERS-CoV", "ORGANISM", 173, 181], ["MERS-CoV", "SPECIES", 173, 181], ["recent infection", "PROBLEM", 47, 63], ["infection", "OBSERVATION", 54, 63], ["infected", "OBSERVATION", 161, 169]]], ["Given the synchronized parturition pattern of dromedary camels, with birthing in the winter months, an increase of epizootic activity might be expected after some latency during the first half of each year.ConclusionsOur data provide particular insight into the timing of infections and transmission.", [["infections", "DISEASE", 272, 282], ["camels", "ORGANISM_SUBDIVISION", 56, 62], ["epizootic activity", "PROBLEM", 115, 133], ["Our data", "TEST", 217, 225], ["infections", "PROBLEM", 272, 282], ["increase", "OBSERVATION_MODIFIER", 103, 111], ["epizootic activity", "OBSERVATION", 115, 133], ["infections", "OBSERVATION", 272, 282]]], ["Antibody titers rose and viral RNA concentrations were already on the decline in the camels while the patient was hospitalized with acute symptoms.", [["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["Antibody titers", "TEST", 0, 15], ["viral RNA concentrations", "PROBLEM", 25, 49], ["acute symptoms", "PROBLEM", 132, 146]]], ["Assuming a time before appearance of antibodies of 10\u201321 days, at least some of the camels would have been actively infected during middle to late October, when some animals showed signs of respiratory illness and the patient acquired his infection.", [["respiratory", "ANATOMY", 190, 201], ["respiratory illness", "DISEASE", 190, 209], ["infection", "DISEASE", 239, 248], ["camels", "ORGANISM", 84, 90], ["patient", "ORGANISM", 218, 225], ["antibodies", "PROTEIN", 37, 47], ["patient", "SPECIES", 218, 225], ["respiratory illness", "PROBLEM", 190, 209], ["his infection", "PROBLEM", 235, 248], ["infected", "OBSERVATION", 116, 124], ["respiratory illness", "OBSERVATION", 190, 209], ["infection", "OBSERVATION", 239, 248]]], ["Nevertheless, we cannot rule out other infectious causes of the animals\u2019 upper respiratory signs.", [["respiratory", "ANATOMY", 79, 90], ["upper respiratory", "ORGANISM_SUBDIVISION", 73, 90], ["other infectious causes", "PROBLEM", 33, 56], ["upper respiratory signs", "PROBLEM", 73, 96], ["infectious", "OBSERVATION", 39, 49], ["upper", "ANATOMY_MODIFIER", 73, 78], ["respiratory signs", "OBSERVATION", 79, 96]]], ["Also, because of the retrospective nature of this investigation, we cannot rule out the possibility of a third source of MERS-CoV infection for camels and humans.", [["infection", "DISEASE", 130, 139], ["MERS-CoV", "ORGANISM", 121, 129], ["camels", "ORGANISM", 144, 150], ["humans", "ORGANISM", 155, 161], ["humans", "SPECIES", 155, 161], ["MERS-CoV", "SPECIES", 121, 129], ["camels", "SPECIES", 144, 150], ["humans", "SPECIES", 155, 161], ["this investigation", "TEST", 45, 63], ["MERS", "PROBLEM", 121, 125], ["CoV infection", "PROBLEM", 126, 139], ["CoV", "OBSERVATION_MODIFIER", 126, 129], ["infection", "OBSERVATION", 130, 139]]]], "8f34431c7a6db1380acb11c1d9c2aeb5764436e0": [["dos: per\u00edodo previo al prendimiento que se extiende desde la infusi\u00f3n hasta la recuperaci\u00f3n de neutr\u00f3filos (20-30 d\u00edas), el per\u00edodo posprendimiento precoz (30-100 d\u00edas) y el per\u00edodo posprendimiento tard\u00edo (despu\u00e9s del d\u00eda 100).", [["el per\u00edodo posprendimiento precoz", "TREATMENT", 121, 154]]], ["El TPH alog\u00e9nico se asocia con un mayor riesgo de infecci\u00f3n durante los tres per\u00edodos, mientras que los receptores de TPH aut\u00f3logos suelen ser m\u00e1s vulnerables durante los 2 primeros.", [["El TPH", "TEST", 0, 6]]], ["En ambos casos, persiste cierta predisposici\u00f3n a las complicaciones infecciosas hasta que no se produce la total recuperaci\u00f3n inmune de las c\u00e9lulas B y T. Las terapias supresoras de linfocitos T (glucocorticoides en dosis altas, anticuerpos antic\u00e9lulas T, an\u00e1logos de purina), la enfermedad de injerto contra hu\u00e9sped (EICH) y la recepci\u00f3n de un injerto con depleci\u00f3n de linfocitos T puede retrasar la recuperaci\u00f3n de c\u00e9lulas T 1 .Periodo previo al prendimientoDurante este per\u00edodo predominan las infecciones nosocomiales favorecidas por el da\u00f1o mucocut\u00e1neo y la neutropenia 2 .", [["neutropenia", "DISEASE", 562, 573], ["T (glucocorticoides en dosis altas", "TREATMENT", 193, 227], ["Durante", "TREATMENT", 460, 467], ["y la neutropenia", "PROBLEM", 557, 573], ["neutropenia", "OBSERVATION", 562, 573]]], ["La mayor\u00eda de los pacientes suelen presentar neutropenia febril, aunque solo en el 20-30% de estos casos se llega a conocer el origen de la infecci\u00f3n 3 .", [["neutropenia febril", "DISEASE", 45, 63], ["neutropenia febril", "PROBLEM", 45, 63]]], ["Hay mayor riesgo de infecci\u00f3n tras un tratamiento mieloablativo, porque se produce una neutropenia m\u00e1s prolongada.", [["neutropenia", "DISEASE", 87, 98], ["una neutropenia m\u00e1s prolongada", "PROBLEM", 83, 113], ["una neutropenia", "OBSERVATION", 83, 98]]], ["La fiebre persistente tiene un amplio diagn\u00f3stico diferencial que incluye infecciones producidas por bacterias, infecci\u00f3n f\u00fangica invasora (IFI), infecci\u00f3n oculta, respuesta inflamatoria al da\u00f1o tisular y fiebre medicamentosa.", [["IFI", "DISEASE", 140, 143], ["La", "TEST", 0, 2], ["producidas", "PROBLEM", 86, 96], ["bacterias", "PROBLEM", 101, 110], ["f\u00fangica invasora (IFI)", "PROBLEM", 122, 144]]], ["En pacientes que no reciben profilaxis v\u00edrica es muy com\u00fan la reactivaci\u00f3n del virus del herpes simple (VHS) que ocasionalmente puede causar esofagitis.DiarreaLa diarrea es frecuente en estos pacientes, y puede deberse a causas infecciosas y no infecciosas.", [["herpes simple", "DISEASE", 89, 102], ["causar esofagitis", "PROBLEM", 134, 151], ["infecciosas", "PROBLEM", 245, 256]]], ["Una de las causas m\u00e1s comunes es la infecci\u00f3n por C. difficile (ICD), cuya incidencia es del 5-10% durante los primeros meses 4 .", [["C. difficile", "DISEASE", 50, 62], ["C. difficile (ICD)", "PROBLEM", 50, 68], ["cuya incidencia", "PROBLEM", 70, 85], ["difficile", "OBSERVATION", 53, 62]]], ["La ICD no se asocia con un mayor \u00edndice de recidivas ni de mortalidad que en otros pacientes.", [["La ICD", "TREATMENT", 0, 6], ["ICD", "OBSERVATION", 3, 6]]], ["No es infrecuente que un paciente portador de C. difficile (con detecci\u00f3n positiva de toxinas en heces) presente diarrea por otro motivo como la EICH 4 .", [["C. difficile", "PROBLEM", 46, 58], ["diarrea", "PROBLEM", 113, 120]]], ["Otra causa frecuente de diarrea es la enterocolitis necrotizante (o tiflitis) cuyo diagn\u00f3stico diferencial debe incluir la ICD, colitis por citomegalovirus (CMV), infecci\u00f3n por norovirus, colitis isqu\u00e9mica, s\u00edndrome de Ogilvie (pseudoobstrucci\u00f3n col\u00f3nica), colangitis y colecistitis 5 .", [["enterocolitis necrotizante", "DISEASE", 38, 64], ["colitis por citomegalovirus", "DISEASE", 128, 155], ["colitis isqu\u00e9mica", "DISEASE", 188, 205], ["frecuente de diarrea es la enterocolitis necrotizante", "PROBLEM", 11, 64], ["diagn\u00f3stico diferencial debe incluir la ICD", "TREATMENT", 83, 126], ["colitis", "PROBLEM", 128, 135], ["citomegalovirus (CMV)", "PROBLEM", 140, 161], ["infecci\u00f3n por norovirus", "PROBLEM", 163, 186], ["colitis isqu\u00e9mica", "PROBLEM", 188, 205], ["s\u00edndrome de Ogilvie (pseudoobstrucci\u00f3n col\u00f3nica)", "PROBLEM", 207, 255], ["colangitis y colecistitis", "PROBLEM", 257, 282], ["la ICD", "OBSERVATION", 120, 126], ["colitis", "OBSERVATION", 128, 135], ["colitis", "OBSERVATION", 188, 195]]], ["Los casos que no responden al reposo intestinal y a antibi\u00f3ticos deben ser tratados con resecci\u00f3n quir\u00fargica del segmento afectado.Infiltrados pulmonaresLos infiltrados de apariencia nodular ( fig. 1 ) pueden estar originados por hongos y menos frecuentemente por bacterias (Gram positivas y Gram negativas).", [["Infiltrados pulmonares", "SPECIES", 131, 153], ["Gram positivas y Gram negativas", "SPECIES", 275, 306], ["Infiltrados pulmonares", "PROBLEM", 131, 153], ["Los infiltrados de apariencia nodular ( fig.", "PROBLEM", 153, 197], ["pueden estar originados", "PROBLEM", 202, 225], ["bacterias", "PROBLEM", 264, 273], ["nodular", "OBSERVATION_MODIFIER", 183, 190]]], ["Cuando es producida por hongos filamentosos se puede producir una necrosis en su interior (signo del creciente lunar) que suele aparecer tras la recuperaci\u00f3n del recuento de neutr\u00f3filos.", [["necrosis", "DISEASE", 66, 74], ["Cuando", "TEST", 0, 6], ["una necrosis", "PROBLEM", 62, 74], ["necrosis", "OBSERVATION", 66, 74]]], ["La afectaci\u00f3n pulmonar difusa puede ser debida a causas no infecciosas (edema pulmonar, da\u00f1o pulmonar por el r\u00e9gimen de acondicionamiento) o por neumon\u00eda v\u00edrica difusa 6 .Periodo posprendimiento tempranoLos principales factores de riesgo de infecci\u00f3n durante este per\u00edodo son la EICH (y su terapia), as\u00ed como mucositis residual y da\u00f1o cut\u00e1neo.Infecci\u00f3n pulmonarLa aspergilosis pulmonar es una causa frecuente de lesiones nodulares detectadas durante este per\u00edodo, especialmente en pacientes con factores de riesgo como EICH, uso de esteroides, infecci\u00f3n por CMV o por el virus respiratorio sinicitial 6 .", [["edema pulmonar", "DISEASE", 72, 86], ["mucositis", "DISEASE", 309, 318], ["CMV", "ORGANISM", 558, 561], ["La afectaci\u00f3n", "TEST", 0, 13], ["infecciosas", "PROBLEM", 59, 70], ["edema", "PROBLEM", 72, 77], ["como mucositis", "PROBLEM", 304, 318], ["Infecci\u00f3n", "TEST", 343, 352], ["nodulares", "PROBLEM", 421, 430], ["edema", "OBSERVATION", 72, 77]]], ["Coincidiendo con la generalizaci\u00f3n de la profilaxis antif\u00fangica, se han detectado IFI menos comunes como las producidas por zigomicetos, Fusarium y Scedosporium.", [["Fusarium y Scedosporium", "DISEASE", 137, 160], ["Coincidiendo con la generalizaci\u00f3n de la profilaxis antif\u00fangica", "TREATMENT", 0, 63]]], ["La afectaci\u00f3n pulmonar difusa durante este periodo suele estar causada por CMV, por virus respiratorios o por Pneumocystis jirovecii.", [["Pneumocystis jirovecii", "DISEASE", 110, 132], ["CMV", "ORGANISM", 75, 78], ["Pneumocystis jirovecii", "ORGANISM", 110, 132], ["Pneumocystis jirovecii", "SPECIES", 110, 132], ["Pneumocystis jirovecii", "SPECIES", 110, 132], ["La afectaci\u00f3n pulmonar difusa durante", "TREATMENT", 0, 37], ["CMV", "PROBLEM", 75, 78], ["Pneumocystis jirovecii", "PROBLEM", 110, 132], ["Pneumocystis jirovecii", "OBSERVATION", 110, 132]]], ["La neumon\u00eda por P. jirovecii (NPJ) puede ser ocasionada por primoinfecci\u00f3n o por reactivaci\u00f3n de una infecci\u00f3n latente previa.", [["latente previa", "DISEASE", 111, 125], ["jirovecii (NPJ)", "TREATMENT", 19, 34], ["previa", "PROBLEM", 119, 125], ["jirovecii", "OBSERVATION", 19, 28]]], ["Suele acompa\u00f1arse de fiebre alta, tos seca, hipoxemia y neumonitis intersticial en pacientes sin profilaxis o con agentes sub\u00f3ptimos (pentamidina en aerosol o dapsona en d\u00edas alternos).", [["tos seca", "PROBLEM", 34, 42], ["hipoxemia", "PROBLEM", 44, 53], ["con agentes sub\u00f3ptimos", "TREATMENT", 110, 132], ["pentamidina en aerosol o dapsona en d\u00edas alternos", "TREATMENT", 134, 183]]], ["La hiperinfestaci\u00f3n por estrongiloidiasis causa un s\u00edndrome de distr\u00e9s respiratorio que ha sido evidenciado en algunos receptores de TPH.", [["La hiperinfestaci\u00f3n", "TREATMENT", 0, 19]]], ["La infecci\u00f3n se desarrolla en el contexto de la infestaci\u00f3n intestinal cr\u00f3nica que se disemina tras la inmunosupresi\u00f3n.", [["La infecci\u00f3n", "PROBLEM", 0, 12], ["desarrolla en el contexto de la infestaci\u00f3n intestinal cr\u00f3nica que se disemina tras la inmunosupresi\u00f3n", "TREATMENT", 16, 118], ["intestinal", "ANATOMY", 60, 70]]], ["La toxoplasmosis diseminada es rara, pero a menudo se asocia con afectaci\u00f3n pulmonar, por lo general con infiltrados difusos en las im\u00e1genes.DiarreaLa diarrea durante este per\u00edodo suele ser debida a EICH aguda, colitis por CMV, medicamentos como el magnesio oral, ICD, adenovirus y virus enteropat\u00f3genos (Coxsackie A, Rotavirus, Norovirus).Afectaci\u00f3n hep\u00e1ticaPuede estar causada por toxicidad medicamentosa, EICH aguda, sobrecarga de hierro, virus de la hepatitis B (VHB) y C (VHC), CMV, virus de Epstein-Barr (VEB), adenovirus y candidiasis diseminada cr\u00f3nica (candidiasis hepatoespl\u00e9nica).", [["toxoplasmosis diseminada", "DISEASE", 3, 27], ["colitis por CMV", "DISEASE", 211, 226], ["adenovirus y virus enteropat\u00f3genos", "DISEASE", 269, 303], ["Coxsackie A", "DISEASE", 305, 316], ["Rotavirus, Norovirus", "DISEASE", 318, 338], ["hepatitis B", "DISEASE", 454, 465], ["candidiasis diseminada cr\u00f3nica", "DISEASE", 530, 560], ["candidiasis hepatoespl\u00e9nica", "DISEASE", 562, 589], ["oral", "ORGANISM_SUBDIVISION", 258, 262], ["adenovirus", "ORGANISM", 269, 279], ["Coxsackie A", "ORGANISM", 305, 316], ["VHB) y C", "ORGANISM", 467, 475], ["CMV", "ORGANISM", 483, 486], ["Epstein-Barr (VEB)", "ORGANISM", 497, 515], ["adenovirus y candidiasis diseminada cr\u00f3nica", "ORGANISM", 517, 560], ["candidiasis hepatoespl\u00e9nica", "ORGANISM", 562, 589], ["diseminada cr\u00f3nica", "SPECIES", 542, 560], ["Epstein-Barr (VEB)", "SPECIES", 497, 515], ["La toxoplasmosis diseminada", "PROBLEM", 0, 27], ["DiarreaLa", "TEST", 141, 150], ["colitis", "PROBLEM", 211, 218], ["CMV", "PROBLEM", 223, 226], ["medicamentos como el magnesio oral", "TREATMENT", 228, 262], ["ICD", "TREATMENT", 264, 267], ["adenovirus y virus enteropat\u00f3genos", "TREATMENT", 269, 303], ["Rotavirus", "PROBLEM", 318, 327], ["Norovirus", "PROBLEM", 329, 338], ["virus de la hepatitis B (VHB) y C (VHC)", "PROBLEM", 442, 481], ["CMV", "PROBLEM", 483, 486], ["adenovirus y candidiasis diseminada", "PROBLEM", 517, 552], ["cr\u00f3nica (candidiasis hepatoespl\u00e9nica)", "PROBLEM", 553, 590], ["toxoplasmosis", "OBSERVATION", 3, 16], ["colitis", "OBSERVATION", 211, 218], ["ICD", "ANATOMY", 264, 267]]], ["En pacientes con serolog\u00eda sugestiva de infecci\u00f3n curada (HBsAc positivo) se puede evidenciar una reactivaci\u00f3n de la infecci\u00f3n con da\u00f1o hep\u00e1tico y presencia de HBsAg postivo (seroconversi\u00f3n inversa) 8,9 .EncefalitisAunque la reactivaci\u00f3n del virus herpes humano (VHH) 6 ocurre en el 30-50% de los pacientes sometidos a TPH alog\u00e9nico, solo una peque\u00f1a proporci\u00f3n de estos pacientes presenta encefalitis 10 .", [["HBsAg", "CHEMICAL", 160, 165], ["herpes humano", "DISEASE", 248, 261], ["herpes", "ORGANISM", 248, 254], ["herpes", "SPECIES", 248, 254], ["Encefalitis", "TEST", 204, 215], ["la reactivaci\u00f3n del virus herpes humano (VHH)", "TREATMENT", 222, 267], ["a TPH alog\u00e9nico", "PROBLEM", 317, 332], ["solo una peque\u00f1a proporci\u00f3n", "TREATMENT", 334, 361]]], ["Otros pat\u00f3genos como Toxoplasma gondii, VHS, virus varicela zoster (VZV) y CMV pueden causar encefalitis.", [["Toxoplasma gondii", "DISEASE", 21, 38], ["varicela zoster", "DISEASE", 51, 66], ["Toxoplasma gondii", "ORGANISM", 21, 38], ["VHS, virus varicela zoster", "ORGANISM", 40, 66], ["VZV", "ORGANISM", 68, 71], ["CMV", "ORGANISM", 75, 78], ["Toxoplasma gondii", "SPECIES", 21, 38], ["virus varicela zoster", "SPECIES", 45, 66], ["Toxoplasma gondii", "SPECIES", 21, 38], ["Otros", "TEST", 0, 5], ["como Toxoplasma gondii", "PROBLEM", 16, 38], ["VHS", "PROBLEM", 40, 43], ["virus varicela zoster", "PROBLEM", 45, 66], ["y CMV pueden causar encefalitis", "PROBLEM", 73, 104], ["causar encefalitis", "OBSERVATION", 86, 104]]], ["La replicaci\u00f3n del poliomavirus en el sistema nervioso central (SNC) puede producir leucoencefalopat\u00eda multifocal progresiva y manifestarse con d\u00e9ficits neurol\u00f3gicos subagudos que incluyen convulsiones, alteraci\u00f3n del estado mental, s\u00edntomas visuales relacionados con defectos del campo visual (hemianopsia y diplop\u00eda), debilidad, hemiparesia o monoparesia y/o ataxia 11 .", [["campo visual", "DISEASE", 281, 293], ["hemianopsia y diplop\u00eda", "DISEASE", 295, 317], ["hemiparesia o monoparesia y", "DISEASE", 331, 358], ["ataxia", "DISEASE", 361, 367], ["hemiparesia o monoparesia y/o ataxia 11", "SPECIES", 331, 370], ["La replicaci\u00f3n del poliomavirus", "TREATMENT", 0, 31], ["multifocal progresiva", "PROBLEM", 103, 124], ["debilidad", "PROBLEM", 320, 329], ["hemiparesia", "PROBLEM", 331, 342], ["ataxia", "PROBLEM", 361, 367]]], ["La mayor\u00eda de las infecciones descritas hasta ahora pueden presentar un empeoramiento parad\u00f3jico coincidiendo con la recuperaci\u00f3n inmune (incremento de los linfocitos o reducci\u00f3n de inmunosupresi\u00f3n o tratamiento esteroideo) que se caracteriza por la aparici\u00f3n de nuevos signos de infecci\u00f3n o el empeoramiento de los previos.Periodo posprendimiento tard\u00edoLos pacientes siguen teniendo un alto riesgo de infecciones, especialmente los que fueron sometidos a un r\u00e9gimen mieloablativo intenso a irradiaci\u00f3n corporal total, receptores alog\u00e9nicos que presentan EICH cr\u00f3nica y en casos de receptor con infecci\u00f3n por CMV con donante sin infecci\u00f3n por CMV 12 .", [["CMV", "ORGANISM", 609, 612], ["Periodo posprendimiento tard\u00edo", "SPECIES", 324, 354], ["a irradiaci\u00f3n corporal total", "TREATMENT", 489, 517], ["receptores alog\u00e9nicos", "TREATMENT", 519, 540], ["cr\u00f3nica y en casos de receptor con infecci\u00f3n", "TREATMENT", 560, 604], ["CMV con donante sin infecci\u00f3n", "TREATMENT", 609, 638]]], ["Se detectan infecciones similares a las padecidas por inmunococompetentes: bacteriemias, infecciones respiratorias y meningitis (producidas por S. pneumoniae, H. influenzae, N. meningitidis) 12 .", [["Se", "CHEMICAL", 0, 2], ["meningitis", "DISEASE", 117, 127], ["infecciones respiratorias", "ORGANISM", 89, 114], ["producidas por S. pneumoniae", "ORGANISM", 129, 157], ["H. influenzae", "ORGANISM", 159, 172], ["N. meningitidis", "ORGANISM", 174, 189], ["las padecidas", "SPECIES", 36, 49], ["S. pneumoniae", "SPECIES", 144, 157], ["H. influenzae", "SPECIES", 159, 172], ["N. meningitidis", "SPECIES", 174, 189], ["S. pneumoniae", "SPECIES", 144, 157], ["H. influenzae", "SPECIES", 159, 172], ["N. meningitidis", "SPECIES", 174, 189], ["Se detectan infecciones", "PROBLEM", 0, 23], ["bacteriemias", "PROBLEM", 75, 87], ["infecciones", "PROBLEM", 89, 100], ["y meningitis", "PROBLEM", 115, 127], ["pneumoniae", "PROBLEM", 147, 157], ["H. influenzae", "PROBLEM", 159, 172]]], ["Tambi\u00e9n se siguen produciendo casos de neumon\u00eda por microorganismos oportunistas como CMV, virus respiratorios, P. jirovecii, Nocardia, Aspergillus y otros hongos filamentosos.Infecci\u00f3n por citomegalovirusCon el uso de profilaxis frente a CMV, la infecci\u00f3n tard\u00eda por CMV se ha convertido en un problema m\u00e1s frecuente.", [["P. jirovecii", "DISEASE", 112, 124], ["CMV", "ORGANISM", 86, 89], ["virus respiratorios", "ORGANISM", 91, 110], ["P. jirovecii", "ORGANISM", 112, 124], ["CMV", "ORGANISM", 239, 242], ["P. jirovecii", "SPECIES", 112, 124], ["P. jirovecii", "SPECIES", 112, 124], ["Aspergillus y otros hongos filamentosos", "SPECIES", 136, 175], ["Tambi\u00e9n", "TREATMENT", 0, 7], ["P. jirovecii", "PROBLEM", 112, 124], ["Nocardia", "PROBLEM", 126, 134], ["Aspergillus", "PROBLEM", 136, 147], ["a CMV", "TEST", 237, 242], ["CMV", "PROBLEM", 268, 271], ["jirovecii", "OBSERVATION", 115, 124]]], ["Los factores predictivos de esta infecci\u00f3n son la discordancia serol\u00f3gica frente a CMV, trasplante con incompatibilidad HLA, la profilaxis anti-CMV y la reactivaci\u00f3n temprana de CMV 13 .", [["CMV", "ORGANISM", 178, 181], ["Los factores", "TEST", 0, 12], ["HLA", "TEST", 120, 123], ["la profilaxis anti-CMV y la reactivaci\u00f3n temprana", "TREATMENT", 125, 174]]], ["La relaci\u00f3n entre un descenso en la cuantificaci\u00f3n de la carga v\u00edrica en sangre de CMV mediante reacci\u00f3n en cadena de la polimerasa (PCR) y la mejor\u00eda del paciente es menos discriminativa que en receptores de trasplante de \u00f3rgano s\u00f3lido (TOS).", [["TOS", "DISEASE", 238, 241], ["La relaci\u00f3n entre un descenso en la cuantificaci\u00f3n de la carga v\u00edrica en sangre de CMV mediante reacci\u00f3n en cadena de la polimerasa (PCR", "TREATMENT", 0, 136], ["y la mejor\u00eda del paciente", "TREATMENT", 138, 163]]], ["La aparici\u00f3n de letermovir, que puede ser empleado en la profilaxis y tratamiento, ha supuesto un avance relevante en el manejo de esta infecci\u00f3n porque no presenta resistencia cruzada con otros antiv\u00edricos y no produce mielosupresi\u00f3n, aunque no tiene actividad frente a otros herpesvirus 14 .Infecci\u00f3n por micobacteriasLa infecci\u00f3n pulmonar por micobacterias es infrecuente (1-3% de los receptores aleg\u00e9nicos) y suele aparecer de forma tard\u00eda.", [["La aparici\u00f3n de letermovir", "TREATMENT", 0, 26], ["Infecci\u00f3n", "TEST", 293, 302], ["micobacteriasLa infecci\u00f3n", "PROBLEM", 307, 332], ["pulmonar por micobacterias", "PROBLEM", 333, 359]]], ["Las micobacterias no tuberculosas pueden afectar al pulm\u00f3n, torrente sangu\u00edneo, cat\u00e9ter, los tejidos blandos, los huesos y las articulaciones.Infecci\u00f3n hep\u00e1ticaEn estos pacientes, la afectaci\u00f3n hep\u00e1tica suele ser debida a micobacterias de crecimiento r\u00e1pido, virus hepatotropos, otros virus (CMV, VEB, VHH 6, adenovirus) y Candida.", [["articulaciones", "CHEMICAL", 127, 141], ["virus hepatotropos", "ORGANISM", 259, 277], ["otros virus", "ORGANISM", 279, 290], ["CMV", "ORGANISM", 292, 295], ["adenovirus", "ORGANISM", 309, 319], ["tuberculosas", "PROBLEM", 21, 33], ["Infecci\u00f3n", "TEST", 142, 151], ["la afectaci\u00f3n", "TEST", 180, 193], ["r\u00e1pido", "TEST", 251, 257], ["virus hepatotropos", "PROBLEM", 259, 277], ["otros virus", "PROBLEM", 279, 290], ["CMV", "PROBLEM", 292, 295], ["VHH", "PROBLEM", 302, 305]]], ["Durante este per\u00edodo puede producirse una reactivaci\u00f3n aislada en el h\u00edgado del VZV y la hepatitis por VHS 16,17 .ListeriosisSuele producir bacteriemia o meningitis (dos tercios de los pacientes) y con menos frecuencia otras formas de infecci\u00f3n cerebral parenquimatosa como la encefalitis y el absceso cerebral (rhombencefalitis).", [["hepatitis", "DISEASE", 89, 98], ["meningitis", "DISEASE", 154, 164], ["absceso cerebral", "DISEASE", 294, 310], ["una reactivaci\u00f3n aislada", "TREATMENT", 38, 62], ["VHS", "TEST", 103, 106], ["ListeriosisSuele producir bacteriemia", "PROBLEM", 114, 151], ["meningitis", "PROBLEM", 154, 164], ["y con menos frecuencia", "TEST", 196, 218], ["cerebral parenquimatosa", "PROBLEM", 245, 268], ["meningitis", "OBSERVATION", 154, 164], ["cerebral", "ANATOMY", 245, 253], ["cerebral", "ANATOMY", 302, 310]]], ["El uso de la profilaxis con cotrimoxazol para la profilaxis de la NPJ y las recomendaciones sobre alimentos generalmente protegen contra la listeriosis.", [["listeriosis", "DISEASE", 140, 151], ["la profilaxis con cotrimoxazol para la profilaxis", "TREATMENT", 10, 59], ["contra la listeriosis", "PROBLEM", 130, 151], ["listeriosis", "OBSERVATION", 140, 151]]], ["En estos casos, hay que hacer el diagn\u00f3stico diferencial con la infecci\u00f3n tuberculosa del SNC, la criptococosis, la toxoplasmosis cerebral y las infecciones f\u00fangicas diseminadas.Infecci\u00f3n por el virus de Epstein-BarrEl VEB en los receptores de TPH produce un cuadro similar a la mononucleosis (primeros meses tras la inducci\u00f3n) por proliferaci\u00f3n benigna de c\u00e9lulas B policlonales.", [["toxoplasmosis cerebral", "DISEASE", 116, 138], ["mononucleosis", "DISEASE", 279, 292], ["la criptococosis", "PROBLEM", 95, 111], ["la toxoplasmosis", "PROBLEM", 113, 129], ["a la mononucleosis", "PROBLEM", 274, 292], ["primeros meses tras la inducci\u00f3n", "TREATMENT", 294, 326], ["la mononucleosis", "OBSERVATION", 276, 292]]], ["Tambi\u00e9n puede ocasionar una forma m\u00e1s grave (enfermedad linfoproliferativa -ELP-) que cursa con fiebre, linfadenopat\u00eda o proliferaci\u00f3n linfomatosa extranodal (h\u00edgado, tracto gastrointestinal, pulm\u00f3n, SNC o m\u00e9dula \u00f3sea).", [["Tambi\u00e9n", "TEST", 0, 7], ["una forma m\u00e1s", "TEST", 24, 37], ["linfoproliferativa", "TEST", 56, 74], ["ELP", "TEST", 76, 79], ["gastrointestinal", "ANATOMY", 174, 190]]], ["Cursa con proliferaci\u00f3n de c\u00e9lulas B monoclonales con anomal\u00edas citogen\u00e9ticas y reordenamientos g\u00e9nicos de inmunoglobulina.", [["Cursa", "TEST", 0, 5]]], ["El riesgo es mayor en pacientes con profunda citopenia de c\u00e9lulas T, discrepancia serol\u00f3gica del VEB del donante/receptor, reactivaci\u00f3n previa del VEB o esplenectom\u00eda 18 .Infecciones en receptor de trasplante de \u00f3rgano s\u00f3lido Introducci\u00f3nLos avances en las t\u00e9cnicas quir\u00fargicas y el empleo de calcineur\u00ednicos han sido factores esenciales para mejorar la supervivencia de los receptores de TOS.", [["TOS", "DISEASE", 389, 392], ["profunda citopenia", "PROBLEM", 36, 54], ["esplenectom\u00eda", "PROBLEM", 153, 166], ["profunda", "ANATOMY", 36, 44]]], ["La mortalidad debida a infecciones ha seguido disminuyendo durante los \u00faltimos a\u00f1os en todos los tipos de TOS.", [["TOS", "DISEASE", 106, 109]]], ["El empleo de otros inmunosupresores como los inhibidores del receptor de la interleucina 2 (basiliximab) y anticuerpos antic\u00e9lulas T (alemtuzumab) ha permitido reducir el deterioro renal y otras alteraciones metab\u00f3licas derivados del uso de calcineur\u00ednicos.", [["basiliximab", "CHEMICAL", 92, 103], ["basiliximab", "CHEMICAL", 92, 103], ["basiliximab", "SIMPLE_CHEMICAL", 92, 103], ["del receptor de la interleucina", "TREATMENT", 57, 88], ["basiliximab) y anticuerpos antic\u00e9lulas T (alemtuzumab) ha permitido reducir el deterioro renal y otras alteraciones", "TREATMENT", 92, 207], ["renal", "ANATOMY", 181, 186]]], ["Entre las causas para desarrollar una infecci\u00f3n en receptores de \u00f3rgano s\u00f3lido se encuentran la transmisi\u00f3n a trav\u00e9s del \u00f3rgano trasplantado, la reactivaci\u00f3n de infecciones latentes del receptor y la adquisici\u00f3n de infecciones en el periodo postrasplante (incluyendo las trasmitidas por hemoderivados).Cronolog\u00eda de las infecciones tras trasplante de \u00f3rgano s\u00f3lidoLa incidencia, localizaci\u00f3n y los microorganismos responsables de las infecciones tras el TOS cumplen, a grandes rasgos, un patr\u00f3n de aparici\u00f3n temporal predecible.Primer mesDurante este per\u00edodo, son frecuentes las infecciones nosocomiales relacionadas con la cirug\u00eda o la estancia en la Unidad de Cuidados Intensivos, como la infecci\u00f3n del cat\u00e9ter, neumon\u00eda, infecci\u00f3n del sitio quir\u00fargico y la ICD.", [["a trav\u00e9s del \u00f3rgano trasplantado", "TREATMENT", 108, 140], ["la reactivaci\u00f3n de infecciones", "TREATMENT", 142, 172], ["y la ICD", "TREATMENT", 755, 763], ["ICD", "OBSERVATION", 760, 763]]], ["Pueden presentarse casos de candidiasis o aspergilosis, especialmente si no se emplea profilaxis antif\u00fangica.", [["candidiasis", "DISEASE", 28, 39], ["candidiasis", "PROBLEM", 28, 39], ["aspergilosis", "PROBLEM", 42, 54], ["especialmente si", "PROBLEM", 56, 72], ["candidiasis", "OBSERVATION", 28, 39]]], ["Las infecciones v\u00edricas son raras durante el primer mes, exceptuando la reactivaci\u00f3n del VHS.", [["del VHS", "OBSERVATION", 85, 92]]], ["Entre ellas destacan las producidas por P. jirovecci, hongos, Toxoplasma gondii, Nocardia y CMV.", [["Toxoplasma gondii", "DISEASE", 62, 79], ["P. jirovecci", "ORGANISM", 40, 52], ["hongos", "ORGANISM", 54, 60], ["Toxoplasma gondii", "ORGANISM", 62, 79], ["CMV", "ORGANISM", 92, 95], ["P. jirovecci", "SPECIES", 40, 52], ["Toxoplasma gondii", "SPECIES", 62, 79], ["P. jirovecci", "SPECIES", 40, 52], ["Toxoplasma gondii", "SPECIES", 62, 79], ["Nocardia y CMV", "SPECIES", 81, 95], ["Entre ellas", "TEST", 0, 11], ["Toxoplasma gondii", "PROBLEM", 62, 79]]], ["Durante los \u00faltimos a\u00f1os se evidencian m\u00e1s casos de infecci\u00f3n por CMV tard\u00eda debido al empleo de profilaxis con ganciclovir o valganciclovir (durante los primeros 3-6 meses tras el TOS).", [["ganciclovir", "CHEMICAL", 112, 123], ["valganciclovir", "CHEMICAL", 126, 140], ["TOS", "DISEASE", 181, 184], ["a\u00f1os", "TEST", 20, 24], ["CMV tard\u00eda debido al empleo de profilaxis", "TREATMENT", 66, 107], ["ganciclovir", "TREATMENT", 112, 123], ["valganciclovir (durante los primeros", "TREATMENT", 126, 162]]], ["Igualmente, el tratamiento preventivo con cotrimoxazol ha reducido mucho las infecciones por P. jirovecii y la toxoplasmosis.", [["P. jirovecii y", "DISEASE", 93, 107], ["toxoplasmosis", "DISEASE", 111, 124], ["P. jirovecii", "ORGANISM", 93, 105], ["P. jirovecii", "SPECIES", 93, 105], ["Igualmente", "TREATMENT", 0, 10], ["el tratamiento preventivo", "TREATMENT", 12, 37], ["cotrimoxazol ha reducido mucho las infecciones", "TREATMENT", 42, 88], ["jirovecii y la toxoplasmosis", "PROBLEM", 96, 124]]], ["La mayor\u00eda de los casos de aspergilosis aparece entre 1-6 meses despu\u00e9s del trasplante 20 .Primer mesInfecciones que aparecen despu\u00e9s de los primeros 6 meses tras trasplante de \u00f3rgano s\u00f3lido Suelen ser infecciones adquiridas en la comunidad y semejantes a las de los pacientes no inmunodeprimidos.", [["inmunodeprimidos", "TREATMENT", 280, 296]]], ["No obs-tante, hay estudios que muestran que la etiolog\u00eda de las infecciones y la mortalidad asociada a las infecciones es similar en ambos per\u00edodos, aunque con una incidencia muy inferior en este \u00faltimo per\u00edodo 6 .", [["obs", "PROBLEM", 3, 6], ["a las infecciones", "PROBLEM", 101, 118], ["obs", "OBSERVATION", 3, 6]]], ["Esto significa que el riesgo de infecciones oportunistas se reduce pero nunca se elimina de forma definitiva, de hecho las infecciones por el VVZ se pueden reactivar en cualquier momento tras el TOS.", [["TOS", "DISEASE", 195, 198]]], ["Durante este per\u00edodo pueden aparecer tumores secundarios a papilomavirus (VPH) y la ELP debida a infecci\u00f3n cr\u00f3nica por VEB.Caracter\u00edsticas de las infecciones en funci\u00f3n del tipo de trasplanteLos receptores de trasplante pulmonar (o cardiopulmonar) presentan m\u00e1s infecciones que los receptores de trasplante renal (con la incidencia m\u00e1s baja).", [["a papilomavirus (VPH)", "PROBLEM", 57, 78], ["renal", "ANATOMY", 307, 312]]], ["Las IFI son frecuentes en los receptores de trasplante de h\u00edgado y trasplante pulmonar; intermedias en el trasplante de coraz\u00f3n e infrecuentes en el trasplante renal 21 .", [["renal", "ANATOMY", 160, 165]]], ["En general, la localizaci\u00f3n de las infecciones guarda relaci\u00f3n con el lugar de la intervenci\u00f3n, incluyendo las colecciones de las infecciones posquir\u00fargicas pr\u00f3ximas al injerto.Receptores de trasplante card\u00edacoLas infecciones m\u00e1s frecuentes despu\u00e9s del trasplante card\u00edaco se localizan en el pulm\u00f3n, v\u00edas urinarias y piel (virus del grupo herpes).", [["grupo herpes", "DISEASE", 333, 345], ["virus del grupo herpes", "ORGANISM", 323, 345]]], ["Las infecciones quir\u00fargicas como mediastinitis e infecci\u00f3n de la herida son m\u00e1s frecuentes en pacientes con diabetes mellitus, reintervenci\u00f3n por hemorragia y tratamiento preventivo del rechazo del injerto.", [["diabetes mellitus", "DISEASE", 108, 125], ["diabetes mellitus", "PROBLEM", 108, 125], ["reintervenci\u00f3n", "TREATMENT", 127, 141]]], ["Las infecciones de los dispositivos de asistencia ventricular se localizan en la v\u00eda de alimentaci\u00f3n, en el bolsillo que rodea al dispositivo o en la parte interna del dispositivo, y son una causa frecuente de bacteriemia.", [["bacteriemia", "DISEASE", 210, 221], ["bacteriemia", "PROBLEM", 210, 221]]], ["Hay que prestar atenci\u00f3n a otros microorganismos menos frecuentes como M. hominis, Legionella, Aspergillus, zigomicetos y Nocardia.", [["Nocardia", "DISEASE", 122, 130], ["M. hominis", "SPECIES", 71, 81], ["Legionella", "PROBLEM", 83, 93], ["Aspergillus", "PROBLEM", 95, 106]]], ["Estos pacientes suelen presentar neumon\u00eda necrotizante, miocarditis y encefalitis semanas o unos pocos meses despu\u00e9s del trasplante y es infrecuente en pacientes que toman profilaxis con cotrimoxazol 22 .", [["cotrimoxazol", "CHEMICAL", 187, 199], ["cotrimoxazol", "CHEMICAL", 187, 199], ["con cotrimoxazol", "TREATMENT", 183, 199]]], ["Las dosis de cotrimoxazol habitualmente empleadas para la profilaxis de la NPJ no consiguen evitar completamente la infecci\u00f3n por Nocardia.", [["Nocardia", "DISEASE", 130, 138], ["Las dosis", "PROBLEM", 0, 9], ["Nocardia", "PROBLEM", 130, 138]]], ["Una complicaci\u00f3n devastadora en los trasplantados por enfermedad de Chagas es su reactivaci\u00f3n (que ocurre en el 25% de los casos) y que suele manifestarse con fiebre, miocarditis y lesiones cut\u00e1neas.", [["Chagas es su reactivaci\u00f3n", "DISEASE", 68, 93], ["Una complicaci\u00f3n devastadora", "TREATMENT", 0, 28]]], ["La endocarditis postrasplante suele ser de adquisici\u00f3n nosocomial y se produce durante el primer a\u00f1o.", [["endocarditis", "DISEASE", 3, 15], ["La endocarditis", "PROBLEM", 0, 15], ["endocarditis", "OBSERVATION", 3, 15]]], ["Hay que se\u00f1alar que los trasplantados card\u00edacos con valvulopat\u00eda deben recibir la profilaxis con amoxicilina en caso de que vayan a someterse a procedimientos odontol\u00f3gicos invasores de la mucosa 23 .Receptores de trasplante de pulm\u00f3nLos pacientes con trasplante de pulm\u00f3n experimentan una tasa elevada de infecciones pulmonares bacterianas, mic\u00f3ticas y v\u00edricas (CMV, fundamentalmente) que son m\u00e1s frecuentes durante las primeras semanas postrasplante.", [["card\u00edacos con valvulopat\u00eda deben recibir la profilaxis con amoxicilina", "TREATMENT", 38, 108], ["bacterianas", "PROBLEM", 329, 340]]], ["Un factor muy relevante es la colonizaci\u00f3n previa del \u00e1rbol respiratorio por bacterias multirresistentes (frecuente en pacientes con fibrosis qu\u00edstica, bronquiectasias secundarias a otras enfermedades) que pueden producir infecci\u00f3n respiratoria tras el trasplante.", [["fibrosis qu\u00edstica", "DISEASE", 133, 150], ["Un factor", "TEST", 0, 9], ["previa del", "PROBLEM", 43, 53], ["bacterias multirresistentes", "PROBLEM", 77, 104], ["fibrosis qu\u00edstica", "PROBLEM", 133, 150], ["a otras enfermedades", "TREATMENT", 180, 200]]], ["Las infecciones pulmonares recidivantes por CMV, VHS, paramixovirus y adenovirus son m\u00e1s frecuentes en casos de bronquiolitis obliterante y contribuyen de manera decisiva a la mortalidad de estos pacientes.", [["CMV", "ORGANISM", 44, 47], ["adenovirus", "ORGANISM", 70, 80], ["CMV", "PROBLEM", 44, 47], ["VHS", "PROBLEM", 49, 52]]], ["Otras complicaciones frecuentes en estos enfermos son las infecciones extrahospitalarias por virus respiratorios (gripe, parainfluenza, virus respiratorio sincitial -VRS-, metaneumovirus, coronavirus, rinovirus y adenovirus) y las infecciones pulmonares por micobacterias at\u00edpicas.", [["adenovirus", "ORGANISM", 213, 223], ["parainfluenza", "SPECIES", 121, 134], ["coronavirus", "SPECIES", 188, 199], ["Otras", "TEST", 0, 5], ["gripe", "TEST", 114, 119], ["parainfluenza", "PROBLEM", 121, 134], ["virus respiratorio", "TEST", 136, 154], ["VRS", "PROBLEM", 166, 169], ["metaneumovirus", "PROBLEM", 172, 186], ["coronavirus", "PROBLEM", 188, 199], ["rinovirus y adenovirus)", "PROBLEM", 201, 224], ["micobacterias at\u00edpicas", "PROBLEM", 258, 280]]], ["La IFI es m\u00e1s frecuente que en los receptores de otros \u00f3rganos.", [["La IFI", "TEST", 0, 6]]], ["Una forma peculiar de aspergilosis en estos pacientes es la afectaci\u00f3n de la mucosa de las v\u00edas respiratorias o de las anastomosis bronquiales, denominada aspergilosis traqueobronquial 24 .", [["anastomosis bronquiales", "DISEASE", 119, 142], ["Una forma peculiar de aspergilosis", "PROBLEM", 0, 34], ["la mucosa", "ANATOMY", 74, 83]]], ["Para prevenir estas infecciones se emplea profilaxis antif\u00fangica con azoles o anfotericina B inhalada.Receptores de trasplante renalLa mayor\u00eda de las infecciones se originan en el ri\u00f1\u00f3n y las v\u00edas urinarias.", [["azoles", "CHEMICAL", 69, 75], ["anfotericina B inhalada", "ORGANISM", 78, 101], ["Para prevenir estas infecciones", "TREATMENT", 0, 31], ["antif\u00fangica con azoles", "TREATMENT", 53, 75]]], ["Los factores de riesgo de infecci\u00f3n m\u00e1s importantes son la obesidad, la diabetes mellitus, la inmunosupresi\u00f3n con micofenolato, las fugas urinarias y la reintervenci\u00f3n.", [["diabetes mellitus", "DISEASE", 72, 89], ["la diabetes mellitus", "PROBLEM", 69, 89], ["la inmunosupresi\u00f3n con micofenolato", "TREATMENT", 91, 126]]], ["Los pacientes que han recibido un regimen inmunosupresor m\u00e1s intenso o muestran una disfunci\u00f3n cr\u00f3nica del ri\u00f1\u00f3n trasplantado tienen m\u00e1s riesgo de infecci\u00f3n tard\u00eda.", [["inmunosupresor", "TREATMENT", 42, 56]]], ["Alteraciones como el reflujo ureteral, estenosis en la uni\u00f3n ureterovesical o la vejiga neur\u00f3gena puede producir infecciones de repetici\u00f3n.", [["Alteraciones", "TEST", 0, 12], ["ureteral", "ANATOMY", 29, 37], ["ureterovesical", "ANATOMY", 61, 75], ["la vejiga", "ANATOMY", 78, 87]]], ["En relaci\u00f3n con la bacteriuria asintom\u00e1tica, no hay datos suficientes para su tratamiento, por lo que no se recomienda la obtenci\u00f3n de urocultivo de contol tras la infecci\u00f3n urinaria.", [["bacteriuria asintom\u00e1tica", "DISEASE", 19, 43], ["la bacteriuria asintom\u00e1tica", "PROBLEM", 16, 43], ["bacteriuria", "OBSERVATION", 19, 30]]], ["Con menos frecuencia pueden aparecer infecciones de orina ocasionadas por M. tuberculosis, Mycoplasma hominis, adenovirus, virus BK.", [["M. tuberculosis", "DISEASE", 74, 89], ["Mycoplasma hominis", "DISEASE", 91, 109], ["M. tuberculosis", "ORGANISM", 74, 89], ["Mycoplasma hominis", "ORGANISM", 91, 109], ["adenovirus, virus BK", "ORGANISM", 111, 131], ["M. tuberculosis", "SPECIES", 74, 89], ["Mycoplasma hominis", "SPECIES", 91, 109], ["M. tuberculosis", "SPECIES", 74, 89], ["Mycoplasma hominis", "SPECIES", 91, 109], ["Con menos frecuencia", "TEST", 0, 20], ["tuberculosis", "PROBLEM", 77, 89], ["Mycoplasma hominis", "PROBLEM", 91, 109], ["adenovirus", "PROBLEM", 111, 121], ["virus BK", "PROBLEM", 123, 131], ["tuberculosis", "OBSERVATION", 77, 89], ["Mycoplasma hominis", "OBSERVATION", 91, 109]]], ["La hepatitis por virus C (VHC) es especialmente frecuente en receptores de trasplante renal, a veces relacionada con el consumo de hemoderivados o la etapa previa de hemodi\u00e1lisis.Receptores de trasplante hep\u00e1ticoLos receptores de trasplante hep\u00e1tico presentan un riesgo de infecci\u00f3n intermedio.", [["hepatitis por", "DISEASE", 3, 16], ["La hepatitis por virus C", "ORGANISM", 0, 24], ["La hepatitis por virus C", "PROBLEM", 0, 24], ["previa de hemodi\u00e1lisis", "PROBLEM", 156, 178], ["hepatitis", "OBSERVATION", 3, 12], ["renal", "ANATOMY", 86, 91]]], ["Los factores de riesgo m\u00e1s importantes para este tipo de infecciones son la insuficiencia renal, el fracaso hep\u00e1tico fulminante, la cirug\u00eda prolongada, el retrasplante, la sobrecarga hep\u00e1tica de hierro y la colonizaci\u00f3n por Candida en el momento del trasplante 26 .", [["renal", "ANATOMY", 90, 95]]], ["Casi un tercio por especies de Candida no albicans (en relaci\u00f3n con profilaxis con fluconazol).", [["fluconazol", "CHEMICAL", 83, 93], ["Candida no albicans", "SPECIES", 31, 50], ["albicans", "PROBLEM", 42, 50], ["en relaci\u00f3n con profilaxis con fluconazol", "TREATMENT", 52, 93]]], ["La aspergilosis invasiva se produce en el 1-8% y casi siempre m\u00e1s de 90 d\u00edas despu\u00e9s del trasplante, lo que se ha relacionado con la profilaxis antif\u00fangica y la aparici\u00f3n tard\u00eda de algunos factores de riesgo como la infecci\u00f3n por CMV.", [["CMV", "ORGANISM", 230, 233], ["La aspergilosis", "TEST", 0, 15], ["relacionado con la profilaxis", "TREATMENT", 114, 143]]], ["La anastomosis del conducto biliar con un asa de yeyuno en Y de Roux, la estenosis biliar o trombosis de la arteria hep\u00e1tica suelen favorecer las infecciones abdominales tras el trasplante de h\u00edgado.", [["La anastomosis del conducto biliar con un asa", "TREATMENT", 0, 45], ["la estenosis biliar o trombosis", "PROBLEM", 70, 101], ["anastomosis", "OBSERVATION", 3, 14], ["Roux", "ANATOMY", 64, 68], ["trombosis", "OBSERVATION", 92, 101], ["la arteria", "ANATOMY", 105, 115]]], ["El diagn\u00f3stico se establece mediante ecograf\u00eda o TC y el tratamiento mediante drenaje y antibioterapia intravenosa.", [["TC y el tratamiento mediante drenaje y antibioterapia intravenosa", "TREATMENT", 49, 114]]], ["Predominan las infecciones pi\u00f3genas intraabdominales y las hemat\u00f3genas.", [["Predominan las infecciones", "PROBLEM", 0, 26]]], ["El intestino trasplantado, igual que el pulm\u00f3n trasplantado, es muy susceptible a la infecci\u00f3n por CMV.", [["CMV", "ORGANISM", 99, 102], ["CMV", "PROBLEM", 99, 102]]], ["La incidencia de s\u00edndromes linfoproliferativos asociados al VEB se aproxima al 10% a los 5 a\u00f1os y suelen afectar al intestino.", [["La incidencia de s\u00edndromes", "PROBLEM", 0, 26]]], ["Son frecuentes las infecciones por CMV o Candida e infecciones del lecho quir\u00fargico.Localizaciones y tipos de infeccionesInfecciones del torrente sangu\u00edneo La bacteriemia aparece en el 5-10% de los receptores renales y card\u00edacos, con tasas m\u00e1s altas (10-25%) en el trasplante hep\u00e1tico y pulmonar.", [["Localizaciones", "TEST", 84, 98], ["con tasas m\u00e1s altas", "TREATMENT", 230, 249]]], ["El aparato respiratorio, la v\u00eda urinaria, la cavidad abdominal (incluidas las v\u00edas biliares), la piel y los tejidos subcut\u00e1neos y las v\u00edas venosas son los or\u00edgenes m\u00e1s frecuentes en estas infecciones.", [["El aparato", "TEST", 0, 10], ["la v\u00eda urinaria", "TEST", 25, 40], ["la cavidad abdominal", "PROBLEM", 42, 62], ["la", "ANATOMY_MODIFIER", 42, 44], ["abdominal", "ANATOMY", 53, 62]]], ["En el 20% de los casos no es posible determinar el foco infeccioso.", [["foco infeccioso", "OBSERVATION", 51, 66]]], ["Las resistencias locales deben considerarse para establecer la terapia antibi\u00f3tica emp\u00edrica en estos pacientes 28 .Infecciones del sistema nervioso centralEl riesgo de estas infecciones es mayor entre el primer y el sexto mes tras el trasplante, aunque la meningitis por criptococo suele aparecer tard\u00edamente.", [["meningitis", "DISEASE", 256, 266], ["aunque la meningitis", "PROBLEM", 246, 266], ["meningitis", "OBSERVATION", 256, 266]]], ["Listeria puede producir bacteriemia, meningitis y cerebritis en estos pacientes.", [["meningitis", "DISEASE", 37, 47], ["Listeria puede", "SPECIES", 0, 14], ["Listeria puede producir bacteriemia", "SPECIES", 0, 35], ["Listeria", "PROBLEM", 0, 8], ["producir bacteriemia", "PROBLEM", 15, 35], ["meningitis y cerebritis", "PROBLEM", 37, 60], ["producir bacteriemia", "OBSERVATION", 15, 35], ["meningitis", "OBSERVATION_MODIFIER", 37, 47], ["cerebritis", "OBSERVATION", 50, 60]]], ["El l\u00edquido cefalorraqu\u00eddeo (LCR) suele mostrar pleocitosis mononuclear con cultivo negativo en m\u00e1s del 50% de los casos.", [["mostrar pleocitosis", "PROBLEM", 39, 58], ["mononuclear con cultivo", "TEST", 59, 82]]], ["El diagn\u00f3stico se suele establecer mediante los hemocultivos o del LCR y presenta tendencia a las recurrencias a pesar de la respuesta inicial a los antimicrobianos.", [["los antimicrobianos", "OBSERVATION", 145, 164]]], ["Al tratarse de una bacteria sensible a cotrimoxazol, su incidencia es menor que la esperada, considerando la inmunodepresi\u00f3n celular de estos pacientes.", [["a cotrimoxazol", "TREATMENT", 37, 51]]], ["La infecci\u00f3n del SNC por Aspergillus suele presentar una v\u00eda de entrada pulmonar, es m\u00e1s frecuente en el trasplante pulmonar y hep\u00e1tico y sus factores de riesgo m\u00e1s importantes son la disfunci\u00f3n renal y una inmunosupresi\u00f3n intensa.", [["Aspergillus", "TEST", 25, 36], ["renal y una inmunosupresi\u00f3n intensa", "TREATMENT", 195, 230], ["renal", "ANATOMY", 195, 200]]], ["La detecci\u00f3n de galactomanano en sangre es una buena herramienta diagn\u00f3stica.", [["La detecci\u00f3n", "TEST", 0, 12]]], ["La meningitis por criptococo suele aparecer despu\u00e9s del primer a\u00f1o postrasplante y se caracteriza por fiebre y s\u00edndrome men\u00edngeo de evoluci\u00f3n subaguda.", [["meningitis", "DISEASE", 3, 13], ["La meningitis", "PROBLEM", 0, 13], ["criptococo", "TEST", 18, 28], ["del primer", "PROBLEM", 52, 62], ["meningitis", "OBSERVATION", 3, 13]]], ["Puede acompa\u00f1arse de neumonitis y fungemia 26 .", [["fungemia", "DISEASE", 34, 42], ["Puede acompa\u00f1arse de neumonitis y fungemia 26", "SPECIES", 0, 45], ["fungemia", "PROBLEM", 34, 42]]], ["Toxoplasma gondii es un protozoo que puede producir distintos tipos de infecci\u00f3n del SNC que se presentan como meningoencefalitis difusa o lesiones cerebrales en forma de absceso.", [["Toxoplasma gondii", "DISEASE", 0, 17], ["Toxoplasma gondii", "ORGANISM", 0, 17], ["Toxoplasma gondii", "SPECIES", 0, 17], ["Toxoplasma gondii", "TEST", 0, 17]]], ["La nocardiosis puede producir meningitis o abscesos cerebrales y suele comenzar mediante la invasi\u00f3n pulmonar, generaliz\u00e1ndose posteriormente.", [["nocardiosis", "DISEASE", 3, 14], ["meningitis", "DISEASE", 30, 40], ["La nocardiosis", "TEST", 0, 14], ["meningitis", "PROBLEM", 30, 40], ["abscesos", "PROBLEM", 43, 51], ["nocardiosis", "OBSERVATION", 3, 14]]], ["Las sulfamidas se emplean en su tratamiento.", [["Las sulfamidas se emplean en su tratamiento", "TREATMENT", 0, 43]]], ["Algunos f\u00e1rmacos como amikacina, imipenem y cefotaxima muestran buena actividad frente a este microorganismo y se pueden utilizar en un tratamietno combinado con cotrimoxazol 29 .Infecciones respiratoriasLos pacientes con neumon\u00eda subaguda (m\u00e1s de 7 d\u00edas de evoluci\u00f3n) que presentan tos no productiva o tienen infiltrados difusos o lesiones nodulares en la radiograf\u00eda de t\u00f3rax requieren un estudio profundo de su etiolog\u00eda y deben someterse a broncoscopia 30 .", [["imipenem", "CHEMICAL", 33, 41], ["cotrimoxazol", "CHEMICAL", 162, 174], ["Algunos f\u00e1rmacos como amikacina", "TREATMENT", 0, 31], ["imipenem", "TREATMENT", 33, 41], ["utilizar en un tratamietno combinado con cotrimoxazol", "TREATMENT", 121, 174], ["respiratorias", "PROBLEM", 191, 204], ["productiva", "PROBLEM", 290, 300]]], ["Las infecciones producidas por virus respiratorios extrahospitalarios, como los virus de la gripe, parainfluenza, VRS, metaneumovirus, coronavirus, rinovirus o adenovirus pueden producir neumon\u00eda en pacientes trasplantados; su diagn\u00f3stico puede realizarse mediante la detecci\u00f3n de ant\u00edgenos, cultivos o PCR 31 .", [["parainfluenza", "DISEASE", 99, 112], ["adenovirus", "ORGANISM", 160, 170], ["Las infecciones producidas", "PROBLEM", 0, 26], ["como los virus de la gripe", "PROBLEM", 71, 97], ["parainfluenza", "PROBLEM", 99, 112], ["VRS", "PROBLEM", 114, 117], ["metaneumovirus", "PROBLEM", 119, 133], ["coronavirus", "PROBLEM", 135, 146], ["adenovirus", "PROBLEM", 160, 170], ["PCR", "TEST", 303, 306], ["parainfluenza", "OBSERVATION", 99, 112]]], ["Apenas hay tratamiento para las neumon\u00edas causadas por virus respiratorios, con excepci\u00f3n de la gripe, con oseltamivir oral.", [["oral", "ANATOMY", 119, 123], ["oseltamivir", "CHEMICAL", 107, 118], ["oral", "ORGANISM_SUBDIVISION", 119, 123], ["Apenas", "TEST", 0, 6], ["oseltamivir oral", "TREATMENT", 107, 123]]], ["Zanamivir por v\u00eda intravenosa estar\u00e1 disponible en los pr\u00f3ximos a\u00f1os 31 .", [["Zanamivir", "TREATMENT", 0, 9]]], ["El diagn\u00f3stico de la infecci\u00f3n por Aspergillus o Nocardia suele requerir la realizaci\u00f3n de broncoscopia.Infecciones intraabdominalesEste tipo de infecciones son m\u00e1s frecuentes en los trasplantados de h\u00edgado, p\u00e1ncreas o intestino delgado.", [["Aspergillus", "PROBLEM", 35, 46], ["Infecciones intraabdominales", "PROBLEM", 104, 132]]], ["Suelen estar relacionadas con trastornos m\u00e9dicos de base, como litiasis biliar, diverticulosis y con el propio acto quir\u00fargico.", [["diverticulosis", "DISEASE", 80, 94], ["como litiasis biliar", "PROBLEM", 58, 78], ["diverticulosis", "PROBLEM", 80, 94], ["diverticulosis", "OBSERVATION", 80, 94]]], ["La ICD se ha convertido en una de las causas m\u00e1s frecuentes de diarrea en pacientes trasplantados, y guarda relaci\u00f3n con las estancias hospitalarias prolongadas y las infecciones bacterianas que son tratadas con antibi\u00f3ticos.", [["La ICD", "TREATMENT", 0, 6], ["ICD", "OBSERVATION", 3, 6]]], ["En una minor\u00eda de casos se desarrolla alguna complicaci\u00f3n como megacolon o perforaci\u00f3n que requerir\u00eda cirug\u00eda.", [["megacolon", "DISEASE", 63, 72], ["megacolon", "PROBLEM", 63, 72]]], ["Igual que en la poblaci\u00f3n general, el 20% de los casos, aproximadamente, desarrollan recurrencias.", [["desarrollan recurrencias", "DISEASE", 73, 97], ["aproximadamente", "TREATMENT", 56, 71], ["desarrollan recurrencias", "PROBLEM", 73, 97]]], ["La infecci\u00f3n por Helicobacter pylori se ha asociado a una neoplasia linfoproliferativa de bajo grado, llamada MALToma.", [["neoplasia linfoproliferativa", "DISEASE", 58, 86], ["La infecci\u00f3n", "PROBLEM", 0, 12], ["Helicobacter pylori", "PROBLEM", 17, 36], ["a una neoplasia", "PROBLEM", 52, 67], ["llamada MALToma", "PROBLEM", 102, 117], ["Helicobacter pylori", "OBSERVATION", 17, 36], ["una neoplasia", "OBSERVATION", 54, 67], ["llamada MALToma", "OBSERVATION", 102, 117]]], ["La mayor parte de estas neoplasias responden bien a la reducci\u00f3n de la inmunosupresi\u00f3n y a la erradicaci\u00f3n de la infecci\u00f3n con antibi\u00f3ticos.", [["a la erradicaci\u00f3n de la infecci\u00f3n con antibi\u00f3ticos", "TREATMENT", 89, 139]]], ["La hiperinfestaci\u00f3n y la infecci\u00f3n diseminada por Strongyloides stercoralis constituyen problemas relevantes en la actualidad dada la escasa sospecha de esta infecci\u00f3n cr\u00f3nica en donantes o receptores de trasplante.", [["Strongyloides stercoralis", "DISEASE", 50, 75], ["La hiperinfestaci\u00f3n y la infecci\u00f3n diseminada", "TREATMENT", 0, 45], ["Strongyloides stercoralis", "PROBLEM", 50, 75], ["problemas", "PROBLEM", 88, 97]]], ["Los microorganismos m\u00e1s comunes son S. aureus, enterococos, bacterias Gram negativas, Candida y M. hominis.", [["S. aureus", "ORGANISM", 36, 45], ["enterococos", "ORGANISM", 47, 58], ["bacterias Gram negativas", "ORGANISM", 60, 84], ["Candida y M. hominis", "ORGANISM", 86, 106], ["S. aureus", "SPECIES", 36, 45], ["Gram negativas", "SPECIES", 70, 84], ["M. hominis", "SPECIES", 96, 106], ["S. aureus", "SPECIES", 36, 45], ["Gram negativas", "SPECIES", 70, 84], ["Candida y M. hominis", "SPECIES", 86, 106], ["Los microorganismos", "TEST", 0, 19], ["S. aureus", "PROBLEM", 36, 45], ["enterococos", "PROBLEM", 47, 58], ["bacterias", "PROBLEM", 60, 69], ["Candida y M. hominis", "PROBLEM", 86, 106], ["aureus", "OBSERVATION", 39, 45]]], ["En raras ocasiones, la nocardiosis, la mucormicosis y la criptococosis tambi\u00e9n pueden dar lugar a celulitis o a infecciones necrosantes cut\u00e1neas 33 .", [["nocardiosis", "DISEASE", 23, 34], ["la nocardiosis", "PROBLEM", 20, 34], ["la mucormicosis", "PROBLEM", 36, 51], ["la", "ANATOMY", 20, 22], ["nocardiosis", "OBSERVATION", 23, 34]]], ["Las verrugas son un problema com\u00fan, sobre todo una vez transcurridos m\u00e1s de 5 a\u00f1os desde el trasplante.HepatitisLas causas m\u00e1s importantes de hepatitis en pacientes trasplantados son el VHB, el VHC y el CMV, y las menos frecuentes VHS, VVZ, adenovirus y VHH 6.", [["hepatitis", "DISEASE", 142, 151], ["adenovirus", "ORGANISM", 241, 251], ["HepatitisLas", "PROBLEM", 103, 115], ["VHS", "PROBLEM", 231, 234], ["VVZ", "PROBLEM", 236, 239], ["adenovirus y VHH", "TREATMENT", 241, 257]]], ["Los candidatos a trasplante hep\u00e1tico con infecci\u00f3n cr\u00f3nica por el VHB suelen infectar al injerto.", [["a trasplante hep\u00e1tico con infecci\u00f3n", "TREATMENT", 15, 50]]], ["La estrategia m\u00e1s conveniente para prevenir la recurrencia del VHB consiste en un tratamiento combinado (por ejemplo, lamivudina y tenofovir) antes y despu\u00e9s del trasplante.", [["tenofovir", "CHEMICAL", 131, 140], ["La estrategia", "TEST", 0, 13], ["un tratamiento combinado", "TREATMENT", 79, 103], ["lamivudina y tenofovir)", "TREATMENT", 118, 141]]], ["Aproximadamente, el 5% de los receptores de trasplantes infectados por el VHC desarrollar\u00e1 colestasis hep\u00e1tica progresiva fatal durante el primer a\u00f1o tras el trasplante.", [["Aproximadamente", "CHEMICAL", 0, 15], ["Aproximadamente", "SIMPLE_CHEMICAL", 0, 15], ["Aproximadamente", "TREATMENT", 0, 15]]], ["Estos casos presentan una elevada carga v\u00edrica y citolisis importante con m\u00ednima inflamaci\u00f3n parenquimatosa.", [["Estos", "TEST", 0, 5]]], ["Los candidatos a trasplante hep\u00e1tico que tienen viremia por el VHC antes del trasplante casi siempre infectan el injerto despu\u00e9s del trasplante y una proporci\u00f3n muy relevante desarrollar\u00e1 una hepatitis durante los primeros a\u00f1os tras el trasplante.", [["hepatitis durante", "DISEASE", 192, 209], ["viremia", "PROBLEM", 48, 55]]], ["Los antiv\u00edricos de acci\u00f3n directa (inhibidores de la proteasa, inhibidores de la polimerasa de ARN, inhibidores de NS5A) consiguen la curaci\u00f3n de la infecci\u00f3n antes del trasplante en casi todos los pacientes 34 .Problemas espec\u00edficos de las infecciones por virus en receptores de trasplante de \u00f3rgano s\u00f3lidoEl VHS suele reactivarse y afectar a la piel en m\u00e1s de la mitad de los casos si no se administra profilaxis con aciclovir.", [["ARN", "DISEASE", 95, 98], ["aciclovir", "CHEMICAL", 419, 428], ["aciclovir", "CHEMICAL", 419, 428], ["aciclovir", "SIMPLE_CHEMICAL", 419, 428], ["Los antiv\u00edricos de acci\u00f3n directa (inhibidores de la proteasa", "TREATMENT", 0, 61], ["inhibidores de la polimerasa de ARN", "TREATMENT", 63, 98], ["se administra profilaxis", "TREATMENT", 390, 414], ["aciclovir", "TREATMENT", 419, 428]]], ["La infecci\u00f3n visceral por VHS es muy infrecuente.", [["visceral", "ANATOMY", 13, 21]]], ["En la mayor parte de los casos se trata de hepatitis por VHS tras el trasplante hep\u00e1tico o neumon\u00eda por VHS tras el trasplante pulmonar.", [["hepatitis por", "DISEASE", 43, 56]]], ["La infecci\u00f3n por CMV es m\u00e1s grave en receptores con serolog\u00eda negativa que reciben un \u00f3rgano de un donante seropositivo (infecci\u00f3n primaria) 34 .", [["CMV", "ORGANISM", 17, 20], ["La infecci\u00f3n", "TEST", 0, 12], ["CMV", "TEST", 17, 20]]], ["La presentaci\u00f3n cl\u00ednica m\u00e1s com\u00fan es el denominado s\u00edndrome v\u00edrico (mononucle\u00f3sico) que cursa con fiebre, leucopenia, trombopenia y elevaci\u00f3n discreta de las enzimas de citolisis.", [["leucopenia", "DISEASE", 106, 116], ["La presentaci\u00f3n", "TEST", 0, 15], ["cl\u00ednica", "TEST", 16, 23], ["m\u00e1s", "TEST", 24, 27], ["v\u00edrico (mononucle\u00f3sico)", "PROBLEM", 60, 83], ["leucopenia", "PROBLEM", 106, 116], ["trombopenia", "PROBLEM", 118, 129], ["leucopenia", "OBSERVATION", 106, 116]]], ["Los \u00f3rganos m\u00e1s afectados en los casos m\u00e1s graves son el pulm\u00f3n, el tubo digestivo y el h\u00edgado 35 .", [["Los \u00f3rganos", "TEST", 0, 11], ["afectados", "TEST", 16, 25]]], ["La neumonitis puede ser grave y se acompa\u00f1a de disnea, hipoxemia y patr\u00f3n intersticial difuso en la radiograf\u00eda.", [["La neumonitis", "PROBLEM", 0, 13]]], ["La afectaci\u00f3n ent\u00e9rica se caracteriza por \u00falceras digestivas que se evidencian por endoscopia y se confirman con la biopsia.", [["La afectaci\u00f3n ent\u00e9rica se caracteriza", "TREATMENT", 0, 37]]], ["La afectaci\u00f3n hep\u00e1tica es m\u00e1s frecuente en receptores de trasplante de h\u00edgado y en la infecci\u00f3n primaria en comparaci\u00f3n con los casos de reactivaci\u00f3n.", [["La", "TEST", 0, 2]]], ["Ganciclovir es el antiv\u00edrico de elecci\u00f3n de la enfermedad por CMV en trasplantados.", [["CMV", "ORGANISM", 62, 65], ["Ganciclovir es el antiv\u00edrico de elecci\u00f3n de la enfermedad", "TREATMENT", 0, 57], ["CMV en trasplantados", "TREATMENT", 62, 82]]], ["En casos leves, valganciclovir (v\u00eda oral) es una alternativa razonable, lo que facilita el alta precoz en algunos casos 36 .", [["valganciclovir", "CHEMICAL", 16, 30], ["valganciclovir", "CHEMICAL", 16, 30], ["valganciclovir", "SIMPLE_CHEMICAL", 16, 30], ["oral", "ORGANISM_SUBDIVISION", 36, 40], ["En casos leves", "TREATMENT", 0, 14], ["valganciclovir (v\u00eda oral", "TREATMENT", 16, 40]]], ["En pacientes con CMV resistente a ganciclovir se puede emplear cidofovir y foscarnet.Problemas espec\u00edficos de las infecciones por virus en receptores de trasplante de \u00f3rgano s\u00f3lidoLa infecci\u00f3n por el VHH 6 suele producirse durante el primer mes postrasplante, por reactivaci\u00f3n de la infecci\u00f3n latente, y puede afectar a un tercio aproximadamente de los pacientes trasplantados, especialmente en quienes no se realiza profilaxis antiv\u00edrica para el CMV.", [["ganciclovir", "CHEMICAL", 34, 45], ["cidofovir", "CHEMICAL", 63, 72], ["foscarnet", "CHEMICAL", 75, 84], ["ganciclovir", "CHEMICAL", 34, 45], ["cidofovir y foscarnet", "CHEMICAL", 63, 84], ["CMV", "ORGANISM", 17, 20], ["foscarnet", "SIMPLE_CHEMICAL", 75, 84], ["CMV", "ORGANISM", 447, 450], ["En pacientes con CMV", "TREATMENT", 0, 20], ["a ganciclovir", "TREATMENT", 32, 45], ["cidofovir y foscarnet", "TREATMENT", 63, 84], ["Problemas", "PROBLEM", 85, 94], ["virus en receptores de trasplante de \u00f3rgano s\u00f3lidoLa infecci\u00f3n", "TREATMENT", 130, 192]]], ["Producen un s\u00edndrome v\u00edrico inespec\u00edfico con fiebre y leucopenia, y rara vez afectaci\u00f3n grave neurol\u00f3gica, respiratoria o hep\u00e1tica.Problemas espec\u00edficos de las infecciones por virus en receptores de trasplante de \u00f3rgano s\u00f3lidoLa infecci\u00f3n por VHH 8 es m\u00e1s frecuente en \u00c1frica central y del sur, en Oriente Medio y en los pa\u00edses europeos cercanos al Mediterr\u00e1neo (fen\u00f3meno diferenciador respecto a otras infecciones del grupo herpes).", [["leucopenia", "DISEASE", 54, 64], ["grupo herpes", "DISEASE", 419, 431], ["leucopenia", "PROBLEM", 54, 64], ["Problemas", "PROBLEM", 131, 140], ["europeos cercanos al Mediterr\u00e1neo (fen\u00f3meno diferenciador respecto", "TREATMENT", 328, 394], ["hep\u00e1tica", "ANATOMY", 122, 130]]], ["Es la causa del sarcoma de Kaposi postrasplante, la enfermedad de Castleman y el linfoma de cavidades 37 .", [["Kaposi postrasplante", "DISEASE", 27, 47], ["Kaposi", "ORGANISM", 27, 33], ["Es la causa del sarcoma", "PROBLEM", 0, 23], ["del sarcoma", "OBSERVATION", 12, 23]]], ["El sarcoma de Kaposi experimenta una regresi\u00f3n cuando se reducen de forma sustancial las dosis de inmunosupresores.", [["Kaposi", "ORGANISM", 14, 20], ["El sarcoma", "PROBLEM", 0, 10], ["sarcoma", "OBSERVATION", 3, 10]]], ["El empleo de sirolimus (que presenta efecto antiproliferativo) en lugar de un calcineur\u00ednico tambi\u00e9n mejora el pron\u00f3stico.", [["sirolimus", "CHEMICAL", 13, 22], ["El empleo de sirolimus (que presenta efecto antiproliferativo", "TREATMENT", 0, 61], ["calcineur\u00ednico tambi\u00e9n mejora el pron\u00f3stico", "TREATMENT", 78, 121]]], ["Si no hay respuesta a estas medidas es necesaria la quimioterapia.Problemas espec\u00edficos de las infecciones por virus en receptores de trasplante de \u00f3rgano s\u00f3lidoLa infecci\u00f3n primaria por VEB se produce aproximadamente en el 75% de los receptores de trasplantes seronegativos.", [["Si", "CHEMICAL", 0, 2]]], ["Tambi\u00e9n hay que se\u00f1alar que el 30% de los trasplantes seropositivos presenta una reactivaci\u00f3n de la infecci\u00f3n evidenciada mediante la PCR en sangre.", [["Tambi\u00e9n", "TREATMENT", 0, 7]]], ["El otro factor de riesgo fundamental es la utilizaci\u00f3n de dosis altas de inmunosupresores 38 .", [["El otro factor", "PROBLEM", 0, 14]]], ["Los f\u00e1rmacos antiv\u00edricos, como aciclovir o ganciclovir, inhiben la fase l\u00edtica de la infecci\u00f3n por el VEB y la producci\u00f3n de viriones, pero no son eficaces contra la replicaci\u00f3n de las c\u00e9lulas con una infecci\u00f3n latente por VEB.", [["aciclovir", "CHEMICAL", 31, 40], ["ganciclovir", "CHEMICAL", 43, 54], ["Los f\u00e1rmacos antiv\u00edricos", "TREATMENT", 0, 24], ["como aciclovir", "TREATMENT", 26, 40], ["ganciclovir", "TREATMENT", 43, 54]]], ["El tratamiento de los casos m\u00e1s graves puede requerir quimioterapia y la infusi\u00f3n de anticuerpos monoclonales contra los ant\u00edgenos de superficie de los linfocitos B 38 .", [["quimioterapia y la infusi\u00f3n", "TREATMENT", 54, 81]]], ["Los tumores de fenotipo m\u00e1s maligno necesitan quimioterapia.Problemas espec\u00edficos de las infecciones por virus en receptores de trasplante de \u00f3rgano s\u00f3lidoLa presencia de poliomavirus en la orina puede detectarse en m\u00e1s de la mitad de los receptores de trasplante renal.Problemas espec\u00edficos de las infecciones por virus en receptores de trasplante de \u00f3rgano s\u00f3lidoEl virus BK ha sido relacionado con disfunci\u00f3n renal transitoria y estenosis ureteral.Problemas espec\u00edficos de las infecciones por virus en receptores de trasplante de \u00f3rgano s\u00f3lidoLos virus JC y SV40 se han detectado como causa de nefropat\u00eda en unos pocos pacientes, aunque su papel patog\u00e9nico est\u00e1 peor establecido.", [["renal", "ANATOMY", 264, 269], ["renal", "ANATOMY", 412, 417], ["SV40", "ORGANISM", 561, 565], ["Los tumores", "TEST", 0, 11], ["Problemas", "PROBLEM", 270, 279], ["\u00f3rgano s\u00f3lidoEl virus BK ha sido relacionado", "TREATMENT", 352, 396], ["renal transitoria y estenosis ureteral", "TREATMENT", 412, 450], ["renal", "ANATOMY", 264, 269], ["renal", "ANATOMY", 412, 417], ["ureteral", "ANATOMY", 442, 450]]], ["La infecci\u00f3n por el virus BK puede originarse de forma primaria, por la transmisi\u00f3n extrahospitalaria o por el donante, o mediante una reactivaci\u00f3n, dado que la mayor\u00eda de los adultos son seropositivos.", [["La infecci\u00f3n", "PROBLEM", 0, 12]]], ["El rechazo del injerto (y su tratamiento) puede ser un factor predisponente importante para esta reactivaci\u00f3n.", [["para esta reactivaci\u00f3n", "TREATMENT", 87, 109]]], ["La detecci\u00f3n de estos virus es posible mediante distintas t\u00e9cnicas, como cultivo, citolog\u00eda, microscopio electr\u00f3nico y PCR.", [["La detecci\u00f3n de estos virus", "PROBLEM", 0, 27]]], ["La reducci\u00f3n de la inmunosupresi\u00f3n es la medida m\u00e1s eficaz para prevenir la progresi\u00f3n de la nefropat\u00eda por el virus BK.", [["La reducci\u00f3n de la inmunosupresi\u00f3n", "TREATMENT", 0, 34]]], ["La afectaci\u00f3n del SNC por el virus JC (leucoencefalopat\u00eda multifocal progresiva) es mucho menos frecuentes que en pacientes infectados por el VIH.", [["La afectaci\u00f3n del SNC", "TREATMENT", 0, 21], ["el virus JC (leucoencefalopat\u00eda multifocal progresiva)", "TREATMENT", 26, 80]]], ["Los pacientes afectados desarrollan un cuadro de varias semanas o meses de duraci\u00f3n, caracterizado por sintomatolog\u00eda motora, sensitiva, visual o cognitiva.", [["visual o cognitiva", "DISEASE", 137, 155]]]], "PMC5759936": [["IntroductionOsteosarcoma is the most common sarcoma of bone.1 In spite of the fact that this cancer type only accounts for 5% to 6% of all childhood tumors, they are ranked among the most frequent causes of cancer-related death, because osteosarcomas have a high probability of metastasis.2 At the time of diagnosis, about 10% to 20% of patients have evidence of metastatic disease, most commonly (90%) in the lungs.3 Current management comprises preoperative chemotherapy followed by surgical removal of all detectable disease and postoperative (adjuvant) chemotherapy.4 Most chemotherapy regimens applied for osteosarcoma have been based on the following drugs: high-dose methotrexate with leucovorin rescue, doxorubicin (adriamycin), cisplatin, and ifosfamide.3 Preoperative \u201cneoadjuvant\u201d chemotherapy is generally administered for a period of about 8 to 10 weeks prior to surgery.", [["sarcoma", "ANATOMY", 44, 51], ["bone", "ANATOMY", 55, 59], ["cancer", "ANATOMY", 93, 99], ["childhood tumors", "ANATOMY", 139, 155], ["cancer", "ANATOMY", 207, 213], ["osteosarcomas", "ANATOMY", 237, 250], ["metastatic disease", "ANATOMY", 363, 381], ["lungs", "ANATOMY", 410, 415], ["osteosarcoma", "ANATOMY", 611, 623], ["IntroductionOsteosarcoma", "DISEASE", 0, 24], ["sarcoma", "DISEASE", 44, 51], ["cancer", "DISEASE", 93, 99], ["tumors", "DISEASE", 149, 155], ["cancer", "DISEASE", 207, 213], ["death", "DISEASE", 222, 227], ["osteosarcomas", "DISEASE", 237, 250], ["metastasis", "DISEASE", 278, 288], ["osteosarcoma", "DISEASE", 611, 623], ["methotrexate", "CHEMICAL", 674, 686], ["leucovorin", "CHEMICAL", 692, 702], ["doxorubicin", "CHEMICAL", 711, 722], ["adriamycin", "CHEMICAL", 724, 734], ["cisplatin", "CHEMICAL", 737, 746], ["ifosfamide", "CHEMICAL", 752, 762], ["methotrexate", "CHEMICAL", 674, 686], ["leucovorin", "CHEMICAL", 692, 702], ["doxorubicin", "CHEMICAL", 711, 722], ["adriamycin", "CHEMICAL", 724, 734], ["cisplatin", "CHEMICAL", 737, 746], ["ifosfamide", "CHEMICAL", 752, 762], ["sarcoma", "CANCER", 44, 51], ["bone", "TISSUE", 55, 59], ["cancer", "CANCER", 93, 99], ["childhood tumors", "CANCER", 139, 155], ["cancer", "CANCER", 207, 213], ["osteosarcomas", "CANCER", 237, 250], ["patients", "ORGANISM", 337, 345], ["metastatic disease", "CANCER", 363, 381], ["lungs", "ORGAN", 410, 415], ["osteosarcoma", "CANCER", 611, 623], ["methotrexate", "SIMPLE_CHEMICAL", 674, 686], ["leucovorin", "SIMPLE_CHEMICAL", 692, 702], ["doxorubicin", "SIMPLE_CHEMICAL", 711, 722], ["adriamycin", "SIMPLE_CHEMICAL", 724, 734], ["cisplatin", "SIMPLE_CHEMICAL", 737, 746], ["ifosfamide", "SIMPLE_CHEMICAL", 752, 762], ["patients", "SPECIES", 337, 345], ["IntroductionOsteosarcoma", "PROBLEM", 0, 24], ["the most common sarcoma of bone", "PROBLEM", 28, 59], ["this cancer type", "PROBLEM", 88, 104], ["all childhood tumors", "PROBLEM", 135, 155], ["cancer", "PROBLEM", 207, 213], ["related death", "PROBLEM", 214, 227], ["osteosarcomas", "PROBLEM", 237, 250], ["metastasis", "PROBLEM", 278, 288], ["metastatic disease", "PROBLEM", 363, 381], ["Current management", "TREATMENT", 418, 436], ["preoperative chemotherapy", "TREATMENT", 447, 472], ["surgical removal", "TREATMENT", 485, 501], ["all detectable disease", "PROBLEM", 505, 527], ["postoperative (adjuvant) chemotherapy", "TREATMENT", 532, 569], ["Most chemotherapy regimens", "TREATMENT", 572, 598], ["osteosarcoma", "PROBLEM", 611, 623], ["high-dose methotrexate", "TREATMENT", 664, 686], ["leucovorin rescue", "TREATMENT", 692, 709], ["doxorubicin (adriamycin)", "TREATMENT", 711, 735], ["cisplatin", "TREATMENT", 737, 746], ["ifosfamide", "TREATMENT", 752, 762], ["Preoperative \u201cneoadjuvant\u201d chemotherapy", "TREATMENT", 765, 804], ["surgery", "TREATMENT", 876, 883], ["most common", "OBSERVATION_MODIFIER", 32, 43], ["sarcoma", "OBSERVATION", 44, 51], ["bone", "ANATOMY", 55, 59], ["cancer", "OBSERVATION", 93, 99], ["tumors", "OBSERVATION", 149, 155], ["cancer", "OBSERVATION", 207, 213], ["metastasis", "OBSERVATION", 278, 288], ["evidence of", "UNCERTAINTY", 351, 362], ["metastatic", "OBSERVATION", 363, 373], ["lungs", "ANATOMY", 410, 415], ["detectable", "OBSERVATION_MODIFIER", 509, 519], ["disease", "OBSERVATION", 520, 527], ["postoperative", "OBSERVATION_MODIFIER", 532, 545], ["osteosarcoma", "OBSERVATION", 611, 623]]], ["Postoperative adjuvant chemotherapy is continued for a period of another 12 to 29 weeks after wound healing.5,6 During the chemotherapy period, other functional supplement plant extracts may be beneficial.IntroductionToona sinensis Roem (Meliaceae; TS), which grows mostly in Asia, is widely used as a medicine and especially as a vegetable.", [["wound", "ANATOMY", 94, 99], ["extracts", "ANATOMY", 178, 186], ["vegetable", "ANATOMY", 331, 340], ["Toona sinensis Roem", "CHEMICAL", 217, 236], ["wound", "PATHOLOGICAL_FORMATION", 94, 99], ["extracts", "ORGANISM_SUBSTANCE", 178, 186], ["Toona sinensis", "ORGANISM", 217, 231], ["Meliaceae; TS", "ORGANISM", 238, 251], ["vegetable", "ORGANISM_SUBDIVISION", 331, 340], ["Toona sinensis", "SPECIES", 217, 231], ["Toona sinensis", "SPECIES", 217, 231], ["Postoperative adjuvant chemotherapy", "TREATMENT", 0, 35], ["wound healing", "PROBLEM", 94, 107], ["the chemotherapy period", "TREATMENT", 119, 142], ["other functional supplement plant extracts", "TREATMENT", 144, 186], ["adjuvant chemotherapy", "OBSERVATION", 14, 35], ["healing", "OBSERVATION", 100, 107]]], ["The bark is used as an astringent and depurative agent, the root is used as refreshment and diuretic agents, the tender leaves are used as carminative and corrective agent, and its fruit is used as astringent and in treatment of eye infections.", [["bark", "ANATOMY", 4, 8], ["root", "ANATOMY", 60, 64], ["tender leaves", "ANATOMY", 113, 126], ["fruit", "ANATOMY", 181, 186], ["eye", "ANATOMY", 229, 232], ["eye infections", "DISEASE", 229, 243], ["bark", "TISSUE", 4, 8], ["root", "ORGAN", 60, 64], ["eye", "ORGAN", 229, 232], ["an astringent and depurative agent", "TREATMENT", 20, 54], ["refreshment", "TREATMENT", 76, 87], ["diuretic agents", "TREATMENT", 92, 107], ["the tender leaves", "PROBLEM", 109, 126], ["carminative", "TREATMENT", 139, 150], ["corrective agent", "TREATMENT", 155, 171], ["eye infections", "PROBLEM", 229, 243], ["bark", "ANATOMY_MODIFIER", 4, 8], ["root", "ANATOMY", 60, 64], ["eye", "ANATOMY", 229, 232], ["infections", "OBSERVATION", 233, 243]]], ["Especially leaves and young shoots, which have been used as a vegetable in China for thousands of years, are used as the treatment of enteritis, dysentery, and itch in oriental medicine.7 The aqueous extract of TS leaf (TSL) possesses antioxidant,8-10 antidiabetes,11 antivirus,12 and antiseptic13 activity.", [["leaves", "ANATOMY", 11, 17], ["shoots", "ANATOMY", 28, 34], ["aqueous extract", "ANATOMY", 192, 207], ["leaf", "ANATOMY", 214, 218], ["enteritis", "DISEASE", 134, 143], ["dysentery", "DISEASE", 145, 154], ["itch", "DISEASE", 160, 164], ["aqueous extract of TS leaf", "CHEMICAL", 192, 218], ["TSL", "CHEMICAL", 220, 223], ["shoots", "ORGANISM_SUBDIVISION", 28, 34], ["vegetable", "ORGANISM_SUBDIVISION", 62, 71], ["aqueous extract", "ORGANISM_SUBSTANCE", 192, 207], ["TS leaf", "ORGANISM", 211, 218], ["TSL", "SIMPLE_CHEMICAL", 220, 223], ["antiseptic13", "GENE_OR_GENE_PRODUCT", 285, 297], ["enteritis", "PROBLEM", 134, 143], ["dysentery", "PROBLEM", 145, 154], ["itch", "PROBLEM", 160, 164], ["oriental medicine", "TREATMENT", 168, 185], ["TS leaf (TSL) possesses antioxidant", "TREATMENT", 211, 246], ["antidiabetes", "TREATMENT", 252, 264], ["antivirus", "TREATMENT", 268, 277], ["enteritis", "OBSERVATION", 134, 143], ["dysentery", "OBSERVATION", 145, 154], ["aqueous", "OBSERVATION_MODIFIER", 192, 199], ["extract", "OBSERVATION_MODIFIER", 200, 207]]], ["In addition, TSL shows potent antiproliferation effect on many types of cancer, including leukemia, lung, oral squamous carcinoma, prostate, and ovary.14-20 Previous studies found that crude extracts from the TSL exerted potent antiproliferative effects on A549 lung cancer cells, H441 cells (lung adenocarcinoma), H661 cells (lung large cell carcinoma), and H520 cells (lung squamous cell carcinoma).16,17,19,21 It was also reported that crude extracts from TSL exert potent antiproliferative effects via decreased Bcl-2 protein accompanied by increased Bax protein level in H441 cells.16 However, the effects of TSL on osteosarcoma cells are rarely investigated.", [["cancer", "ANATOMY", 72, 78], ["leukemia", "ANATOMY", 90, 98], ["lung", "ANATOMY", 100, 104], ["oral squamous carcinoma", "ANATOMY", 106, 129], ["prostate", "ANATOMY", 131, 139], ["ovary", "ANATOMY", 145, 150], ["extracts", "ANATOMY", 191, 199], ["A549 lung cancer cells", "ANATOMY", 257, 279], ["H441 cells", "ANATOMY", 281, 291], ["lung adenocarcinoma", "ANATOMY", 293, 312], ["H661 cells", "ANATOMY", 315, 325], ["lung large cell carcinoma", "ANATOMY", 327, 352], ["H520 cells", "ANATOMY", 359, 369], ["lung squamous cell carcinoma", "ANATOMY", 371, 399], ["extracts", "ANATOMY", 445, 453], ["H441 cells", "ANATOMY", 576, 586], ["osteosarcoma cells", "ANATOMY", 621, 639], ["TSL", "CHEMICAL", 13, 16], ["cancer", "DISEASE", 72, 78], ["leukemia", "DISEASE", 90, 98], ["oral squamous carcinoma", "DISEASE", 106, 129], ["prostate, and ovary", "DISEASE", 131, 150], ["TSL", "CHEMICAL", 209, 212], ["lung cancer", "DISEASE", 262, 273], ["lung adenocarcinoma", "DISEASE", 293, 312], ["lung large cell carcinoma", "DISEASE", 327, 352], ["lung squamous cell carcinoma", "DISEASE", 371, 399], ["16,17,19,21", "CHEMICAL", 401, 412], ["TSL", "CHEMICAL", 459, 462], ["TSL", "CHEMICAL", 614, 617], ["osteosarcoma", "DISEASE", 621, 633], ["TSL", "CHEMICAL", 13, 16], ["TSL", "SIMPLE_CHEMICAL", 13, 16], ["cancer", "CANCER", 72, 78], ["leukemia", "CANCER", 90, 98], ["lung", "ORGAN", 100, 104], ["oral squamous carcinoma", "CANCER", 106, 129], ["prostate", "CANCER", 131, 139], ["ovary", "ORGAN", 145, 150], ["extracts", "ORGANISM_SUBSTANCE", 191, 199], ["TSL", "SIMPLE_CHEMICAL", 209, 212], ["A549 lung cancer cells", "CELL", 257, 279], ["H441 cells", "CELL", 281, 291], ["lung adenocarcinoma", "CANCER", 293, 312], ["H661 cells", "CELL", 315, 325], ["lung large cell carcinoma", "CANCER", 327, 352], ["H520 cells", "CELL", 359, 369], ["lung squamous cell carcinoma", "CANCER", 371, 399], ["extracts", "ORGANISM_SUBSTANCE", 445, 453], ["TSL", "SIMPLE_CHEMICAL", 459, 462], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 516, 521], ["Bax", "GENE_OR_GENE_PRODUCT", 555, 558], ["H441 cells", "CELL", 576, 586], ["TSL", "SIMPLE_CHEMICAL", 614, 617], ["osteosarcoma cells", "CELL", 621, 639], ["TSL", "PROTEIN", 13, 16], ["A549 lung cancer cells", "CELL_LINE", 257, 279], ["H441 cells", "CELL_LINE", 281, 291], ["H661 cells", "CELL_LINE", 315, 325], ["H520 cells", "CELL_LINE", 359, 369], ["Bcl-2 protein", "PROTEIN", 516, 529], ["Bax", "PROTEIN", 555, 558], ["H441 cells", "CELL_LINE", 576, 586], ["TSL", "PROTEIN", 614, 617], ["osteosarcoma cells", "CELL_TYPE", 621, 639], ["TSL", "TEST", 13, 16], ["potent antiproliferation effect", "PROBLEM", 23, 54], ["cancer", "PROBLEM", 72, 78], ["leukemia", "PROBLEM", 90, 98], ["lung, oral squamous carcinoma, prostate, and ovary", "PROBLEM", 100, 150], ["Previous studies", "TEST", 157, 173], ["crude extracts", "PROBLEM", 185, 199], ["the TSL", "PROBLEM", 205, 212], ["A549 lung cancer cells", "PROBLEM", 257, 279], ["H441 cells (lung adenocarcinoma)", "PROBLEM", 281, 313], ["H661 cells", "PROBLEM", 315, 325], ["lung large cell carcinoma", "PROBLEM", 327, 352], ["H520 cells (lung squamous cell carcinoma", "PROBLEM", 359, 399], ["crude extracts", "PROBLEM", 439, 453], ["decreased Bcl", "PROBLEM", 506, 519], ["increased Bax protein level in H441 cells", "PROBLEM", 545, 586], ["TSL on osteosarcoma cells", "PROBLEM", 614, 639], ["potent", "OBSERVATION_MODIFIER", 23, 29], ["antiproliferation effect", "OBSERVATION", 30, 54], ["cancer", "OBSERVATION", 72, 78], ["leukemia", "OBSERVATION", 90, 98], ["lung", "ANATOMY", 100, 104], ["oral", "ANATOMY", 106, 110], ["squamous carcinoma", "OBSERVATION", 111, 129], ["prostate", "ANATOMY", 131, 139], ["ovary", "ANATOMY", 145, 150], ["potent", "OBSERVATION_MODIFIER", 221, 227], ["antiproliferative", "OBSERVATION_MODIFIER", 228, 245], ["lung", "ANATOMY", 262, 266], ["cancer cells", "OBSERVATION", 267, 279], ["H441 cells", "OBSERVATION", 281, 291], ["lung", "ANATOMY", 293, 297], ["adenocarcinoma", "OBSERVATION", 298, 312], ["lung", "ANATOMY", 327, 331], ["large", "OBSERVATION_MODIFIER", 332, 337], ["cell carcinoma", "OBSERVATION", 338, 352], ["lung", "ANATOMY", 371, 375], ["squamous cell carcinoma", "OBSERVATION", 376, 399], ["increased", "OBSERVATION_MODIFIER", 545, 554], ["Bax protein", "OBSERVATION", 555, 566], ["H441 cells", "OBSERVATION", 576, 586], ["osteosarcoma cells", "OBSERVATION", 621, 639]]], ["In this study, we tested the effects of TSL-1, an advanced fraction of TSL crude extraction, on cell viability and cytotoxicity in human osteosarcoma cell lines, U2-OS, Saos-2, and MG-63, and on tumor growth in xenograft tumor.Preparation and Fractionation of TSL ::: Materials and MethodsThe specimen was confirmed by previous studies.21-23 The leaves used in this preparation were obtained from TS grown in Tuku (Yunlin County, Taiwan) and were picked and washed briskly with water.", [["cell", "ANATOMY", 96, 100], ["osteosarcoma cell lines", "ANATOMY", 137, 160], ["U2-OS", "ANATOMY", 162, 167], ["Saos-2", "ANATOMY", 169, 175], ["MG-63", "ANATOMY", 181, 186], ["tumor", "ANATOMY", 195, 200], ["xenograft tumor", "ANATOMY", 211, 226], ["specimen", "ANATOMY", 293, 301], ["leaves", "ANATOMY", 346, 352], ["TSL-1", "CHEMICAL", 40, 45], ["osteosarcoma", "DISEASE", 137, 149], ["tumor", "DISEASE", 195, 200], ["xenograft tumor", "DISEASE", 211, 226], ["TSL-1", "CHEMICAL", 40, 45], ["TSL-1", "GENE_OR_GENE_PRODUCT", 40, 45], ["TSL", "SIMPLE_CHEMICAL", 71, 74], ["cell", "CELL", 96, 100], ["human", "ORGANISM", 131, 136], ["osteosarcoma cell lines", "CELL", 137, 160], ["U2-OS", "CELL", 162, 167], ["Saos-2", "CELL", 169, 175], ["MG-63", "CELL", 181, 186], ["tumor", "CANCER", 195, 200], ["xenograft tumor", "CANCER", 211, 226], ["human osteosarcoma cell lines", "CELL_LINE", 131, 160], ["U2", "CELL_LINE", 162, 164], ["OS", "CELL_LINE", 165, 167], ["Saos-2", "CELL_LINE", 169, 175], ["MG-63", "CELL_LINE", 181, 186], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["this study", "TEST", 3, 13], ["TSL", "TEST", 40, 43], ["TSL crude extraction", "TREATMENT", 71, 91], ["cell viability", "TEST", 96, 110], ["cytotoxicity", "TEST", 115, 127], ["U2", "TEST", 162, 164], ["OS", "TEST", 165, 167], ["Saos", "TEST", 169, 173], ["MG", "TEST", 181, 183], ["tumor growth in xenograft tumor", "PROBLEM", 195, 226], ["previous studies", "TEST", 319, 335], ["TSL", "OBSERVATION_MODIFIER", 71, 74], ["crude extraction", "OBSERVATION", 75, 91], ["cell viability", "OBSERVATION", 96, 110], ["osteosarcoma cell lines", "OBSERVATION", 137, 160], ["tumor", "OBSERVATION", 195, 200], ["growth", "OBSERVATION_MODIFIER", 201, 207], ["xenograft tumor", "OBSERVATION", 211, 226]]], ["Reverse osmosis water was added to the leaves at a proportion of 4 liters water to 1 kg leaves.", [["leaves", "ANATOMY", 39, 45], ["Reverse osmosis water", "TREATMENT", 0, 21], ["osmosis", "OBSERVATION", 8, 15]]], ["The mixture of water and leaves was boiled for 30 minutes and then cooled down slowly for at least 2 hours at room temperature.", [["leaves", "ANATOMY", 25, 31], ["water", "SIMPLE_CHEMICAL", 15, 20], ["leaves", "ORGANISM_SUBDIVISION", 25, 31]]], ["The debris was then removed and remaining liquid was concentrated by incubating in low heat and filtered with a sieve (70-mesh).", [["debris", "ANATOMY", 4, 10], ["The debris", "PROBLEM", 0, 10], ["a sieve (70-mesh)", "TREATMENT", 110, 127], ["debris", "OBSERVATION", 4, 10], ["liquid", "OBSERVATION_MODIFIER", 42, 48], ["low heat", "OBSERVATION_MODIFIER", 83, 91]]], ["The filtered concentrate was lyophilized with a Virtis apparatus to obtain a crude extract.", [["extract", "ANATOMY", 83, 90], ["a Virtis apparatus", "TREATMENT", 46, 64], ["a crude extract", "TREATMENT", 75, 90]]], ["Following this procedure, different fractions of TSL\u2014TSL-1, TSL-5, and TSL-7\u2014were obtained following the aforementioned procedure by high-performance liquid chromatography.", [["TSL-5", "CHEMICAL", 60, 65], ["TSL", "SIMPLE_CHEMICAL", 49, 52], ["TSL-1", "GENE_OR_GENE_PRODUCT", 53, 58], ["TSL-5", "SIMPLE_CHEMICAL", 60, 65], ["TSL-7", "SIMPLE_CHEMICAL", 71, 76], ["this procedure", "TREATMENT", 10, 24], ["TSL\u2014TSL", "TEST", 49, 56], ["TSL", "TEST", 60, 63], ["TSL", "TEST", 71, 74], ["the aforementioned procedure", "TREATMENT", 101, 129]]], ["Furthermore, the powder was then dissolved in 99.5% ethanol and was centrifuged at 3000 rpm at 4\u00b0C (Beckman AvantiTM J-30I) for 12 minute to give a supernatant portion and a precipitate portion.", [["supernatant", "ANATOMY", 148, 159], ["ethanol", "CHEMICAL", 52, 59], ["ethanol", "CHEMICAL", 52, 59], ["ethanol", "SIMPLE_CHEMICAL", 52, 59], ["the powder", "TREATMENT", 13, 23], ["Beckman AvantiTM J", "TREATMENT", 100, 118], ["a supernatant portion", "TREATMENT", 146, 167]]], ["The supernatant portion was further lyophilized with a Virtis apparatus to obtain the lyophilized powder, TSL-2.19Cell Culture ::: Materials and MethodsThe human osteosarcoma cell lines U2OS, Saos-2, and MG-63 were obtained from the American Type Culture Collection (Manassas, VA), and Saos-2 and MG-63 were maintained in Dulbecco\u2019s modified Eagle\u2019s medium (DMEM; Gibco BRL, Bethesda, MD) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Bethesda, MD) and 100 U/mL penicillin.", [["supernatant", "ANATOMY", 4, 15], ["Cell", "ANATOMY", 114, 118], ["osteosarcoma cell lines U2OS", "ANATOMY", 162, 190], ["Saos-2", "ANATOMY", 192, 198], ["MG-63", "ANATOMY", 204, 209], ["MG-63", "ANATOMY", 297, 302], ["fetal bovine serum", "ANATOMY", 411, 429], ["FBS", "ANATOMY", 431, 434], ["osteosarcoma", "DISEASE", 162, 174], ["BRL", "CHEMICAL", 442, 445], ["penicillin", "CHEMICAL", 474, 484], ["penicillin", "CHEMICAL", 474, 484], ["TSL-2.19Cell Culture", "CELL", 106, 126], ["human", "ORGANISM", 156, 161], ["osteosarcoma cell lines U2OS", "CELL", 162, 190], ["Saos-2", "CELL", 192, 198], ["MG-63", "CELL", 204, 209], ["Saos-2", "CELL", 286, 292], ["MG-63", "CELL", 297, 302], ["bovine", "ORGANISM", 417, 423], ["serum", "ORGANISM_SUBSTANCE", 424, 429], ["FBS", "ORGANISM_SUBSTANCE", 431, 434], ["penicillin", "SIMPLE_CHEMICAL", 474, 484], ["human osteosarcoma cell lines", "CELL_LINE", 156, 185], ["U2OS", "CELL_LINE", 186, 190], ["Saos-2", "CELL_LINE", 192, 198], ["MG-63", "CELL_LINE", 204, 209], ["human", "SPECIES", 156, 161], ["bovine", "SPECIES", 417, 423], ["human", "SPECIES", 156, 161], ["bovine", "SPECIES", 417, 423], ["a Virtis apparatus", "TREATMENT", 53, 71], ["the lyophilized powder", "TREATMENT", 82, 104], ["TSL", "TEST", 106, 109], ["Cell Culture", "TEST", 114, 126], ["Materials", "TREATMENT", 131, 140], ["Methods", "TEST", 145, 152], ["The human osteosarcoma cell lines", "TEST", 152, 185], ["U2OS", "TEST", 186, 190], ["Saos", "TEST", 192, 196], ["MG", "TEST", 204, 206], ["Manassas", "TEST", 267, 275], ["Saos", "TEST", 286, 290], ["MG", "TEST", 297, 299], ["10% fetal bovine serum (FBS", "TREATMENT", 407, 434], ["penicillin", "TREATMENT", 474, 484], ["osteosarcoma cell lines U2OS", "OBSERVATION", 162, 190]]], ["U2-OS was cultured in McCoy\u2019s 5A medium (Sigma, St Louis, MO) supplemented with 10% fetal FBS, 2 mM L-glutamine, and 100 unit/mL penicillin.", [["fetal FBS", "ANATOMY", 84, 93], ["L-glutamine", "CHEMICAL", 100, 111], ["penicillin", "CHEMICAL", 129, 139], ["L-glutamine", "CHEMICAL", 100, 111], ["penicillin", "CHEMICAL", 129, 139], ["St Louis", "ORGANISM", 48, 56], ["FBS", "ORGANISM_SUBSTANCE", 90, 93], ["L-glutamine", "SIMPLE_CHEMICAL", 100, 111], ["penicillin", "SIMPLE_CHEMICAL", 129, 139], ["U2", "DNA", 0, 2], ["10% fetal FBS", "TREATMENT", 80, 93], ["2 mM L-glutamine", "TREATMENT", 95, 111], ["penicillin", "TREATMENT", 129, 139]]], ["The cultures were maintained in a humidified atmosphere with 5% CO2 at 37\u00b0C. Osteoblast cell lines (MT3T3-E1) were isolate cultured in DMEM with 10% FBS and 100 unit/mL penicillin for 1 week and then discarded.", [["Osteoblast cell lines", "ANATOMY", 77, 98], ["MT3T3-E1", "ANATOMY", 100, 108], ["FBS", "ANATOMY", 149, 152], ["CO2", "CHEMICAL", 64, 67], ["penicillin", "CHEMICAL", 169, 179], ["CO2", "CHEMICAL", 64, 67], ["penicillin", "CHEMICAL", 169, 179], ["CO2", "SIMPLE_CHEMICAL", 64, 67], ["Osteoblast cell lines", "CELL", 77, 98], ["MT3T3-E1", "CELL", 100, 108], ["FBS", "ORGANISM_SUBSTANCE", 149, 152], ["penicillin", "SIMPLE_CHEMICAL", 169, 179], ["Osteoblast cell lines", "CELL_LINE", 77, 98], ["MT3T3", "CELL_LINE", 100, 105], ["E1", "CELL_LINE", 106, 108], ["The cultures", "TEST", 0, 12], ["a humidified atmosphere", "TREATMENT", 32, 55], ["5% CO2", "TREATMENT", 61, 67], ["Osteoblast cell lines", "TREATMENT", 77, 98], ["MT3T3-E1", "TREATMENT", 100, 108], ["10% FBS", "TREATMENT", 145, 152], ["penicillin", "TREATMENT", 169, 179], ["cell lines", "OBSERVATION", 88, 98]]], ["The attached bone cells were cultured in DMEM with 10% FBS, 100 U/mL penicillin, 50 \u00b5g/mL ascorbic acid and 100 mg/mL nonessential amino acids solution.", [["bone cells", "ANATOMY", 13, 23], ["FBS", "ANATOMY", 55, 58], ["penicillin", "CHEMICAL", 69, 79], ["ascorbic acid", "CHEMICAL", 90, 103], ["amino acids", "CHEMICAL", 131, 142], ["penicillin", "CHEMICAL", 69, 79], ["ascorbic acid", "CHEMICAL", 90, 103], ["amino acids", "CHEMICAL", 131, 142], ["bone cells", "CELL", 13, 23], ["FBS", "ORGANISM_SUBSTANCE", 55, 58], ["penicillin", "SIMPLE_CHEMICAL", 69, 79], ["ascorbic acid", "SIMPLE_CHEMICAL", 90, 103], ["amino acids", "AMINO_ACID", 131, 142], ["attached bone cells", "CELL_LINE", 4, 23], ["The attached bone cells", "TEST", 0, 23], ["FBS", "TEST", 55, 58], ["penicillin", "TREATMENT", 69, 79], ["ascorbic acid", "TREATMENT", 90, 103], ["nonessential amino acids solution", "TREATMENT", 118, 151], ["bone", "ANATOMY", 13, 17]]], ["Cells were cultured at 37\u00b0C in a 5% CO2 incubator.Cell Viability Assays ::: Materials and MethodsHuman osteosarcoma cell lines (U2OS, Saos-2, and MG-63), human lung adenocarcinoma epithelial cell line (H441), and normal osteoblasts were seeded in 96-well plates (5000 cells/well) and incubated overnight.", [["Cells", "ANATOMY", 0, 5], ["Cell", "ANATOMY", 50, 54], ["MethodsHuman osteosarcoma cell lines", "ANATOMY", 90, 126], ["U2OS", "ANATOMY", 128, 132], ["Saos-2", "ANATOMY", 134, 140], ["MG-63", "ANATOMY", 146, 151], ["lung adenocarcinoma epithelial cell line", "ANATOMY", 160, 200], ["H441", "ANATOMY", 202, 206], ["osteoblasts", "ANATOMY", 220, 231], ["cells", "ANATOMY", 268, 273], ["CO2", "CHEMICAL", 36, 39], ["osteosarcoma", "DISEASE", 103, 115], ["lung adenocarcinoma", "DISEASE", 160, 179], ["CO2", "CHEMICAL", 36, 39], ["Cells", "CELL", 0, 5], ["CO2", "SIMPLE_CHEMICAL", 36, 39], ["Cell", "CELL", 50, 54], ["MethodsHuman osteosarcoma cell lines", "CELL", 90, 126], ["U2OS", "CELL", 128, 132], ["Saos-2", "CELL", 134, 140], ["MG-63", "CELL", 146, 151], ["human", "ORGANISM", 154, 159], ["lung adenocarcinoma epithelial cell line", "CELL", 160, 200], ["H441", "CELL", 202, 206], ["osteoblasts", "CELL", 220, 231], ["cells", "CELL", 268, 273], ["MethodsHuman osteosarcoma cell lines", "CELL_LINE", 90, 126], ["U2OS", "CELL_LINE", 128, 132], ["Saos-2", "CELL_LINE", 134, 140], ["MG-63", "CELL_LINE", 146, 151], ["human lung adenocarcinoma epithelial cell line", "CELL_LINE", 154, 200], ["H441", "CELL_LINE", 202, 206], ["normal osteoblasts", "CELL_TYPE", 213, 231], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["a 5% CO2 incubator", "TREATMENT", 31, 49], ["Materials", "TEST", 76, 85], ["MethodsHuman osteosarcoma cell lines", "TREATMENT", 90, 126], ["U2OS", "TEST", 128, 132], ["Saos", "TEST", 134, 138], ["MG", "TEST", 146, 148], ["human lung adenocarcinoma epithelial cell line", "PROBLEM", 154, 200], ["osteosarcoma cell lines", "OBSERVATION", 103, 126], ["lung", "ANATOMY", 160, 164], ["adenocarcinoma", "OBSERVATION", 165, 179], ["epithelial cell line", "OBSERVATION", 180, 200], ["normal osteoblasts", "OBSERVATION", 213, 231]]], ["The cells were then incubated in 10% FBS media containing different amounts of TSL fractions and gallic acid for 24 hours or 48 hours (TSL-1 treated group).", [["cells", "ANATOMY", 4, 9], ["FBS", "ANATOMY", 37, 40], ["TSL", "CHEMICAL", 79, 82], ["gallic acid", "CHEMICAL", 97, 108], ["TSL-1", "CHEMICAL", 135, 140], ["gallic acid", "CHEMICAL", 97, 108], ["cells", "CELL", 4, 9], ["FBS", "ORGANISM_SUBSTANCE", 37, 40], ["TSL", "SIMPLE_CHEMICAL", 79, 82], ["gallic acid", "SIMPLE_CHEMICAL", 97, 108], ["10% FBS media", "TREATMENT", 33, 46], ["TSL fractions", "TREATMENT", 79, 92], ["gallic acid", "TREATMENT", 97, 108], ["TSL", "TEST", 135, 138]]], ["Then, cells were cultured in media containing 2 mg/mL of MTT (3-(4,5-dimethylthiazol-2-yl)]-2,5-diphenyltetrazolium bromide; Sigma-Aldrich, St Louis, MO) for 4 hours.", [["cells", "ANATOMY", 6, 11], ["MTT", "CHEMICAL", 57, 60], ["3-(4,5-dimethylthiazol-2-yl)]-2,5-diphenyltetrazolium bromide", "CHEMICAL", 62, 123], ["MTT", "CHEMICAL", 57, 60], ["3-(4,5-dimethylthiazol-2-yl)]-2,5-diphenyltetrazolium bromide", "CHEMICAL", 62, 123], ["cells", "CELL", 6, 11], ["MTT", "SIMPLE_CHEMICAL", 57, 60], ["3-(4,5-dimethylthiazol-2-yl)]-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 62, 123], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 125, 138], ["St Louis", "SIMPLE_CHEMICAL", 140, 148], ["cells", "TREATMENT", 6, 11], ["MTT", "TREATMENT", 57, 60], ["dimethylthiazol", "TREATMENT", 69, 84], ["diphenyltetrazolium bromide", "TREATMENT", 96, 123]]], ["Then, reaction of MTT was terminated by adding 100 \u00b5L of dimethyl sulfoxide, and absorbance OD values were measured at 540 nm by using a microplate reader (Molecular Probes Inc, Eugene, OR).Lactate Dehydrogenase Leakage Assay ::: Materials and MethodsLactate dehydrogenase (LDH) leakage from cells was measured to quantify the cytotoxicity using a cytotoxicity detection kit (Roche, Mannheim, Germany).24 Saos-2 cells were seeded in 24-well plates (5 \u00d7 104 cells/well) and were not treated with drugs until 80% confluence.", [["cells", "ANATOMY", 292, 297], ["Saos-2 cells", "ANATOMY", 405, 417], ["cells", "ANATOMY", 457, 462], ["MTT", "CHEMICAL", 18, 21], ["dimethyl sulfoxide", "CHEMICAL", 57, 75], ["Lactate", "CHEMICAL", 190, 197], ["MethodsLactate", "CHEMICAL", 244, 258], ["MTT", "CHEMICAL", 18, 21], ["dimethyl sulfoxide", "CHEMICAL", 57, 75], ["Lactate", "CHEMICAL", 190, 197], ["MethodsLactate", "CHEMICAL", 244, 258], ["MTT", "SIMPLE_CHEMICAL", 18, 21], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 57, 75], ["Lactate", "SIMPLE_CHEMICAL", 190, 197], ["MethodsLactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 244, 272], ["LDH", "GENE_OR_GENE_PRODUCT", 274, 277], ["cells", "CELL", 292, 297], ["Saos-2 cells", "CELL", 405, 417], ["cells", "CELL", 457, 462], ["MethodsLactate dehydrogenase", "PROTEIN", 244, 272], ["LDH", "PROTEIN", 274, 277], ["Saos-2 cells", "CELL_LINE", 405, 417], ["MTT", "TEST", 18, 21], ["dimethyl sulfoxide", "TREATMENT", 57, 75], ["absorbance OD values", "TEST", 81, 101], ["a microplate reader", "TREATMENT", 135, 154], ["Lactate Dehydrogenase Leakage Assay", "TEST", 190, 225], ["Materials", "TEST", 230, 239], ["MethodsLactate dehydrogenase (LDH) leakage from cells", "PROBLEM", 244, 297], ["the cytotoxicity", "TEST", 323, 339], ["a cytotoxicity detection", "TEST", 346, 370], ["Saos", "TEST", 405, 409], ["cells", "TEST", 457, 462], ["drugs", "TREATMENT", 495, 500], ["Dehydrogenase Leakage", "OBSERVATION", 198, 219]]], ["After drug treatment, the supernatants and cell layers of the cultures were collected for assay.", [["supernatants", "ANATOMY", 26, 38], ["cell layers", "ANATOMY", 43, 54], ["cultures", "ANATOMY", 62, 70], ["cell layers", "CELL", 43, 54], ["cultures", "CELL", 62, 70], ["drug treatment", "TREATMENT", 6, 20], ["the supernatants", "TREATMENT", 22, 38], ["the cultures", "TEST", 58, 70], ["assay", "TEST", 90, 95]]], ["According to the manufacturer\u2019s guidelines, cell layers were lysed with 1% Triton X-100.", [["cell layers", "ANATOMY", 44, 55], ["Triton X-100", "CHEMICAL", 75, 87], ["Triton X-100", "CHEMICAL", 75, 87], ["cell layers", "CELL", 44, 55], ["Triton X-100", "SIMPLE_CHEMICAL", 75, 87], ["cell layers", "TREATMENT", 44, 55], ["1% Triton", "TREATMENT", 72, 81]]], ["Both cell lysine and supernatant of each sample were transferred to a 96-well plate for assay.", [["cell", "ANATOMY", 5, 9], ["supernatant", "ANATOMY", 21, 32], ["sample", "ANATOMY", 41, 47], ["lysine", "CHEMICAL", 10, 16], ["lysine", "CHEMICAL", 10, 16], ["cell", "CELL", 5, 9], ["Both cell lysine", "TREATMENT", 0, 16], ["assay", "TEST", 88, 93], ["cell lysine", "OBSERVATION", 5, 16]]], ["Briefly, 100 \u00b5L of catalyst solution was added to each assay well for 20 minutes.", [["catalyst solution", "TREATMENT", 19, 36]]], ["Absorbance was measured using an ELISA reader with a 490-nm filter.", [["a 490-nm filter", "TREATMENT", 51, 66]]], ["LDH leakage from osteoblasts was calculated using the following formula:Lactate Dehydrogenase Leakage Assay ::: Materials and Methods", [["osteoblasts", "ANATOMY", 17, 28], ["Lactate", "CHEMICAL", 72, 79], ["Lactate", "CHEMICAL", 72, 79], ["LDH", "GENE_OR_GENE_PRODUCT", 0, 3], ["osteoblasts", "CELL", 17, 28], ["Lactate Dehydrogenase", "SIMPLE_CHEMICAL", 72, 93], ["osteoblasts", "CELL_TYPE", 17, 28], ["LDH leakage from osteoblasts", "PROBLEM", 0, 28], ["Lactate Dehydrogenase Leakage", "TEST", 72, 101], ["Methods", "TREATMENT", 126, 133], ["leakage", "OBSERVATION", 4, 11], ["osteoblasts", "ANATOMY", 17, 28]]]], "a3dc52f2158ddddb91e723dfbb7ce868103dd462": [["Alterations in pancreatic function and structure were examined in suckling mice infected intraperitoneally with reovirus type 3.", [["pancreatic", "ANATOMY", 15, 25], ["intraperitoneally", "ANATOMY", 89, 106], ["pancreatic", "ORGAN", 15, 25], ["mice", "ORGANISM", 75, 79], ["reovirus type 3", "ORGANISM", 112, 127], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["Alterations in pancreatic function", "PROBLEM", 0, 34], ["pancreatic", "ANATOMY", 15, 25]]], ["The results were compared to pancreatic zymogen enzyme activities and histology in adult mice infected with the same virus.", [["pancreatic", "ANATOMY", 29, 39], ["pancreatic zymogen", "GENE_OR_GENE_PRODUCT", 29, 47], ["mice", "ORGANISM", 89, 93], ["pancreatic zymogen enzyme", "PROTEIN", 29, 54], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 89, 93], ["pancreatic zymogen enzyme activities", "TEST", 29, 65], ["histology", "TEST", 70, 79], ["the same virus", "PROBLEM", 108, 122], ["pancreatic", "ANATOMY", 29, 39]]], ["No effect of the reovirus type 3 on the adult mice could be elicited.", [["reovirus type 3", "ORGANISM", 17, 32], ["mice", "ORGANISM", 46, 50], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["effect", "OBSERVATION_MODIFIER", 3, 9], ["reovirus", "OBSERVATION", 17, 25]]]]}